<SEC-DOCUMENT>0001628280-19-007420.txt : 20190531
<SEC-HEADER>0001628280-19-007420.hdr.sgml : 20190531
<ACCEPTANCE-DATETIME>20190531082628
ACCESSION NUMBER:		0001628280-19-007420
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20190529
FILED AS OF DATE:		20190531
DATE AS OF CHANGE:		20190531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		19868656

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>auph-2019agm6xk.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1012DA54E5CF5CCFA7CA53E9823FD0EF"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Washington, D.C. 20549</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 6-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Dated May 31, 2019</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File Number 001-36421</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Exact name of Registrant as specified in its charter)</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Translation of Registrant's Name)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">#1203-4464 Markham Street</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Victoria, British Columbia</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">V8Z 7X8</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(250) 708-4272</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address and telephone number of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant files of will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Form 20-F&#160;&#9744;      &#160;&#160;Form 40-F&#160;&#160; &#9746;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): &#9744;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):  &#9744;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Yes&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160; &#9744;</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This Form 6-K is hereby filed and incorporated by reference in the registrant's Registration Statement on Form F-10 (File No. 333-222413).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">_________________________________________________________</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><a name="s8A0A406AB3B159578A4D601B2E36F4BE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:8%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Date:&#160;May&#160;31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aurinia Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/ Dennis Bourgeault</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Name:</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dennis Bourgeault</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:16px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:13%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">Document</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="a9912019noticeofagmofshare.htm"><font style="font-family:inherit;font-size:9pt;">99.1</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Notice of Annual General Meeting of Shareholders</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="a9922019informationcircular.htm"><font style="font-family:inherit;font-size:9pt;">99.2</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Information Circular</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="a9932019formofproxy.htm"><font style="font-family:inherit;font-size:9pt;">99.3</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Form of Proxy</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="a9942019shareholderletter.htm"><font style="font-family:inherit;font-size:9pt;">99.4</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Shareholder Letter</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exhibits 99.1, 99.2, 99.3 and 99.4 included with this report on Form 6-K are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a9912019noticeofagmofshare.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s94D0274D938651608CEED49EC725839F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Notice of Annual General Meeting of Shareholders</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOTICE</font><font style="font-family:Arial;font-size:10pt;">&#32;is hereby given that the Annual General Meeting (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Meeting</font><font style="font-family:Arial;font-size:10pt;">") of shareholders of Aurinia Pharmaceuticals Inc. (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:Arial;font-size:10pt;">") will be held at the Westin Calgary, 320 4 Ave SW,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Calgary, Alberta  T2P 2S6, on Wednesday, June 26, 2019, at 10:00 AM, Mountain Time, for the following purposes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to fix the number of directors at eight;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to elect the directors for the ensuing year; </font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to receive the audited consolidated financial statements of the Company for the financial year ended December 31, 2018, and the report of the auditors thereon;</font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company; </font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to consider a non-binding advisory "say on pay" resolution regarding the Company&#8217;s approach to executive compensation; and </font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to transact such further and other business as may properly be brought before the Meeting or any adjournment thereof.</font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management of the Company is soliciting proxies on the accompanying </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">voting instruction form.  Shareholders who are unable to attend the Meeting are requested to vote and submit their </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form in advance so that as large a representation of shareholders as possible may be had at the Meeting.  Specific details of the matters being put before the Meeting are set forth in more detail in the accompanying management information circular. Your vote is important to us, regardless of the number of shares held. Please vote your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form today.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A special committee of the board of directors of the Company (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:10pt;">") has determined that only holders of record of the common shares of the Company at the close of business on May 9, 2019 will be entitled to vote in respect of the items set out in this notice of meeting at the Meeting.  If you are a registered shareholder, your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy must be returned to the Company&#8217;s transfer agent, Computershare Investor Services Inc., Attention: Proxy Department, 100 University Avenue, 9th Floor, Toronto, Ontario, M5J 2Y1 by 10:00 AM, Mountain Time, on Monday, June 24, 2019 or, if the Meeting is adjourned or postponed, by not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time and date for the reconvened meeting.  Failure to properly complete or deposit a proxy may result in its invalidation. If you are a non-registered shareholder, the intermediary (usually a bank, trust company, broker, securities dealer or other financial institution) through which you hold common shares of the Company will send you instructions on how to vote your common shares at the Meeting. </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Please note that ILJIN SNT Co. Ltd. (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ILJIN</font><font style="font-family:Arial;font-size:10pt;">&#8221;) has stated its intention to nominate four nominees for election as directors at the Meeting. You may receive solicitation materials from ILJIN seeking your proxy to vote for its nominees. The Company is not responsible for the accuracy of any information provided by, or relating to, ILJIN or its nominees contained in any proxy solicitation materials filed or disseminated by, or on behalf of, ILJIN or any other statements that ILJIN may otherwise make. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management is soliciting proxies for the election to the Board the persons named on the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy and urges you NOT to sign or return or vote any proxy card sent to you by ILJIN. If you have already voted using a proxy card sent to you by ILJIN, you can recast your vote using the Company's YELLOW proxy prior to the proxy voting deadline or you can revoke it by an instrument in writing executed by you or by your attorney duly authorized in writing, or if you (as a shareholder) are a corporation, executed under your corporate seal or by an officer or attorney duly authorized in writing, and deposited with the Company, c/o Computershare at the address set out above, at any time up to and including the last business day preceding the day of the Meeting, or any adjournment of that Meeting, or with the Chair of the Board on the day of the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under such proxy&#8217;s authority. Non-registered shareholders should closely follow the instructions provided to them from their intermediary.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">You should carefully follow the instructions received from your intermediary to make sure that your common shares of the Company are represented and voted at the Meeting.</font></div><div style="line-height:150%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DATED</font><font style="font-family:Arial;font-size:10pt;">&#32;this 29</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;day of May, 2019.</font></div><div style="line-height:150%;padding-bottom:32px;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BY ORDER OF A SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS</font></div><div style="line-height:150%;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Peter Greenleaf&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">Peter Greenleaf</font></div><div style="line-height:150%;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director and Chief Executive Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a9922019informationcircular.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s00B50277414D5BD0980430044DAEAFA5"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exhibit 99.2</font></div><div style="line-height:120%;text-align:center;"><img src="aurinialogoweb700pxa02.jpg" alt="aurinialogoweb700pxa02.jpg" style="height:90px;width:233px;"></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">NOTICE OF ANNUAL GENERAL MEETING</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">OF SHAREHOLDERS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">TO BE HELD ON</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">June 26, 2019</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">MANAGEMENT INFORMATION CIRCULAR</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">Dated May 29, 2019</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4994994994995%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">YOUR VOTE IS IMPORTANT.</font></div><div style="padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THE BOARD OF AURINIA RECOMMENDS VOTING THE </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#ffc000;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;PROXY:</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;"><img src="checkmarka08.jpg" alt="checkmarka08.jpg" style="height:33px;width:37px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;fixing the number of directors at eight</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;"><img src="checkmarka09.jpg" alt="checkmarka09.jpg" style="height:33px;width:37px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;the election of Aurinia&#8217;s nominees for directors</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;"><img src="checkmarka10.jpg" alt="checkmarka10.jpg" style="height:33px;width:37px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;the appointment of PricewaterhouseCoopers LLP as auditor</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;"><img src="checkmarka11.jpg" alt="checkmarka11.jpg" style="height:33px;width:37px;"></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">the approval of an advisory &#8220;Say on Pay&#8221; vote</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">YOUR </font><font style="font-family:Arial;font-size:10pt;color:#ffc000;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;PROXY MUST BE RECEIVED BY 10:00 A.M. (MOUNTAIN TIME) ON JUNE 24, 2019.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If you have any questions, or require any assistance with voting your shares, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">please call Aurinia&#8217;s Proxy Solicitation Agent:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Laurel Hill Advisory Group </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">North American Toll Free: 1-877-452-7184</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Collect Calls Outside North America: 1-416-304-0211</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Email</font><font style="font-family:Arial;font-size:10pt;">: assistance@laurelhill.com</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB460812F84075FE695C3ACF085DE92E8"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Notice of Annual General Meeting of Shareholders</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOTICE</font><font style="font-family:Arial;font-size:10pt;">&#32;is hereby given that the Annual General Meeting (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Meeting</font><font style="font-family:Arial;font-size:10pt;">") of shareholders of Aurinia Pharmaceuticals Inc. (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:Arial;font-size:10pt;">") will be held at the Westin Calgary, 320 4 Ave SW,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Calgary, Alberta  T2P 2S6, on Wednesday, June 26, 2019, at 10:00 AM, Mountain Time, for the following purposes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to fix the number of directors at eight;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to elect the directors for the ensuing year; </font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to receive the audited consolidated financial statements of the Company for the financial year ended December 31, 2018, and the report of the auditors thereon;</font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company; </font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to consider a non-binding advisory "say on pay" resolution regarding the Company&#8217;s approach to executive compensation; and </font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to transact such further and other business as may properly be brought before the Meeting or any adjournment thereof.</font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management of the Company is soliciting proxies on the accompanying </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">voting instruction form.  Shareholders who are unable to attend the Meeting are requested to vote and submit their </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form in advance so that as large a representation of shareholders as possible may be had at the Meeting.  Specific details of the matters being put before the Meeting are set forth in more detail in the accompanying management information circular. Your vote is important to us, regardless of the number of shares held. Please vote your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form today.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A special committee of the board of directors of the Company (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:10pt;">") has determined that only holders of record of the common shares of the Company at the close of business on May 9, 2019 will be entitled to vote in respect of the items set out in this notice of meeting at the Meeting.  If you are a registered shareholder, your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy must be returned to the Company&#8217;s transfer agent, Computershare Investor Services Inc., Attention: Proxy Department, 100 University Avenue, 9th Floor, Toronto, Ontario, M5J 2Y1 by 10:00 AM, Mountain Time, on Monday, June 24, 2019 or, if the Meeting is adjourned or postponed, by not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time and date for the reconvened meeting.  Failure to properly complete or deposit a proxy may result in its invalidation. If you are a non-registered shareholder, the intermediary (usually a bank, trust company, broker, securities dealer or other financial institution) through which you hold common shares of the Company will send you instructions on how to vote your common shares at the Meeting. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ii</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Please note that ILJIN SNT Co. Ltd. (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ILJIN</font><font style="font-family:Arial;font-size:10pt;">&#8221;) has stated its intention to nominate four nominees for election as directors at the Meeting. You may receive solicitation materials from ILJIN seeking your proxy to vote for its nominees. The Company is not responsible for the accuracy of any information provided by, or relating to, ILJIN or its nominees contained in any proxy solicitation materials filed or disseminated by, or on behalf of, ILJIN or any other statements that ILJIN may otherwise make. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management is soliciting proxies for the election to the Board the persons named on the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy and urges you NOT to sign or return or vote any proxy card sent to you by ILJIN. If you have already voted using a proxy card sent to you by ILJIN, you can recast your vote using the Company's YELLOW proxy prior to the proxy voting deadline or you can revoke it by an instrument in writing executed by you or by your attorney duly authorized in writing, or if you (as a shareholder) are a corporation, executed under your corporate seal or by an officer or attorney duly authorized in writing, and deposited with the Company, c/o Computershare at the address set out above, at any time up to and including the last business day preceding the day of the Meeting, or any adjournment of that Meeting, or with the Chair of the Board on the day of the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under such proxy&#8217;s authority. Non-registered shareholders should closely follow the instructions provided to them from their intermediary.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">You should carefully follow the instructions received from your intermediary to make sure that your common shares of the Company are represented and voted at the Meeting.</font></div><div style="line-height:150%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DATED</font><font style="font-family:Arial;font-size:10pt;">&#32;this 29</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;day of May, 2019.</font></div><div style="line-height:150%;padding-bottom:32px;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BY ORDER OF A SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS</font></div><div style="line-height:150%;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Peter Greenleaf&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">Peter Greenleaf</font></div><div style="line-height:150%;text-align:justify;padding-left:312px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director and Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iii</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s67619945549F5FF181EA464D4CF33E6A"></a></div><div><br></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8998998998999%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:95%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s975BD58303A55FCB8268EC0F002ED022"><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART 1 VOTING INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s975BD58303A55FCB8268EC0F002ED022"><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">1</font></a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sB087189257FC51C79A490797A84E9D77"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.1 SOLICITATION OF YELLOW PROXIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sB087189257FC51C79A490797A84E9D77"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1</font></a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sB98FD146585F5A1AB07CC362CE6589CA"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.2 APPOINTMENT AND REVOCATION OF YELLOW PROXIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sB98FD146585F5A1AB07CC362CE6589CA"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1</font></a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sC46F4ECA565C579DAA238CAF1CC63BAB"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.3 REGISTERED SHAREHOLDERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sCF0275FD5B1F574C9565CFC91599C83F"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.4 NON-REGISTERED SHAREHOLDERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s23B9F0759EAF5F9599F8891DC461BA49"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.5 DESCRIPTION OF THE COMPANY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s905AAD93BBE95CD39CA54FE0C3DC8790"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.6 VOTING OF YELLOW PROXIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s4961F42EB551569FBC0BDF215C910568"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">1.7 VOTING SHARES AND PRINCIPAL HOLDERS THEREOF</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s1EBD0A0068605FE5B1EC445DF3733CCE"><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART 2 BUSINESS OF THE MEETING</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sC96735DA59E259A9AA3F129D64355574"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2.1 ELECTION OF DIRECTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s55CA77D590C85A418779F89766E5E13A"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2.2 PRESENTATION OF FINANCIAL STATEMENTS AND AUDITOR&#8217;S REPORT</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sF2FD8D18CE7258FF9FE9488F473E7567"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2.3 APPOINTMENT AND REMUNERATION OF AUDITORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s00f197beb4fc43f28a4406844cac82f1"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2.4 ADVISORY 'SAY ON PAY' VOTE ON EXECUTIVE COMPENSATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sFC4AB0FFCAD75CB1B2FCDBE7026A5B93"><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART 3  STATEMENT OF EXECUTIVE COMPENSATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s18BD7A5B90955378B28C85DBBD5DC2C8"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">3.1 COMPENSATION OF EXECUTIVES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sBCC55C409ED852F480FD494B6D14342E"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">3.2 COMPENSATION OF DIRECTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s207C9E6C928057F78768D98FA3A00AF8"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">3.3 EQUITY COMPENSATION PLAN</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s338F1CBD7F9E5FE59AD55A15A46D386C"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">3.4 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s937259000EC65177BAC0E6D393FE15A4"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">3.5 INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s7E976D6249CA5C85B4E2405A7E46E0F7"><font style="font-family:Arial;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART 4 REPORT ON CORPORATE GOVERNANCE AND OTHER ITEMS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">44</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s63FC96CA064B5AFB9DC3423F4C5AFCD2"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">4.1 COMMITTEES OF THE BOARD</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s72E448471D805CF8BA1E8D81AB7EF140"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">4.2 INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s7E467C75108355288D140D4695B4B334"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">4.3 SHAREHOLDER PROPOSALS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s7B8C40D83DDA5C918A52166A13D66D95"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">4.4 ADDITIONAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s04789c974623407d8ad8adc54f9bfd9e"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">4.5 CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:14px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.6</font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s8FEEBC0D1AEF5F08BFE791A755B71648"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">&#160;APPROVAL BY DIRECTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9C36BC0F6E0D519A933F3D285780F258"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">APPENDIX &#8220;A&#8221; &#8211; STATEMENT OF CORPORATE GOVERNANCE PRACTICES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9C36BC0F6E0D519A933F3D285780F258"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">A-1</font></a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sFD30760A6A4D5E68B5E09FD9CC2C16BF"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">APPENDIX &#8220;B&#8221; &#8211; MANDATE OF THE BOARD OF DIRECTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#sFD30760A6A4D5E68B5E09FD9CC2C16BF"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">B-1</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iv</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9F325290C5815C92BBCA3953F878593F"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">MANAGEMENT INFORMATION CIRCULAR</font></div><div><a name="s975BD58303A55FCB8268EC0F002ED022"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART 1 <br>VOTING INFORMATION</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This management information circular (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Circular</font><font style="font-family:Arial;font-size:10pt;">") is furnished in connection with the solicitation by the management of Aurinia Pharmaceuticals Inc. ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Aurinia</font><font style="font-family:Arial;font-size:10pt;">" or the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:Arial;font-size:10pt;">") of </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxies to be voted at the annual general meeting of shareholders (each a "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Shareholder</font><font style="font-family:Arial;font-size:10pt;">") of the Company (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Meeting</font><font style="font-family:Arial;font-size:10pt;">"), to be held at the Westin Calgary, 320 4 Ave SW, Calgary, Alberta T2P 2S6, on June 26,&#160;2019, at 10:00 AM, Mountain Time, for the purposes set forth in the accompanying Notice of the Meeting, and at any adjournment thereof.  Except as otherwise stated, the information contained herein is given as at May 9, 2019, and all dollar amounts and references to $ or to US$ are to United States dollars and references to CDN$ are to Canadian dollars.  The 2018 annual average exchange rate for conversion of United States dollars into Canadian dollars was US$1.00 = CDN$1.2957 based upon the Bank of Canada closing rate.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sB087189257FC51C79A490797A84E9D77"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;SOLICITATION OF </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROXIES</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxies for the Meeting are being solicited by the management of the Company and the expenses of solicitation of </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxies will be borne by the Company.  The solicitation will be made primarily by mail; however, directors, officers and certain employees of the Company may also solicit </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxies by telephone, electronic mail or in person. The Company has also retained Laurel Hill Advisory Group ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Laurel Hill</font><font style="font-family:Arial;font-size:10pt;">") to assist it in connection with the Company&#8217;s solicitation of </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxies and communications with Shareholders, recommending corporate governance best practices, where applicable, liaising with advisory firms, developing and implementing shareholder communication strategies and advice with respect to the Meeting and proxy protocol. In connection with these services, Laurel Hill is expected to receive a fee for these services of CDN$250,000, plus taxes and expenses.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sB98FD146585F5A1AB07CC362CE6589CA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.2 &#160;&#160;&#160;&#160;APPOINTMENT AND REVOCATION OF </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;PROXIES</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy as management&#8217;s nominees to act as proxyholders are directors of the Company ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Directors</font><font style="font-family:Arial;font-size:10pt;">") or officers of the Company ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Officers</font><font style="font-family:Arial;font-size:10pt;">").  </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Each Shareholder is entitled to appoint any other person to represent him or her at the Meeting, and at any adjournment thereof.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Registered Shareholders who are unable to attend the Meeting in person are requested to complete, sign, date and return the enclosed </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy to the Company c/o Computershare Investor Services Inc. ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Computershare</font><font style="font-family:Arial;font-size:10pt;">"), the Company&#8217;s transfer agent: Attention: Proxy Department, 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1 by 10:00 AM, Mountain Time, on Monday, June 24, 2019 (or, if the meeting is adjourned or postponed, by not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time and date for the reconvened meeting) to ensure that there is as large a representation as possible at the Meeting and your voice is heard. Non-registered Shareholders should closely follow the instructions provided to them from their intermediary. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY SHARES YOU HOLD. PLEASE COMPLETE AND SUBMIT YOUR YELLOW PROXY WITHOUT DELAY. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A registered Shareholder desiring to appoint another person (who need not be a Shareholder) to represent them at the Meeting, and at any adjournment thereof, may do so either by striking out the names of the management nominees set </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">forth in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy and inserting such person&#8217;s name therein or by completing another proper proxy and, in either case, sending the completed proxy in the reply envelope for delivery by 10:00 AM, Mountain Time, on Monday, June 24, 2019 (or, if the meeting is adjourned or postponed, by not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time and date for the reconvened meeting). Non-registered Shareholders should closely follow the instructions provided to them from their intermediary.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A registered Shareholder giving a </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy pursuant to this solicitation may revoke any such </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy by an instrument in writing executed by the Shareholder or by their attorney duly authorized in writing, or if the Shareholder is a corporation, executed under its corporate seal or by an officer or attorney duly authorized in writing, and deposited with the Company, c/o Computershare at the address set out above in this section, at any time up to and including the last business day preceding the day of the Meeting, or any adjournment of that Meeting, or with the Chair of the board of directors of the Company (the &#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:10pt;">&#8221;) on the day of the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy&#8217;s authority. Non-registered Shareholders should closely follow the instructions provided to them from their intermediary.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sC46F4ECA565C579DAA238CAF1CC63BAB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;REGISTERED SHAREHOLDERS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The close of business on May 9, 2019 is the record date for the Meeting (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Record Date</font><font style="font-family:Arial;font-size:10pt;">"). </font><font style="font-family:Arial;font-size:10pt;">Only Shareholders at the close of business on the Record Date are entitled to vote at the Meeting, or any adjournment thereof, either in person or by proxy, in respect of all matters which may properly come before the Meeting, or any adjournment thereof. You are a registered Shareholder if your common shares in the capital of the Company (each a "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Common Share</font><font style="font-family:Arial;font-size:10pt;">") are held directly in your own name and not in the name of your broker or another intermediary (collectively an &#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Intermediary</font><font style="font-family:Arial;font-size:10pt;">&#8221;). </font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a registered Shareholder, you can vote in person, or by proxy by signing the accompanying </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy and returning it to Computershare by mail or delivery to Computershare, Attention: Proxy Department, 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1, or by fax to 1-866-249-7775 for faxes sent from within Canada and the U.S (or 1-416-263-9524 for faxes sent from outside Canada and the U.S). </font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sCF0275FD5B1F574C9565CFC91599C83F"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.4&#160;&#160;&#160;&#160;NON-REGISTERED SHAREHOLDERS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Persons who beneficially own Common Shares as of the Record Date, but whose Common Shares are held in the name of an Intermediary will not appear on the list of Shareholders.  If you are not a registered Shareholder of the Company, in order to vote you must (i) obtain the material relating to the Meeting from your Intermediary; (ii) complete the request for voting instructions sent to you by the Intermediary; and (iii) follow the directions of the Intermediary with respect to voting procedures.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In accordance with National Instrument 54-101 - Communications with Beneficial Owners of Securities of a Reporting Issuer ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NI 54-101</font><font style="font-family:Arial;font-size:10pt;">"), the Company is distributing copies of the material related to the Meeting to clearing agencies and Intermediaries for distribution to non-registered holders.  Such agencies and Intermediaries must forward the material related to the Meeting to non-registered holders. Management of the Company also intends to pay for Intermediaries to forward the meeting materials to objecting beneficial owners under NI 54-101.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or voting instruction form supplied to you by your Intermediary will be similar to the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy provided to registered Shareholders. However, its purpose is limited to instructing the Intermediary on how to vote your Common Shares on your behalf. You should carefully follow the procedures set out in your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or voting instruction form, depending on which type of document you receive. Most Intermediaries delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Broadridge</font><font style="font-family:Arial;font-size:10pt;">&#8221;) in the United States and in Canada. Broadridge typically mails a scannable voting instruction form instead of a form of proxy. Non-registered Shareholders are asked to complete the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form and return it to Broadridge by mail or facsimile. Alternatively, non-registered Shareholders may submit their votes by telephone or via the internet at www.proxyvote.com. The various voting methods will be set out by Broadridge on the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;voting instruction form.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In either case, the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or voting instruction form from your Intermediary is to permit non-registered Shareholders to direct the voting of the Common Shares they beneficially own. Should a non-registered Shareholder who receives one of the above forms wish to vote in person at the Meeting, or any adjournment(s) or postponement(s) thereof (or have another person attend and vote on behalf of the non-registered Shareholder), the non-registered Shareholder should insert the non-registered Shareholder's or such other person's name in the blank space provided for this purpose. Non-registered Shareholders should carefully follow the instructions of their Intermediary, including those regarding when and where the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy or voting instruction form is to be delivered. Non-registered Shareholders may also contact Laurel Hill for assistance with voting their Common Shares at the Meeting.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If you are a non-registered Shareholder, you may revoke voting instructions which have been given to an Intermediary by carefully following the instructions provided by the Intermediary.  </font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NON-REGISTERED SHAREHOLDERS ARE ENCOURAGED TO VOTE ONLINE OR BY TELEPHONE TO AVOID DELAYS.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s23B9F0759EAF5F9599F8891DC461BA49"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.5&#160;&#160;&#160;&#160;DESCRIPTION OF THE COMPANY</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is organized pursuant to the provisions of the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:Arial;font-size:10pt;">&#32;(Alberta) (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ABCA</font><font style="font-family:Arial;font-size:10pt;">") and is registered extra-provincially in the Province of British Columbia pursuant to the provisions of the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:Arial;font-size:10pt;">&#32;(British Columbia).</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s905AAD93BBE95CD39CA54FE0C3DC8790"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.6&#160;&#160;&#160;&#160;VOTING OF </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROXIES</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy will vote or withhold from voting the Common Shares in respect of which they are appointed in accordance with the directions of the Shareholders appointing them.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the absence of such directions, such Common Shares will be voted:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;fixing the number of directors at eight;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;the election of each of the nominees for election as a Director of the Company set forth in this Circular; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;the re-appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company; and</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;the approval of a non-binding advisory "say on pay" resolution regarding the Company&#8217;s approach to executive compensation.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All matters to be voted upon at the Meeting will be decided by a majority of the votes cast by the Shareholders entitled to vote thereon. In the event that there are more nominees for the election of directors than there are spaces on the Board, the election of directors will be determined by a plurality of votes cast by Shareholders entitled to vote thereon.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy confers discretionary authority upon the persons named therein with respect to amendments or variations to matters identified in the accompanying notice of the Meeting or with respect to such other matters as may properly come before the Meeting, or any adjournment thereof.  At the date hereof, management of the Company knows of no such amendments, variations or other matters to be presented for action at the Meeting, or any adjournment thereof.  However, if any other matters which are not now known to management should properly come before the Meeting, or any adjournment thereof, the persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy will vote on such matters in accordance with their best judgment.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Please note that ILJIN SNT Co. Ltd. (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ILJIN</font><font style="font-family:Arial;font-size:10pt;">&#8221;) has stated its intention to nominate four nominees for election as directors at the Meeting. You may receive solicitation materials from ILJIN seeking your proxy to vote for its nominees. The Company is not responsible for the accuracy of any information provided by, or relating to, ILJIN or its nominees contained in any proxy solicitation materials filed or disseminated by, or on behalf of, ILJIN or any other statements that ILJIN may otherwise make. </font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management is soliciting proxies for the election to the Board the persons named on the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy and urges you NOT to sign or return or vote any proxy card sent to you by ILJIN. If you have already voted using a proxy card sent to you by ILJIN, you can recast your vote using the Company's YELLOW proxy prior to the proxy voting deadline or revoke it by an instrument in writing executed by you or by your attorney duly authorized in writing, or if you (as a shareholder) are a corporation, executed under your corporate seal or by an officer or attorney duly authorized in writing, and deposited with the Company, c/o Computershare at the address set out above, at any time up to and including the last business day preceding the day of the Meeting, or any adjournment of that Meeting, or with the Chair of the Board on the day of the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under such proxy&#8217;s authority. Non-registered shareholders should closely follow the instructions provided to them from their intermediary.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s4961F42EB551569FBC0BDF215C910568"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.7&#160;&#160;&#160;&#160;VOTING SHARES AND PRINCIPAL HOLDERS THEREOF</font></div><div style="line-height:150%;padding-bottom:21px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is authorized to issue an unlimited number of Common Shares without nominal or par value.  As at the Record Date,</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">there were 91,792,958 Common Shares issued and outstanding as fully paid and non-assessable, each carrying the right to one vote per Common Share. To the knowledge of the Directors and Officers, as at the Record Date, no person beneficially owned, directly or indirectly, or exercised control or direction over, Common Shares of the Company carrying 10% or more of the voting rights attached to all outstanding voting Common Shares of the Company, except as follows:</font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.65900383141762%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:3%;"></td><td style="width:33%;"></td><td style="width:3%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of Common Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Percentage of Class</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">ILJIN Group*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13,716,567</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.94%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:6px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Common Shares held by ILJIN, ILJIN STEEL Co., Ltd. and ILJIN Semiconductor Co., Ltd. This information was taken from the Schedule 13D filing of ILJIN, ILJIN Semiconductor Co., Ltd., ILJIN Steel Co., Ltd., ILJIN C&amp;S Co. Ltd., Sae Kyoung Huh and Chin Kyu Huh dated April 8, 2019.</font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s1EBD0A0068605FE5B1EC445DF3733CCE"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART 2 <br>BUSINESS OF THE MEETING</font></div><div><a name="sC96735DA59E259A9AA3F129D64355574"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;ELECTION OF DIRECTORS </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table states the names of all of the persons proposed to be nominated by the Company for election as Directors, their municipality, province or state and country of residence, their age, their principal occupation, their position in the Company (if any), the period during which each proposed nominee has served as a Director, if applicable, and the number of Common Shares beneficially owned, directly or indirectly, by each of them or over which they exercise control or direction.  </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy intend to cast the votes to which the Common Shares represented by such </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy are entitled:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;FOR fixing the number of directors at eight; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;FOR the election of each of the nominees to the Board set forth in this Circular, </font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">unless otherwise directed by the Shareholders instructing them.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is not aware that any of the above nominees will be unable or unwilling to serve; however, should the Company become aware of such an occurrence before the election of directors takes place at the Meeting, if one of the persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#32;proxy is appointed as proxyholder, it is intended that the discretionary power granted under such proxy will be used to vote for any substitute nominee or nominees whom the Company in its discretion may select.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If elected, each Director elected will hold office until the next annual meeting of Shareholders or until his successor is duly elected, unless his office is vacated earlier in accordance with the by-laws of the Company or the ABCA. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:17%;"></td><td style="width:8%;"></td><td style="width:24%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Name, province or state, and country of residence</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Age</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(at May 9, 2019)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Present Principal Occupation</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Period During Which Served as a Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Common Shares Beneficially Owned, Controlled or Directed</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">No. of Securities Underlying Unexercised Stock Options</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. George M. Milne, Jr. </font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Boca Grande, Florida</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">United States</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">75</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Venture Partner at Radius Ventures LLC, a venture capitalist firm; Lead Director at Charles River Laboratories, a pre-clinical and clinical laboratory services corporation; and Director of Amylyx Pharmaceuticals, Inc., a pharmaceutical company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director, Chairman of the Board</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since May 8, 2017</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">80,000</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Peter Greenleaf</font></div><div style="padding-bottom:2px;padding-top:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Bethesda, Maryland</font></div><div style="padding-bottom:2px;padding-top:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">United States</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">49</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Chief Executive Officer ("</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">CEO</font><font style="font-family:Arial;font-size:8pt;">") of the Company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">and</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">CEO</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">CEO and Director since April 29, 2019</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1,600,000</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:16%;"></td><td style="width:8%;"></td><td style="width:24%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Name, province or state, and country of residence</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Age</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(at May 9, 2019)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Present Principal Occupation</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Period During Which Served as a Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Common Shares Beneficially Owned, Controlled or Directed</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">No. of Securities Underlying Unexercised Stock Options</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. David R.W. Jayne</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)(4)</sup></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Cambridge</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">United Kingdom</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">62</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Professor of Clinical Autoimmunity in the Department of Medicine at the University of Cambridge, UK; fellow of the Royal Colleges of Physicians of London and Edinburgh, and the Academy of Medical Science; certified nephrologist and an Honorary Consultant Physician at Addenbrooke&#8217;s Hospital, Cambridge UK; medical advisor to UK, U.S. and EU regulatory bodies, patient groups and professional organizations; elected the first President of the European Vasculitis Society in 2011; member of the ERA-EDTA immunopathology working group; co-chair of the EULAR/ERA-EDTA task force on lupus nephritis</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since May 26, 2015</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">90,000</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Hyuek Joon ("Joon") Lee</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)(3)</sup></font></div><div style="padding-bottom:8px;padding-top:8px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Seoul, Korea</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">52</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Managing Director of Business Development, ILJIN Group</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since May 26, 2015</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">90,000</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Joseph P. Hagan </font></div><div style="padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">La Jolla, California</font></div><div style="padding-bottom:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">United States</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">50</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">President and CEO of Regulus Therapeutics Inc., a biopharmaceutical company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 7, 2018</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">50,000</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Michael Hayden</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div><div style="padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Vancouver, British Columbia</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Canada</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">67</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director, Translational Laboratory in Genetic Medicine (TLGM), Agency for Science, Technology and Research (A*STAR), Singapore; Distinguished Professor, National University of Singapore; Killam Professor (Highest recognition), University of British Columbia, Vancouver, BC; Canada Research Chair, Human Genetics and Molecular Medicine; Senior Scientist, Centre for Molecular Medicine and Therapeutics, Vancouver, BC; Professor, Department of Medical Genetics, University of British Columbia, Vancouver, BC</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 21, 2018</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">50,000</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Daniel G. Billen</font></div><div style="padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Mississauga, Ontario</font></div><div style="padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Canada</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">66</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Retired, previously commercial GM/VP at Amgen Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Since April 29, 2019</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">20,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">50,000</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:17%;"></td><td style="width:8%;"></td><td style="width:24%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Name, province or state, and country of residence</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Age</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(at May 9, 2019)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Present Principal Occupation</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Period During Which Served as a Director</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Common Shares Beneficially Owned, Controlled or Directed</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">No. of Securities Underlying Unexercised Stock Options</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. R. Hector MacKay-Dunn, Q.C.</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">[Vancouver, British Columbia</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Canada]</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Senior Partner, Farris, Vaughan, Wills &amp; Murphy</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">none</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">n/a</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Member of the Audit Committee of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Member of the Compensation Committee of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Member of the Governance &amp; Nomination Committee of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:6.666666666666667px;"><div style="line-height:120%;text-align:justify;font-size:8pt;text-indent:-6.666666666666667px;"><font style="font-family:Arial;font-size:8pt;">Member of the Standing Research Committee of the Company. </font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Residency Requirements</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In considering nominees for election to the Board, in addition to looking at the expertise and experience necessary to support the Company&#8217;s strategy and operations, the Boards&#8217; selection is informed by certain limits imposed by Canadian and United States securities and corporate law.  The ABCA requires that at least one quarter (1/4) of the Company&#8217;s Directors be resident Canadians. In addition, in order to maintain its &#8220;foreign private issuer&#8221; status in the United States, among other things, not more than 50% of the Company&#8217;s Directors may be US citizens or residents (including green card holders).</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s nominees for election as Directors, as a group, would result in the Company remaining in compliance with its corporate and securities law obligations set out above.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Majority Voting Policy</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has adopted a majority voting policy where any nominee proposed for election as a Director is required to forthwith tender their resignation if the Director receives more </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">withheld</font><font style="font-family:Arial;font-size:10pt;">&#32;votes than </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">for</font><font style="font-family:Arial;font-size:10pt;">&#32;votes (i.e., a majority of withheld votes) at any meeting where Shareholders vote on the uncontested election of Directors. An </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">uncontested election</font><font style="font-family:Arial;font-size:10pt;">&#32;means the number of Director nominees for election is the same as the number of Directors to be elected to the Board.  Within 90&#160;days of the relevant Shareholders&#8217; meeting, the Board will make its determination whether or not to accept the resignation and issue a press release either announcing the resignation of the Director or explaining the reasons justifying its decision not to accept the resignation. The Board will accept the resignation absent exceptional circumstances and such resignation will be effective when accepted by the Board.  A Director who tenders a resignation pursuant to this policy will not participate in any meeting of the Board or any committee at which the resignation is considered.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As noted in the accompanying letter to shareholders, the Company has received notice from ILJIN that ILJIN intends to nominate four alternative nominees for election.  If ILJIN does proceed with nominating those alternative nominees at the Meeting, that will result in the Meeting being a contested election (meaning there are more nominees for the election of Directors than there are spaces on the Board) for the purposes of the majority voting policy and the majority voting </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">policy will accordingly not apply. In the event the Meeting has a contested election, the election of directors will be determined by a plurality of votes cast by Shareholders entitled to vote thereon.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Advance Notice Requirements</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s by-laws include advance notice provisions (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Advance Notice Provisions</font><font style="font-family:Arial;font-size:10pt;">") that require that advance notice must be provided to the Company in circumstances where nominations of persons for election to the Board are made by Shareholders other than pursuant to: (i) a "proposal" made in accordance with the ABCA; or (ii) a requisition of the Shareholders made in accordance with the ABCA.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Among other things, the Advance Notice Provisions fix a deadline by which holders of record of Common Shares must submit Director nominations to the secretary of the Company prior to any annual or special meeting of Shareholders and sets forth the specific information a Shareholder must include in the written notice to the secretary of the Company for an effective nomination to occur.  No person will be eligible for election as a Director unless nominated in accordance with the provisions of the Advance Notice Provisions.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the case of an annual meeting of Shareholders, notice to the Company must be made not less than 30 nor more than 65 days prior to the date of the annual meeting; provided, however, in the event that the annual meeting is to be held on a date that is less than 60 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the tenth day following such public announcement.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the case of a special meeting of Shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of business on the tenth day following the day on which the first public announcement of the date of the special meeting was made.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board may, in its sole discretion, waive any requirement of the Advance Notice Provisions.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Nominee Biographies</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A biography for each of the proposed nominees to the Board is set out below.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dr. George M. Milne, Jr., PhD</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">, Director, Chairman of the Board</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. George Milne has over 30 years of experience in pharmaceutical research and product development.  Dr. Milne currently serves on the boards of Amylyx Pharmaceuticals, Inc. and Charles River Laboratories, Inc. where he is the lead director.  He has retired from Pfizer Inc. where he served as Executive Vice President of Global Research and Development and President, Worldwide Strategic and Operations Management.  He joined Pfizer Inc. in 1970 and held a variety of positions conducting both chemistry and pharmacology research.  Dr. Milne became director of the department of immunology and infectious diseases at Pfizer Inc. in 1981, was its executive director from 1984 to 1985, and was Vice President of research and development from 1985 to 1988.  He was appointed Senior Vice President in 1988.  In 1993 he was appointed President of Pfizer Central Research and a Senior Vice President of Pfizer Inc. with global responsibility for human and veterinary medicine research and development.  Dr. Milne has also previously served on multiple corporate boards including Mettler-Toledo, Inc. (a manufacturer of laboratory instruments), MedImmune, Athersys, Biostorage </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technologies, Aspreva and Conor Medsystems.  Dr. Milne received his B.Sc. in Chemistry from Yale University and his Ph.D. in Organic Chemistry from Massachusetts Institute of Technology.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mr. Peter Greenleaf, MBA, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Director, CEO</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board since April 29, 2019. Prior to this, Mr. Greenleaf served as the Chief Executive Officer of Cerecor, Inc. (NASDAQ: CERC). Mr. Greenleaf remains on the board of directors of Cerecor, Inc., where he has served as a member of the board of directors since May 2017. From March 2014 to February 2018, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a company that focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide until it was sold in February 2018 to U.K. pharmaceutical giant Mallincrodt PLC. Mr. Greenleaf also served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Mr. Greenleaf also served as President of Medlmmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of Medlmmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of MedImmune, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson &amp; Johnson) from 1998 to 2006, and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority. He is also currently a member of the board of directors of Antares Pharmaceuticals, Inc (NASDAQ: ATRS), EyeGate Pharmaceuticals, Inc (NASDAQ: EYEG), and Chairman of the board of directors of BioDelivery Sciences International, Inc (NASDAQ: BDSI). Mr. Greenleaf earned an MBA degree from St. Joseph&#8217;s University and a BS degree from Western Connecticut State University.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dr. Hyuek Joon Lee, PhD, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Director</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Joon Lee is the Managing Director of Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. Dr. Lee has over 20 years of experience in consulting, management, business development and strategic planning in a number of industries including information technology, chemical and media.  Dr. Lee received his B.S. in Chemistry from Seoul National University, and his M.S.E. and Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dr. David R.W. Jayne, MD FRCP FRCPE FMedSci,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Director</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. David Jayne is Professor of Clinical Autoimmunity in the Department of Medicine at the University of Cambridge, UK.  Dr. Jayne received his MBBChir in Surgery and Medicine from Cambridge University, Cambridge, England.  He received postgraduate training at several London hospitals and Harvard University.  He is a fellow of the Royal Colleges of Physicians of London and Edinburgh, and the Academy of Medical Science.  He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke&#8217;s Hospital, Cambridge UK.  Dr. Jayne is a medical advisor to UK, U.S. and EU regulatory bodies, patient groups and professional organizations.  He has published more than 400 peer-reviewed journal articles, book chapters and reviews.  He was elected the first President of the European Vasculitis Society in 2011 and is a member of the ERA-EDTA immunopathology working group and he co-chairs the EULAR/ERA-EDTA task force on </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">lupus nephritis.  Dr. Jayne&#8217;s research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and SLE with collaborators on five continents.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mr. Joseph P. </font><font style="font-family:Arial;font-size:10pt;">"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Jay</font><font style="font-family:Arial;font-size:10pt;">"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;Hagan, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Director</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Joseph Hagan is President and Chief Executive Officer of Regulus Therapeutics. Mr. Hagan joined Regulus Therapeutics in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017.  Mr. Hagan&#8217;s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and head of corporate development for Amgen Inc.  Mr. Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value.  Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences.  Mr. Hagan currently serves on the board of directors of Zosano Pharma (NASDAQ: ZSAN), a publicly traded biotechnology company.  He received an MBA from Northeastern University and a BS in Physiology and Neuroscience from the University of California, San Diego.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dr. Michael Hayden, CM OBC MB ChB PhD FRCP(C) FRSC, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Director, Chair of the Standing Research Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Michael Hayden is the co-founder of five biotechnology companies: Prilenia Therapeutics, 89Bio, NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp.  Dr. Hayden sits on different boards including Xenon Pharmaceuticals Inc. and Ionis Pharmaceuticals.  Author of over 860 peer-reviewed publications and invited submissions, Dr. Hayden has focused his research primarily on genetic diseases, including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive and personalized medicine.  Dr. Hayden was inducted into the Canadian Medical Hall of Fame in 2017.  He was named one of PharmaVoice&#8217;s "100 of the Most Inspiring People" (2015); awarded an Honorary Doctor of Science by the University of Gottingen (2014); the Luminary award by the Personalized Medicine World Conference (2014); and the Diamond Jubilee Medal (2012), on behalf of HRH Queen Elisabeth II, in recognition of his significant contributions and achievements.  Dr. Hayden has also been awarded the Order of Canada (2011), and the Order of British Columbia (2010).  He was named Canada&#8217;s Health Researcher of the Year by CIHR (NIH of Canada) in 2008, and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dr. Daniel G. Billen</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">, </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PhD,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Director</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Daniel Billen has over 40 years of experience in commercialization of pharmaceutical and biotech products both in Europe and North America. He started with Janssen Pharmaceutica in their Belgian headquarters in cardiovascular global marketing in 1979.  Dr. Billen became head of marketing and sales for Janssen Pharmaceutica&#8217;s newly formed affiliate in Canada in 1983 launching multiple products into the Canadian market. In 1991, Dr. Billen moved over to Amgen Inc. to lead its Canadian operations as their first General Manager. He moved to Amgen&#8217;s headquarters in California in 2011 where he lead the US Commercial Operations Business Unit and later the combined Nephrology and Inflammation business unit as their VP/GM.  In 2017, Dr. Billen took on the role of VP of Global Commercial initiatives with focus on the evolving US payer landscape.  Dr. Billen received his PhD in chemistry from the University of Louvain in Belgium.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mr. R. Hector MacKay-Dunn, J.D., Q.C., </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Director Nominee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. MacKay-Dunn has over 30 years of practice experience providing legal advice to high growth public and private companies, many of which achieving valuations exceeding CDN$1billion over a broad range of industry sectors including life sciences, health, and technology, advising on corporate domestic and cross-border public and private securities offerings, mergers and acquisitions and international partnering and licensing transactions, and boards of directors and independent board committees on corporate governance matters.  Mr. MacKay-Dunn is recognized by Lexpert, as being among the Top 100 Canada/US Cross-Border Corporate Lawyers in Canada, has consistently been named among The Leading 500 Lawyers in Canada, and is recognized among Canada&#8217;s leading lawyers in mergers &amp; acquisitions, technology and biotechnology.  Mr. MacKay-Dunn received the Queen&#8217;s Counsel designation upon recommendation by the Attorney General of British Columbia for exceptional merit and contribution to the legal profession, the &#8220;AV Preeminent 5.0 out of 5&#8221; legal ability rating from Martindale-Hubbell, and is regularly recognized as a leading lawyer nationally by Chambers Canada within the Life Sciences category. Mr. MacKay-Dunn has served as board member or officer with Aspreva Pharmaceuticals Corporation, Arbutus Biophara Corp., XBiotech Inc., MedGenesis Therapeutix Inc., and QLT Inc., is a board member of the BC (British Columbia) Tech Association, previously board chair of the Innovation Council of British Columbia, and board member of LifeSciences British Columbia and Genome British Columbia.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Skills Matrix</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s director nominees bring a number of skills and experience to the Board. The image below gives a snapshot of the top skills of each director nominee. You can read about each nominee in the director nominee profiles above.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:22%;"></td><td style="width:9%;"></td><td style="width:9%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Dr. George M. Milne, Jr.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Mr. Peter Greenleaf</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#ffffff;font-weight:bold;">Dr. Hyuek Joon Lee</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Dr. David R.W. Jayne</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Mr. Joseph P. Hagan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Dr. Michael Hayden</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Dr. Daniel G. Billen</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;color:#ffffff;font-weight:bold;">Mr. R. Hector MacKay-Dunn</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Management/operations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">CEO/CFO/COO experience</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Industry experience</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Commercialization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Manufacturing/supply chain</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Government relations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Finance/financial industry</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Accounting/auditing</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Risk management</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Strategy development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mergers &amp; acquisitions</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Legal/regulatory</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Corporate governance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Capital markets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Executive compensation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Information technology</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Research/development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Clinical development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Business development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8730;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s15155C5E7D18544B99702C5C194961D2"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1.1&#160;&#160;&#160;&#160;Corporate Cease Trade Orders, Bankruptcies, Penalties or Sanctions</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To the knowledge of the Directors and Officers of the Company, no proposed Director of the Company:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">is, as at the date of this Circular, or has been, within ten years before the date of this Circular, a director, CEO or Chief Financial Officer ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CFO</font><font style="font-family:Arial;font-size:10pt;">") of any company, that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation that was issued while the proposed director was acting in the capacity as director, CEO or CFO that was in effect for a period of more than 30 consecutive days; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation that was issued after the proposed director ceased to be a director, CEO or CFO and which resulted from an event that occurred while that </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">person was acting in the capacity as director, CEO or CFO that was in effect for a period of more than 30 consecutive days; or</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">is, as at the date of this Circular, or has been within ten years before the date of this Circular, a director or executive officer of any company, that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">has, within the ten years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold its assets; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">has been subject to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable security holder in deciding whether to vote for a proposed director.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s0872E4E84039560B858F479616C8D44B"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1.2&#160;&#160;&#160;&#160;Directors&#8217; Attendance at Board and Committee Meetings  </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table sets forth the number of meetings held by the Board and each of its committees during the fiscal year ended December 31, 2018, and the attendance of each Director (in the case of committees of the Board, the attendance of each member of such committees) at those meetings. </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:21%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Director</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Board</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Audit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Compensation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Governance</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Research</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total Attendance</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Richard Glickman</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/10 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Benjamin Rovinski</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4 of 4</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3 of 3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">17/17 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Joon Lee</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4 of 4</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3 of 3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1 of 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">18/18 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. David Jayne</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1 of 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">2 of 2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">13/13 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Jeff Randall</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4 of 4</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3 of 3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">17/17 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. George M.  Milne, Jr.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9 of 10</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1 of 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/11 (91%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Joseph P. Hagan</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8 of 8</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8/8 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Michael Hayden</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8 of 8</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">2 of 2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/10 (100%)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Attendance Rate:</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">98.7%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">103/104 (99.0%)</font></div></td></tr></table></div></div><div style="line-height:150%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Joseph P Hagan was appointed as a Director on February 7, 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Michael Hayden was appointed as a Director on February 21, 2018.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s365ADA26F36E59849E6AF6BF5EAA5493"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1.3&#160;&#160;&#160;&#160;Other Board Membership</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table identifies the Directors and nominees for election as Directors who also act as directors for other reporting issuers.</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:29%;"></td><td style="width:38%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name of Issuer</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name of Exchange of Market</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Peter Greenleaf</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cerecor, Inc.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Antares Pharma, Inc.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">BioDelivery Sciences International, Inc.</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Eyegate Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:CERC</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ;ATRS</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:BDSI</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:EYEG</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. George Milne, Jr.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Charles River Laboratories International, Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NYSE:CRL</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Joseph P. Hagan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Zosano Pharma Corporation</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Regulus Therapeutics Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:ZSAN</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:RGLS</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Michael Hayden</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Xenon Pharmaceuticals Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ:XENE</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. R. Hector MacKay-Dunn</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Copper Fox Metals Inc.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">TSXV:CUU</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2B7D909B670458B88A45A35FBB083BBE"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1.4&#160;&#160;&#160;&#160;Directors&#8217; and Officers&#8217; Insurance and Indemnification</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains directors&#8217; and officers&#8217; liability insurance, which, subject to the provisions contained in the policy, protects the Directors and Officers, as such, against certain claims made against them in these capacities.  Such insurance currently provides for an aggregate of $40,000,000 annual protection against liability (less a deductible of up to $1,500,000 payable by the Company depending on the nature of the claim).  The premium for this coverage for the period June 4, 2018 to June 4, 2019 was $678,950.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">The Company has entered into indemnification agreements with each of its Directors and Officers and the officers of its subsidiaries. The indemnification agreements generally require that the Company indemnify and hold the indemnitees harmless to the greatest extent permitted by law for liabilities arising out of the indemnitees&#8217; service to the Company or its subsidiaries as Directors and Officers, provided that the indemnitees acted honestly and in good faith and in a manner the indemnitees reasonably believed to be in or not opposed to the Company&#8217;s best interests and, with respect to criminal and administrative actions or proceedings that are enforced by monetary penalty, the indemnitees had no reasonable grounds to believe that his or her conduct was unlawful. The indemnification agreements also provide for the advancement of defense expenses to the indemnitees by the Company.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s55CA77D590C85A418779F89766E5E13A"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;PRESENTATION OF FINANCIAL STATEMENTS AND AUDITORS' REPORT</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">audited</font><font style="font-family:Arial;font-size:10pt;">&#32;consolidated financial statements of the Company and the report of the auditors thereon, for the financial year ended December 31, 2018 will be tabled at the Meeting.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sF2FD8D18CE7258FF9FE9488F473E7567"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;APPOINTMENT AND REMUNERATION OF AUDITORS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board recommends that Shareholders vote for the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company and the authorization of the Audit Committee to fix the auditors&#8217; </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">remuneration.  </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy intend to cast the votes to which the Common Shares represented by such </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy are entitled FOR the re-appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company for the term expiring with the next annual meeting of Shareholders, and to authorize the Audit Committee to fix their remuneration, unless otherwise directed by the Shareholders appointing them.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Principal Accountant Fees and Services</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The aggregate fees recorded for professional services rendered by PricewaterhouseCoopers LLP for the Company for the years ended December 31, 2018 and 2017, respectively, are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Fiscal year ended</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fees</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Audit fees (for audit of the Company&#8217;s annual financial statements and services provided in connection with statutory and regulatory filings)</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">95,124</font></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31.5</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">130,583</font></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50.2</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Audit related fees, including review of the Company&#8217;s quarterly financial statements</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">37,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tax fees (tax compliance, tax advice and planning)</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">110,496</font></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">36.6</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">44,935</font></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17.3</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">All other fees</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">46,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">302,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">259,952</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">These fees include professional services provided by the external auditor for the statutory audits of the annual financial statements.  The total for 2018 is comprised of $56,910 related to interim billings for the 2018 audit and $38,214 related to fees for the 2017 audit billed in 2018.  The total for 2017 is comprised of $61,688 related to interim billings for the 2017 audit and $68,895 related to fees for the 2016 audit billed in 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">These fees relate to performing review engagement services on the Company&#8217;s quarterly financial statements and other audit related services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">These fees include professional services for transfer pricing, tax compliance, tax advice, tax planning and various taxation matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">These fees for 2018 include professional services for assistance in filing the short form base shelf prospectus from March 2018, the prospectus supplement related to the re-sale of Common Shares, the at-the-market prospectus supplement and various other advisory services.   These fees for 2017 include professional services for assistance in filing prospectus supplements for the December 2016 bought deal financing and the March 20, 2017 public offering, and a preliminary short form base shelf prospectus.   </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s00f197beb4fc43f28a4406844cac82f1"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;ADVISORY 'SAY ON PAY' VOTE ON EXECUTIVE COMPENSATION</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has determined to provide its Shareholders the opportunity to vote on the Company&#8217;s approach to executive compensation at the Meeting. Since the resolution is advisory in nature, it will not be binding. However, the Company, together with the Compensation Committee, will consider the outcome of the vote as part of its ongoing review of executive compensation. For information on the Company&#8217;s approach to executive compensation, see "Statement of Executive Compensation" beginning on page 18. </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The persons named in the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy intend to cast the votes to which the Common Shares represented by such </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;proxy are entitled FOR this advisory resolution, unless otherwise directed by the Shareholders appointing them.</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company considers that receiving feedback from its Shareholders on its approach to executive compensation to be best practices in terms of good governance. The Company believes that its approach to executive compensation (and the current levels of compensation of its executive team) is reasonable and aligned with best practices. However, the Company wishes to be responsive if a significant number of its Shareholders have concerns with respect to its current approach to executive compensation.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The full text of the advisory resolution on the Company&#8217;s approach to executive compensation is as follows: </font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">"BE IT RESOLVED, on an advisory basis and not to diminish the role and responsibilities of the Board, that the shareholders accept the approach to executive compensation disclosed in the Company&#8217;s information circular for the annual general meeting of shareholders of the Company held on June 26, 2019."</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFC4AB0FFCAD75CB1B2FCDBE7026A5B93"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART 3  <br>STATEMENT OF EXECUTIVE COMPENSATION</font></div><div><a name="s18BD7A5B90955378B28C85DBBD5DC2C8"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;COMPENSATION OF EXECUTIVES</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Composition and Mandate of the Compensation Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s compensation committee (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Compensation Committee</font><font style="font-family:Arial;font-size:10pt;">") consists of Dr. Benjamin Rovinski (Chair), Dr. Joon Lee and Mr. Jeff Randall.  All members of the Compensation Committee are independent.  The Compensation Committee is charged, on behalf of the Board, to discuss, review and approve compensation applicable to executive officers, including determining the benchmarks, criteria and performance metrics upon which executive compensation such as base salary, annual cash incentive, equity compensation and other benefits are based.  The Compensation Committee approves, among other things, the compensation of each of the Company&#8217;s Named Executive Officers (defined below), other than the CEO (whose compensation is determined by the Board, on recommendation from the Compensation Committee).</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All members of the Compensation Committee have direct experience that is relevant to their responsibilities in executive compensation, as set out below:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Benjamin Rovinski, the Chair of the Compensation Committee, has served on the Boards of several biotechnology companies for the past 15 years, and he has been a member of numerous compensation and audit committees.  Dr. Rovinski also was responsible for the design and implementation of benefit programs and compensation of senior non-executive employees in his previous capacity as Senior Scientist and Head of the Molecular Virology Department at Sanofi Pasteur.  In that leadership role, he also oversaw global project teams and implemented various performance management systems for the evaluation of corporate and strategic objectives and performance of senior level project team members. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Joon Lee has served as director and managing director in a number of companies in Korea, where he participated in the processes of evaluating corporate objectives and performance reviews of senior level managers and employees. As of October 2014, he joined the board of directors of Life Science Enterprises in Massachusetts, a privately held company focusing on advanced biomaterials that promote bone repair, and oversaw performance reviews, compensation and benefit packages of the senior management. In addition, his experience as a founding member of an information technology start-up grants him added insight into the dynamics of early stage companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Jeff Randall has over 30 years of experience serving in financial and operating roles spanning biotechnology, pharmaceuticals and manufacturing.  He has led a number of companies through multi-million-dollar financings and mergers and acquisitions.  In addition to his current board positions, Mr. Randall served on the board of directors of Nanosphere, Inc. from 2008 to 2016, most recently as Chairman of the Board.  From 2004 to 2006, Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company.</font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s3B90A727904A5CF6B7DA5BE5BC8C4095"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.1&#160;&#160;&#160;&#160;Compensation Discussion and Analysis</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following compensation discussion and analysis provides information regarding all significant elements of compensation paid, awarded or otherwise provided by the Company to its Named Executive Officers (defined below).  Specific information is provided for Dr. Richard Glickman, Chairman of the Board and CEO until April 29, 2019; Mr. Dennis Bourgeault, CFO; and the three other most highly compensated executive officers or individuals whose total individual compensation for the year ended December 31, 2018, was more than $150,000: namely, Dr. Neil Solomons, Chief Medical Officer; Mr. Michael Martin, Chief Operating Officer; and Dr.. Robert Huizinga, Executive Vice President, Corporate Development (collectively, the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Named Executive Officers</font><font style="font-family:Arial;font-size:10pt;">" or the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NEOs</font><font style="font-family:Arial;font-size:10pt;">").</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Information about the compensation awarded to the NEOs can be found in the "</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Summary Compensation Table</font><font style="font-family:Arial;font-size:10pt;">" and related compensation tables below.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s executive compensation program and strategy is designed to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">assist the Company in attracting and retaining talented executives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide a strong incentive for executives and key employees to work toward achievement of the Company&#8217;s goals and strategic objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">align management&#8217;s interests with those of Shareholders and other stakeholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">motivate executives towards the enhancement of long-term Shareholder value; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">be competitive with other companies of similar size and business.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To further these objectives, the Compensation Committee designs pay and performance systems that reflect the level of job responsibility with specific considerations while aligning the Company&#8217;s compensation programs with those of pharmaceutical companies of similar size and clinical stage.  It also aligns the annual cash incentive (bonus) program to the achievement of objectives that will drive future success and enhance Shareholder value by linking a significant portion of the bonus program to overall corporate performance and attainment of specific value enhancing goals and milestones.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annually, specific and measurable performance objectives are defined for each executive officer.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For 2018, the objectives, against which the executive officers were evaluated, included product development goals/milestones, organizational and business development objectives, and budget targets. There were no measurable performance goals based on share price or earnings per share.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s compensation program and strategy for its executive officers consists primarily of three main elements: base salary, an annual cash incentive (bonus), and equity-based compensation consisting of the grants of stock options.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Base salary is intended to provide a base compensation that reflects the executive&#8217;s experience and responsibilities and which is competitive with salaries of executives with similar responsibilities and experience at comparable companies.  Base salary provides regular compensation for assuming the responsibilities of the position and is paid in cash.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The annual cash incentive is intended to provide a greater incentive for executive officers to work toward achievement of the Company&#8217;s goals and strategic objectives.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The equity-based compensation is intended to better align the compensation of the CEO, other executive officers and key employees with the long-term interests of the Shareholders and reward the achievement of the long term strategic goals and objectives of the Company.  The equity-based compensation, which consists of the granting of time-release stock options, is awarded on a prospective, go-forward basis, to motivate, reward and retain executive officers, rather than as compensation for performance in the prior year.  The stock options are awarded on a discretionary basis by the Compensation Committee (other than to the CEO, which are awarded on a discretionary basis by the Board, on recommendation from the Compensation Committee), based on the combination of recommendations of independent third-party executive compensation consultants, contractual requirements and/or subjective assessments by the Compensation Committee.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Role of Executive Officers in Compensation Decisions</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Compensation Committee assesses the performance of the Company&#8217;s CEO and makes recommendations to the Board, and the Board approves all decisions regarding his compensation.  The Compensation Committee consults with and receives input and recommendations from the CEO regarding the performance, assessment and compensation of all the other executive officers and determines the compensation of such executives.  Although the Compensation Committee generally considers recommendations from the CEO, decisions regarding the compensation of the Company&#8217;s executive officers are made by the Compensation Committee and may reflect factors and consideration other than information and recommendations provided by the CEO.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Setting Executive Compensation</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Performance goals are determined early in the year for each executive officer and relate to milestones and/or achievements which aim to facilitate the Company&#8217;s overall goals and objectives.  These performance goals are assessed by the Compensation Committee. The Board makes the final determination in respect of setting the Company&#8217;s goals each year, based on the recommendation of the Compensation Committee. These objectives can be altered at the discretion of the Board if appropriate due to changes in business factors or conditions.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company annually determines the corporate objectives for purposes of the annual cash incentive bonus program.  Following the end of the year, the Compensation Committee assesses the achievement of such objectives with input from the CEO and based on such assessment, determines an aggregate cash incentive bonus for each executive officer.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The awarding of equity-based compensation is subject to the discretion of the Compensation Committee and Board, exercised annually, and is not subject to any minimum amount.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As part of its review of management compensation and incentive programs, the Compensation Committee, in conjunction with the CEO, retains external independent consultants to review and provide benchmark data of a comparator group of companies.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the fourth quarter of 2017, the Company engaged Arnosti Consulting Inc. ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Arnosti</font><font style="font-family:Arial;font-size:10pt;">"), to assist in updating the benchmarking data and provide advice on the total direct compensation (base salary, annual short and long-term incentives) for the NEO&#8217;s (and the Company&#8217;s other officers) for the 2018 fiscal year.  The Compensation Committee must pre-approve any additional services that Arnosti would provide to the Company at the request of management of the Company.  As part of its benchmarking and review process, Arnosti developed a comparator group, comprising 29 US-listed and /or Canadian-listed development stage companies (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2017 Peer Group</font><font style="font-family:Arial;font-size:10pt;">").  The Company&#8217;s market capitalization at the time fell into the middle of the market cap range.  The equity data used by Arnosti was obtained from Equilar, Inc. and Radford&#8217;s 2017 Global Life Sciences survey (mid-size public company data used for equity benchmarking).  The 2017 Peer Group consisted of the following 29 public companies:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:31%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Achaogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Calithera Biosciences, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reata Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aduro Biotech, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cara Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rigel Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alder Biopharmaceuticals Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Concert Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sangamo Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Abeona Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cytokinetics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sienna Biopharmaceuticals, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Akebia Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Epizyme, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Seres Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arbutus Biopharma Corp.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Glycomimetics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tetraphase Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Atara Biotherapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Kala Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">TG Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Axovant Sciences Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Keryx Biopharmaceuticals Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Xencor Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bellicum Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Karyopharm Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Zogenix, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biohaven Pharmaceutical Holding Co Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">La Jolla Pharmaceutical Co.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arnosti provided the Compensation Committee with its recommendations regarding NEO total direct compensation based on the benchmarking work it performed.  The Compensation Committee considered the advice from Arnosti where appropriate and in conjunction with its own assessment of competitive compensation requirements the Compensation Committee adjusted base salary levels as indicated in section 3.1.5.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company further engaged Arnosti in the fourth quarter of 2018 to assist in updating the benchmarking data and provide advice on the total direct compensation (base salary, annual short and long-term incentives) for the NEO&#8217;s (and the Company&#8217;s other officers) for the 2019 fiscal year.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As part of its 2019 benchmarking and review process, Arnosti (in consultation with the Compensation Committee) developed a 2019 comparator group, comprising 25 US-listed development stage companies (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2019 Peer Group</font><font style="font-family:Arial;font-size:10pt;">").  The Company&#8217;s market capitalization at the time fell into the middle of the market cap range.  The equity data used by Arnosti was obtained from Equilar, Inc. and Radford&#8217;s 2018 Global Life Sciences survey (mid-size public company data used for equity benchmarking).  The 2019 Peer Group consisted of the following 25 public companies:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:28%;"></td><td style="width:39%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acceleron</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bellicum Pharmaceuticals, Inc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Omeros</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aduro Biotech, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biohaven Pharmaceutical Holding Co Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paratek</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aerie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cara Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aimmune</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chemocentryx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Seres Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Akebia Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Concert Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sienna Biopharmacetuticals, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alder Biopharmaceuticals Inc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Epizyme, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tetraphase Pharmaceuticals Inc</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ardelyx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Glyconimetics Inc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">TG Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Atara Biotherapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Kala Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Axovant Sciences Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Karyopharm Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arnosti provided the Compensation Committee with its recommendations regarding 2019 NEO (and the Company&#8217;s other officers) total direct compensation based on the benchmarking work it performed.  The Compensation Committee considered the advice from Arnosti where appropriate, and in conjunction with its own assessment of competitive compensation requirements, the Compensation Committee adjusted its base salary levels as it deemed appropriate. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In general, the Company aims to achieve competitive compensation based on the comparator group.  Individual elements comprise base salary, bonus and total direct compensation (total cash compensation plus long-term incentive awards).  </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The elements of compensation are targeted at the 50</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile of the comparator group. In 2018, base salary for each of the NEOs, other than Richard Glickman (the Company&#8217;s prior CEO), was under the 25</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile for comparable roles in the comparator group.  Base salary for Richard Glickman was under the 50</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile for CEOs in the comparator group.  In addition, the percentage of salary payable as a bonus to each of the NEOs, other than Richard Glickman, was at the 50</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile for comparable roles in the comparator group. Richard Glickman&#8217;s percentage of salary payable as a bonus was above the 50</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile for CEOs in the comparator group. Further, the number of stock options granted as equity awards to each of the NEOs, other than Robert Huizinga, were between the 25</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;and 50</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;percentile for comparable roles in the comparator group based on equity ownership awards to comparable roles in the comparator group.  Robert Huizinga&#8217;s stock option grant in 2018 was the first time stock options had been granted to him since his promotion to Executive Vice President, Corporate Development in mid-2017, and was intended to reflect that elevation in role and responsibility.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Executive Compensation-Related Fees</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia was previously billed $15,000 in 2017 by Radford, a business unit of Aon plc ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Radford</font><font style="font-family:Arial;font-size:10pt;">") for executive compensation consulting services provided to the Company for the 2017 compensation review.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia was billed $7,200 in 2018 and $4,655 in 2017 by Arnosti for executive compensation consulting services provided to the Company for the 2018 compensation review.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia was also billed $11,250 in 2018 and $5,000 in 2019 by Arnosti for executive compensation consulting services related to the 2019 compensation review.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">All Other Fees</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company did not pay any fees to Arnosti or Radford or any other compensation consultant for any other consulting services in 2018.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s9F5C5D59460058B38DBE198DD014E1AE"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.2&#160;&#160;&#160;&#160;Managing Compensation Risk</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On an annual basis, or otherwise more frequently as circumstances require, the Compensation Committee considers whether the executive compensation programs create or incentivize any inappropriate risk-taking.  It is important to undertake such an analysis because it is expected that going forward annual performance-based incentives will continue to play a primary role in NEO&#8217;s and other senior management&#8217;s compensation programs.  Therefore, the Company must ensure that these incentives do not result in actions being taken that are not in the long-term interest of the Company.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The compensation plan and program utilized for the NEOs in 2018 considered both short-term incentives and long-term incentives to enhance the balance between risk and reward in relation to the Company&#8217;s overall business strategy and to further discourage the taking of unnecessary or excessive risks.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2018 Executive Compensation Elements</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the fiscal year ended December 31, 2018, the principal components of compensation for the Company&#8217;s CEO and the other NEOs consisted of base salary, annual cash incentive bonus program and equity-based program consisting of stock option grants.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Base Salary</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On February 6, 2017, Dr. Glickman was appointed President and CEO of the Company with a base salary of US $504,000 per year (which was converted to CDN$661,097 based on the noon Bank of Canada rate on February 6, 2017).  Dr. Glickman&#8217;s salary was payable in Canadian dollars and paid semi-monthly.  See also "</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Employment Contracts with Named Executive Officers</font><font style="font-family:Arial;font-size:10pt;">".  Dr. Glickman&#8217;s base salary was approved by the Board based on the recommendation of the Compensation Committee at the time.  In determining recommendations for his total compensation as the new CEO, the Compensation Committee considered Dr. Glickman&#8217;s experience and expertise, the needs of the Company, the compensation of the previous CEO, and CEO compensation with pharmaceutical companies of a similar size and nature.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The base salary levels for the other NEOs of the Company are based on the executive&#8217;s overall experience and responsibilities and are reviewed annually.  The salaries of the NEOs for 2018 were determined primarily on the basis of the Compensation Committee&#8217;s review of an independent compensation review conducted in 2017.  See "</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Employment Contracts with Named Executive Officers</font><font style="font-family:Arial;font-size:10pt;">" for the base salary information.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">b) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Annual Cash Incentive Bonus Program</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The annual cash incentive bonus program generally provides a performance-based cash incentive to NEOs.  The program awards individual performance that leads to the achievement of annual corporate objectives.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The executive officers, pursuant to their employment agreements, are entitled to receive a target annual cash bonus.  The 2018 annual cash bonus target for the CEO was 70% of base salary and 40% for the other NEOs which was unchanged from 2017.  However, the actual cash bonus that each NEO receives can be higher or lower than the target value based on the formula for determining the amount of actual cash bonus that each NEO may be entitled to under the incentive program and may be subject to further adjustments at the discretion of the Compensation Committee and the Board.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After the end of the year, the Compensation Committee reviewed and approved bonuses to be paid based on the achievement of the performance objectives that had been set and approved by the Compensation Committee at the beginning of the 2018 fiscal year.  The Company accrued the amount of the approved bonuses in 2018 as they were earned by the NEOs during the year.  The Company paid the bonuses in the first quarter of 2019.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the beginning of 2018, key corporate objectives were set by the Board to represent a broad range of activities that span the Company&#8217;s business.  The weights are intended to reflect the relative priority, importance and impact of each objective on the Company&#8217;s success.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For 2018, the Company&#8217;s corporate objectives were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Clinical and regulatory objectives</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clinical and regulatory activities were a major focus of the 2018 corporate objectives.  These objectives included target dates related to completion of patient enrollment in the AURORA Phase 3 LN clinical trial, VOS trial initiation and completion, and FSGS trial initiation.   A total of 70% of the corporate objectives was allocated to the clinical and regulatory components.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other objectives</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other objectives comprised 30% of the 2018 corporate objectives and were focused on budget targets, development of a research plan, and industry, patient and investor awareness and visibility programs.  Measurement of these objectives was based on internal metrics.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Compensation Committee determined that a 90% score appropriately reflected the Company&#8217;s overall strong corporate performance results, particularly with regards to the clinical objectives, against the targeted achievement level.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Glickman, as CEO, was eligible, pursuant to his employment agreement, for a bonus based on 70% of base salary upon achieving specific corporate performance objectives as approved by the Board.  For the year ended December 31, 2018, he earned a bonus of $343,000 based on the overall corporate performance result of 90%.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the year ended December 31, 2018, Mr. Bourgeault, Dr. Solomons, Mr. Martin and Dr. Huizinga were entitled to receive bonuses based on 40% of base salary weighted as 60% against corporate objectives as listed above and 40% against personal objectives, as agreed and approved by the CEO and the Compensation Committee.  The Compensation Committee awarded bonuses to these NEOs which ranged from 88.7% to 96.8% of the combined corporate and personal objectives for 2018.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the year ended December 31, 2018, Mr. Bourgeault, Dr. Solomons, Mr. Martin and Dr. Huizinga earned bonuses of $86,220, $130,856, $97,882 and $115,935 respectively, related to the achievement of 2018 objectives.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">c) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Option-based Awards</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Stock Option Plan, the Board may, in its discretion, grant options to purchase Common Shares to Directors, Officers, employees and consultants of the Company or any of its subsidiaries.  The exercise price of options under the Stock Option Plan must not be less than the closing price of the Common Shares on the TSX immediately preceding the date of the grant.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company makes grants under the Stock Option Plan on a prospective going-forward basis. The options granted to Officers and other key employees are granted by the Compensation Committee, other than options to be granted to the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CEO or Directors, which are granted by the Board.  In determining whether or not to make option grants, the Board, the Compensation Committee and the CEO take into account previous and other awards of stock options to the grantees, relative ownership position and length of service to the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The number of stock options granted to the NEOs in 2018 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.49425287356321%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:53%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Richard Glickman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">400,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Dennis Bourgeault</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">150,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Neil Solomons</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">175,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Michael Martin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">150,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Robert Huizinga</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">225,000</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s53B07114B0B354BBBCC98287A2162A36"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.3&#160;&#160;&#160;&#160;Performance Graph</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following chart sets out the performance of the Common Shares on the TSX and TSX Venture Exchange for the past five years, as compared to the most appropriate indexes (the S&amp;P TSX Composite Index and NASDAQ Biotechnology Index), assuming an investment of $100 at the beginning of such period.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Common Shares were traded under the symbol "ISA" on the TSX from the commencement of the applicable period to September 27, 2013.  The Common Shares commenced trading on the TSX Venture Exchange on September 30, 2013 under the same symbol.  On October 23, 2013, the Company changed its name to Aurinia Pharmaceuticals Inc. and commenced trading under the symbol "AUP", remaining on the TSX Venture Exchange.  On that same date, the Company conducted a consolidation of its Common Shares on a 50:1 basis.  The Company recommenced trading on the TSX under the symbol "AUP" on June 2, 2014.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The values set out in the graph below have been adjusted to reflect the consolidation having occurred throughout the entire period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="perfgraph.jpg" alt="perfgraph.jpg" style="height:248px;width:576px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:22%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aurinia</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$100.00 </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$110.67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$92.80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$75.47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$152.53</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$247.47</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">S&amp;P TSX Composite</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$100.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$107.64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$95.70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$112.46</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$119.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$105.36</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NASDAQ Biotechnology Index </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$100.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$133.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$149.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$116.82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$143.37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$127.86</font></div></td></tr></table></div></div><div style="line-height:150%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The trend in overall compensation paid to the NEO&#8217;s over the past five years has generally not tracked the performance of the market price of the Common Shares nor has it tracked the S&amp;P/TSX Composite Index during the period.  The Company has not included market price targets of the Common Shares as a component in any part of the Company&#8217;s executive compensation program and strategy.  As the Company is currently a research and development company, the Company requires significant employee contribution for long periods while it conducts research, the efforts and value of which are unlikely to be fully reflected in the Company&#8217;s market price until such time as the research and development is completed and announced. </font></div><div style="line-height:150%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s7E40737B98C05EDBA78FE9014D785A00"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.4&#160;&#160;&#160;&#160;Anti-Hedging Protection</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has a written code of business conduct (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Code</font><font style="font-family:Arial;font-size:10pt;">") for its Directors, Officers and employees, which is filed on the Company&#8217;s website at www.auriniapharma.com.  The Code requires that all employees act at all times in full compliance with all laws applicable to the business of the Company.  The Board implemented a written anti-hedging policy for all employees, Directors and senior officers of the Company on March 8, 2012.  This policy specifically prohibits a Director or NEO from purchasing financial instruments designed to hedge or offset a decrease in market value of any Common Shares granted as compensation or held, directly or indirectly, by the NEO or Director.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s25F3B6CF91A755C583A04B680E5669D4"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.5&#160;&#160;&#160;&#160;Summary Compensation Table</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table details the compensation information for each of the Company&#8217;s three most recently completed financial years for the NEOs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:13%;"></td><td style="width:6%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:9%;"></td><td style="width:8%;"></td><td style="width:15%;"></td><td style="width:13%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name and principal position</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Year</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Salary</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Share-based awards ($)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option-based awards</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-equity incentive plan compensation </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Pension value</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">All other compensation</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(17)</sup></font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">compensation</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Annual incentive plans</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Long-term incentive plans</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Richard Glickman</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Chairman,</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">President and CEO</font><font style="font-family:Arial;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2018</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">544,250</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">914,874</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">343,000</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,802,124</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">465,628</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,249,019</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(10)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">396,568</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(16)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,111,215</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">103,220</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(18)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">103,220</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Dennis Bourgeault</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Chief Financial Officer</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2018</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">242,969</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">351,432</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,220</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">680,621</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2017</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">215,528</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">374,836</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(11)</sup></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90,956</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">681,320</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2016</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">203,175</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">67,313</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(15)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">58,126</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">328,614</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Neil Solomons</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Chief Medical Officer</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2018</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">340,351</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">410,004</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">130,856</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">881,211</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">329,375</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">325,572</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(12)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">137,233</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">792,180</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">244,939</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">67,313</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(15)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89,864</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">402,116</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Robert Huizinga</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Executive Vice President, Corporate Development</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2018</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">320,330</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">527,149</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(8)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">115,935</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">963,414</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2017</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">290,312</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">235,611</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(13)</sup></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">121,880</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">647,803</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">188,125</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">67,313</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(15)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69,340</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">324,778</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Michael Martin</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-style:italic;">Chief Operating Officer</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2018</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">252,688</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">351,432</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">97,882</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">702,002</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">231,492</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">192,773</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(14)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101,851</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">526,116</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">218,225</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">67,313</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(15)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,431</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">347,969</font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:4px;padding-top:8px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">otes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Glickman did not receive any additional remuneration relating to his position as a Director or as the Chairman of the Board in 2017 and 2018. Dr. Glickman's 2017 salary was for the period between February 6, 2017 (the date he was appointed Chief Executive Officer) and December 31, 2017.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The salaries of the NEOs are paid in Canadian dollars which is converted into US dollars at an average quarterly rate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculated as of the grant date using the Black-Scholes option pricing model.  The value shown is calculated by multiplying the number of stock options granted by the Canadian dollar exercise price at the time of grant by the Black-Scholes valuation factor and converting the value into US$ using the Bank of Canada closing rate</font><font style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">on the date of granting of the options.  The value is the same as the accounting fair value of the full grant but is not adjusted by the vesting schedule.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Annual Incentive Plan amounts for each NEO are calculated initially in Canadian dollars and converted into US dollars at the year-end rate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 400,000 options at an exercise price of CDN$6.42; Black-Scholes valuation factor = CDN$2.8314- converted into US$ at a rate of US$1.00 = CDN$1.2379. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 150,000 options at an exercise price of CDN$6.52; Black-Scholes valuation factor = CDN$2.8800 - converted into US$ at a rate of US$1.00 = CDN$1.2293. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 175,000 options at an exercise price of CDN$6.52; Black-Scholes valuation factor = CDN$2.8800 - converted into US$ at a rate of US$1.00 = CDN$1.2293. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 225,000 options at an exercise price of CDN$6.52; Black-Scholes valuation factor = CDN$2.8800 - converted into US$ at a rate of US$1.00 = CDN$1.2293. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 150,000 options at an exercise price of CDN$6.52; Black-Scholes valuation factor = CDN$2.8800 - converted into US$ at a rate of US$1.00 = CDN$1.2293. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 1,050,000 options at an exercise price of CDN$4.21; Black-Scholes valuation factor = CDN$2.8147 - converted into US$ at a rate of US$1.00 = CDN$1.3141. These options were granted in connection with the appointment of Dr. Glickman as the Company&#8217;s Chief Executive Officer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 175,000 options at an exercise price of CDN$4.21; Black-Scholes valuation factor = CDN$2.8147 - converted into US$ at a rate of US$1.00 = CDN$1.3141. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 152,000 options at an exercise price of CDN$4.21; Black-Scholes valuation factor = CDN$2.8147 - converted into US$ at a rate of US$1.00 = CDN$1.3141. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 110,000 options at an exercise price of CDN$4.21; Black-Scholes valuation factor = CDN$2.8147 - converted into US$ at a rate of US$1.00 = CDN$1.3141. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(14)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 90,000 options at an exercise price of CDN$4.21; Black-Scholes valuation factor = CDN$2.8147 - converted into US$ at a rate of US$1.00 = CDN$1.3141. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(15)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 40,000 options at an exercise price of CDN$3.91; Black-Scholes valuation factor = CDN$2.3824 - converted into US$ at a rate of US$1.00 = CDN$1.2965.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(16)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Represents the one-time bonus of $50,000 paid to Dr. Glickman upon entering into his employment agreement, plus the 2017 earned bonus of $346,568.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(17)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The total amount of other annual compensation including perquisites for the remaining NEO&#8217;s on an aggregate basis, generally including group insurance benefits, does not exceed the lesser of $50,000 and 10% of their annual cash compensation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(18)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Represents fees of $88,419 and option-based awards of $14,801 earned as a Chairman of the Board.</font></div></td></tr></table><div style="line-height:150%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="sD5174FBE41355FDC8BE730021CB258BC"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.6&#160;&#160;&#160;&#160;Narrative Discussion of Compensation </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of the employment agreements for each of the NEOs of the Company:</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Dr. Richard M. Glickman, Former Chairman, President and CEO</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On February 6, 2017, Dr. Glickman entered into an employment agreement with the Company for the position of CEO.  In addition to the base salary, Dr. Glickman was also eligible to receive a cash bonus with a target payment of 70% of his base salary if the Board, in its sole discretion, determined that the Company&#8217;s performance had met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  In addition, Dr. Glickman was entitled to participate in the Company&#8217;s benefits program and to vacation of 30 business days per year.  The base salary is reviewed annually by the Board.  Dr. Glickman agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Dr. Glickman&#8217;s employment agreement, termination and change of control benefits were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Glickman&#8217;s employment is terminated by the Company without cause after the first year of his employment, he is entitled to receive a payment in lieu of notice equivalent to 12 months of his then current base salary, plus one additional month&#8217;s base salary for each full year of employment beyond the first 12 months of employment, up to a maximum of 18 months.  If some or all bonus objectives have been satisfied prior to his last day of work for the Company, he will be entitled to a performance bonus pursuant to the performance bonus section of the employment agreement for the year of termination, with the amount to be determined based on the objectives satisfied.  In addition, the Company is to maintain health and medical benefits pursuant to the benefits section of </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-left:36px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">the employment agreement for the duration of the notice period.  Notwithstanding the terms of the Company&#8217;s Stock Option Plan, all vested stock options will be extended to the original expiry date of the vested stock options.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Glickman&#8217;s employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Dr. Glickman is entitled to receive a lump sum payment in lieu of notice equal to 18 months of his then current base salary, and if awarded and payable, the bonus for that year.  In addition, the Company is to maintain health and medical benefits pursuant to the benefits section of the employment agreement during the 12-month period following the termination date.  All of Dr. Glickman&#8217;s unexercised stock options will immediately vest upon the termination of his employment and shall be fully exercisable in accordance with the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 29, 2019, Dr. Richard Glickman, who previously announced his plans to retire on November 6, 2018, resigned from his position as an officer and director of the Company.  The Company entered into a Retirement Transition Agreement with him (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Retirement Agreement</font><font style="font-family:Arial;font-size:10pt;">") whereby Dr. Glickman agreed to remain as an advisor to the Company&#8217;s new CEO for a period of 12 months from the date he ceased his duties as CEO.  Pursuant to the Retirement Agreement, Dr. Glickman is entitled to receive the cash bonus he would have been eligible to receive pursuant to his employment agreement had he not retired, such bonus to be pro-rated to May 6, 2019.  In addition, any stock options that remain unvested as at May 6, 2019 will vest equally on the last day of each month (over 12 months) during which Dr. Glickman has made himself reasonably available to the Company&#8217;s new CEO. All Dr. Glickman's vested options will be permitted to be exercised for a period of 15 months following May 6, 2019.  Pursuant to the Retirement Agreement, Dr. Glickman continues to be bound by the non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions of the employment agreement, with the exception that the restrictive covenants have been extended from six months to 12 months from May 6, 2019.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Peter Greenleaf was appointed as CEO on April 29, 2019.  Although Mr. Greenleaf is not an NEO as at December 31, 2018, the key terms of his compensation and employment agreement are set out later in this section.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Dr. Neil Solomons, MD, Chief Medical Officer</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 12, 2012, Dr. Neil Solomons entered into an employment agreement with Aurinia Pharma Corp. for the position of Chief Medical Officer.  The employment agreement became effective 15 days after the completion of the Plan of Arrangement between Aurinia Pharma Corp. and the Company on September 20, 2013.  The agreement provides that Dr. Solomons will devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis.  In addition to his base salary, which is reviewed annually by the Board, Dr. Solomons is eligible to receive a cash bonus with a target payment of 40% of his base salary if the Board, in its sole discretion, determines that the Company&#8217;s performance has met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  Dr. Solomons is entitled to receive stock options pursuant to the Stock Option Plan as may be determined by the Board from time to time.  In addition, Dr. Solomons is entitled to participate in the Company&#8217;s benefits program and to paid vacation of 30 business days per year.  Dr. Neil Solomons agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Dr. Solomons&#8217; employment agreement, termination and change of control benefits are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Solomons&#8217; employment is terminated by the Company without cause, he will be entitled to receive a payment in lieu of notice equivalent to 12 months of his then current base salary, plus one additional month&#8217;s base salary for each full year of employment, up to a maximum of 18 months in the aggregate, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement for the duration of the notice period.  All of Dr. Solomons&#8217; unexercised vested options would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Solomons&#8217; employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Dr. Solomons is entitled to receive a lump sum payment in lieu of notice equal to 150% of 12 months of his then current base salary, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement during the 12-month period.  All of Dr. Solomons&#8217; unexercised stock options would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Mr. Michael Martin, Chief Operating Officer</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 12, 2012, Mr. Michael Martin entered into an employment agreement with Aurinia Pharma Corp. for the position of Chief Operating Officer.  The employment agreement became effective 15 days after the completion of the Plan of Arrangement between Aurinia Pharma Corp. and the Company on September 20, 2013.  The agreement provides that Mr. Martin will devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis.  His salary is reviewed annually by the Company.  Mr. Martin is eligible to receive a cash bonus with a target payment of 40% of his base salary if the Board, in its sole discretion, determines that the Company&#8217;s performance has met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  Mr. Martin is entitled to receive stock options pursuant to the Stock Option Plan as may be determined by the Board from time to time.  In addition, Mr. Martin is entitled to participate in the Company&#8217;s benefits program and to paid vacation of 30 business days per year.  Michael Martin agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Mr. Martin&#8217;s employment agreement, termination and change of control benefits are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Martin&#8217;s employment is terminated by the Company without cause, he will be entitled to receive a payment in lieu of notice equivalent to 12 months of his then current base salary, plus one additional month&#8217;s base salary for each full year of employment, up to a maximum of 18 months in the aggregate, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement for the duration of the notice period.  All of Mr. Martin&#8217;s unexercised vested options would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Martin&#8217;s employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Mr. Martin is entitled to receive a lump sum payment in lieu of notice equal to 150% of 12 months of his then current base salary, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement during the 12-month period.  All of Mr. Martin&#8217;s unexercised stock options would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Mr. Dennis Bourgeault, CFO</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Dennis Bourgeault entered into a new employment agreement effective October 1, 2018 respecting his employment as an executive of the Company, replacing the previous employment contract entered into on June 19, 2009. The agreement provides that Mr. Bourgeault will devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis.  His salary is reviewed annually by the Company.  Mr. Bourgeault is eligible to receive a cash bonus with a target payment of 40% of his base salary if the Board, in its sole discretion, determines that the Company&#8217;s performance has met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  Mr. Bourgeault is entitled to receive stock options pursuant to the Stock Option Plan as may be determined by the Board from time to time.  In addition, Mr. Bourgeault is entitled to participate in the Company&#8217;s benefits program and to paid vacation of 30 business days per year.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Bourgeault is also entitled to receive a retention incentive, granted to him in 2012, whereby he shall receive 0.1675% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.025% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company.  Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger, Mr. Bourgeault will be entitled to receive 0.025% of the value attributable to voclosporin in the transaction, and his entitlement to further royalty or sales payments shall end.  The entitlement to receive any payments pursuant to this section will immediately end if Mr. Bourgeault is terminated with cause. Should his employment be terminated without "cause", Mr. Bourgeault will have a continuing right to receive payments pursuant to this section.  Further, in the event his employment ends after October 1, 2019 as a result of (i) resignation for "good reason" (ii) retirement or (iii) a frustration of contract arising from a disability, Mr. Bourgeault will be entitled to receive payments pursuant to this section.  Notwithstanding any of the foregoing, Mr. Bourgeault&#8217;s right to receive payments pursuant to this section shall immediately terminate upon death.  Dennis Bourgeault agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Mr. Bourgeault&#8217;s employment agreement, termination and change of control benefits are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Bourgeault&#8217;s employment is terminated by the Company without cause or by the executive for "good reason", Mr. Bourgeault is entitled to receive a cash payment in lieu of notice equivalent to 18 months of his annualized base salary then in effect, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement. All of Mr. Bourgeault&#8217;s unexercised vested options would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Bourgeault&#8217;s employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Mr. Bourgeault is entitled to receive a lump sum payment in lieu of notice equal to 150% of 12 months of his annualized base salary then in effect, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement during the 12-month period.  All of Mr. Bourgeault&#8217;s unexercised stock options would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Dr. Robert B. Huizinga, Executive Vice President, Corporate Development</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Robert Huizinga entered into a new employment agreement effective October 1, 2018 respecting his employment as an executive of the Company, replacing the previous employment contract entered into on January 1, 2012. The agreement provides that Dr. Huizinga will devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis.  His salary is reviewed at least annually by the Company.  Dr. Huizinga is eligible to receive a cash bonus with a target payment of 40% of his base salary if the Board, in its sole discretion, determines that the Company&#8217;s performance has met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  Dr. Huizinga is entitled to receive stock options pursuant to the Stock Option Plan as may be determined by the Board from time to time.  In addition, Dr. Huizinga is entitled to participate in the Company&#8217;s benefits program and to paid vacation of 30 business days per year.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Huizinga is also entitled to receive a retention incentive, granted to him in 2012, whereby he shall receive 0.1675% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.025% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company.  Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger, Dr. Huizinga will be entitled to receive 0.025% of the value attributable to voclosporin in the transaction, and his entitlement to further royalty or sales payments shall end.  The entitlement to receive any payments pursuant to this section will immediately end if Dr. Huizinga is terminated with cause. Should his employment be terminated without "cause", Dr. Huizinga will have a continuing right to receive payments pursuant to this section.  Further, in the event his employment ends after October 1, 2019 as a result of (i) resignation for "good reason" (ii) retirement or (iii) a frustration of contract arising from a disability, Dr. Huizinga will be entitled to receive payments pursuant to this section.  Notwithstanding any of the foregoing, Dr. Huizinga&#8217;s right to receive payments pursuant to this section shall immediately terminate upon death.   Dr. Robert Huizinga agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Dr. Huizinga&#8217;s employment agreement, termination and change of control benefits are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Huizinga&#8217;s employment is terminated by the Company without cause or by the executive for "good reason", Dr. Huizinga is entitled to receive a cash payment in lieu of notice equivalent to 18 months of his annualized base salary then in effect, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement. All of Dr. Huizinga&#8217;s unexercised vested options would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Dr. Huizinga&#8217;s employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Dr. Huizinga is entitled to receive a lump sum payment in lieu of notice equal to 150% of 12 months of his annualized base salary then in effect, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, the Company is to maintain the benefits pursuant to the benefits section of the employment agreement during the 12-month period.  All of Dr. Huizinga&#8217;s unexercised stock options would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Mr. Peter Greenleaf, CEO (Effective April 29, 2019)</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, Mr. Peter Greenleaf entered into an employment agreement with the Company for the position of CEO commencing on April 29, 2019.  The agreement provides that Mr. Greenleaf devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis and that he will serve as a member of the Board.  In addition to his base salary of $650,000, Mr. Greenleaf will receive a signing bonus of $250,000 conditional upon his remaining employed by the Company for a period of 12 months from April 29, 2019.  Mr. Greenleaf is eligible to receive a performance bonus with a target payment of 70% of his base salary if the Board, in its sole discretion, determines that the Company&#8217;s performance had met certain short-term and long-term business performance objectives established from time to time by the Board, subject to any rules the Company may develop regarding the bonus scheme.  Mr. Greenleaf is entitled to receive an initial grant of 1,600,000 stock options subject to the Company&#8217;s insider trading guidelines and the blackout provisions therein. In addition, Mr. Greenleaf is entitled to participate in the Company&#8217;s benefit program and to vacation of 30 business days per year.  The base salary is reviewed annually by the Board.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Greenleaf&#8217;s base salary was approved by the Board based on the recommendation of the Compensation Committee at the time.  In determining recommendations for his total compensation as the new CEO, the Compensation Committee considered Mr. Greenleaf&#8217;s experience and expertise, the needs of the Company, the compensation of the previous CEO, and CEO compensation with pharmaceutical companies of a similar size and nature.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to Mr. Greenleaf&#8217;s employment agreement, termination and change of control benefits are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Greenleaf&#8217;s employment is terminated by the Company without cause, he is entitled to receive continuing payments of severance pay for a period of 12 months, plus one additional month for each full year of employment, up to a maximum of 18 months in the aggregate, equal to his then current base salary, plus such other sums, if granted, pursuant to the performance bonus section of the employment agreement.  In addition, to the extent permitted by law and subject to the terms and conditions of any benefit plans in effect from time to time, the Company is to maintain health and medical benefits pursuant to the benefits section of the employment agreement for the duration of the severance period.  Any options forming part of the initial option </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">grant that are unvested as of the termination date, but would have vested during the severance period, would immediately vest upon termination.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that Mr. Greenleaf&#8217;s employment is terminated by the Company without cause or by the executive for "good reason" within 12 months following a change in control of the Company, Mr. Greenleaf is entitled to receive a lump sum payment equal to 18 months of his then current base salary, and if awarded and payable, the target bonus for the year of termination.  In addition, the Company is to maintain health and medical benefits pursuant to the benefits section of the employment agreement during the 12-month period following the termination date.  All of Mr. Greenleaf&#8217;s unexercised stock options will immediately vest upon the termination of his employment and shall be fully exercisable in accordance with the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Estimated Termination Payments</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below reflects amounts that would have been payable to each NEO if the NEO&#8217;s employment had been terminated on December 31, 2018 either (i) without cause, or (ii) following or in connection with a change in control.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:12%;"></td><td style="width:12%;"></td><td style="width:19%;"></td><td style="width:12%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Termination Without Cause</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Termination Following Change in Control</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Severance</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accelerated Vesting of Options</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Continuation of Benefits</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Severance</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Accelerated Vesting of Options</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Continuation of Benefits</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Richard Glickman</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">925,132</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,275</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,138,924</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,743,741</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,715</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Dennis Bourgeault</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">496,063</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">496,063</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">472,084</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,741</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Neil Solomons</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">668,303</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">4)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,584</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">695,043</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">475,370</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,648</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Robert Huizinga</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">640,766</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">640,766</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">487,727</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,414</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Michael Martin</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">454,130</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,670</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">473,983</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(8)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">349,237</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,414</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 13 months' salary in the sum of $555,858, plus accrued bonus of $343,000 and accrued vacation pay of $26,274.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 18 months&#8217; salary in the sum of $769,650 plus accrued bonus of $343,000 and accrued vacation pay of $26,274.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 18 months&#8217; salary in the sum of $343,595 plus accrued bonus of $86,220 and accrued vacation pay of $66,248. The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 17 months&#8217; salary in the sum of $454,567 plus accrued bonus of $130,856 and accrued vacation pay of $82,880.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 18 months&#8217; salary in the sum of $481,307 plus accrued bonus of $130,856 and accrued vacation pay of $82,880.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 18 months&#8217; salary in the sum of $452,994 plus accrued bonus of $115,935 and accrued vacation pay of $71,837.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 17 months&#8217; salary in the sum of $337,485 plus accrued bonus of $97,882 and accrued vacation pay of $18,763.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Severance amount is comprised of 18 months&#8217; salary in the sum of $357,338 plus accrued bonus of $97,882 and accrued vacation pay of $18,763.  The bonus was paid out in the first quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Represents the value of unvested in-the-money options that would vest upon termination of employment as at December 31, 2018.  Closing share price on TSX on December 31, 2018 was CDN$9.28= US$6.80, converted to US$ at a rate of US$1.00 = CDN$1.3643.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><a name="sC3999EEE18EE5E5EB6486467CF790A3A"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1.7&#160;&#160;&#160;&#160;Incentive Plan Awards</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">a)&#160;&#160;&#160;&#160;Outstanding Share-Based Awards and Option Based Awards</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table indicates for each of the NEOs all awards outstanding at the end of the 2018 financial year.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.89272030651341%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:16%;"></td><td style="width:13%;"></td><td style="width:9%;"></td><td style="width:16%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:12%;"></td><td style="width:12%;"></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Option-based Awards</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Share-based Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of securities underlying unexercised options</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Option exercise price</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Option expiration date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value of unexercised in-the-money options</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of shares or units of shares that have not vested </font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Market or payout value of share-based awards that have not vested </font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Market or payout value of vested share-based awards not paid out or distributed</font></div><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Richard Glickman</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">400,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 5, 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">838,552</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1,050,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.20</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 9, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3,902,126</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">200,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 18, 2024</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">847,348</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.08</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March 23, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">38,996</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">36,870</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Dennis Bourgeault</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">150,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.30</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 1, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">303,462</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">175,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.20</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 9, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">650,354</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">40,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.02</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March 30, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">157,448</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">93,337</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.40</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">August 17, 2020</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">330,449</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">137,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">506,736</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Neil Solomons</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">175,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.30</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 1, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">354,039</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">152,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.20</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 9, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">564,879</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">40,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.02</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March 30, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">157,448</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">147,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">543,606</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Michael Martin</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">150,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.30</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 1, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">303,462</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">90,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.20</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 9, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">334,468</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">40,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.02</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March 30, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">157,448</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">147,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">543,606</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td rowspan="6" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Robert Huizinga</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">225,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.30</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 1, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">455,193</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">110,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.20</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">February 9, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">408,794</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">16,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.45</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">December 11, 2022</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">67,788</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">40,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.02</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March 30, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">157,448</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">31,529</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.40</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">August 17, 2020</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">111,625</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">100,008</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">368,728</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Closing share price on TSX on December 31, 2018 was CDN$9.28; closing price on the NASDAQ on December 31, 2018 was US$6.82.  The value of unexercised in-the-money options was determined using the TSX closing price multiplied by the number of options converted to US dollars at a rate of US$1.00 = CDN$1.3643.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Option exercise price was determined based on the Canadian dollar exercise price at the time of the grant converted into US$ using the Bank of Canada closing rate on the date of granting of the options.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:77px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">b)&#160;&#160;&#160;&#160;Value Vested or Earned on Incentive Plan Awards during the Most Recently Completed Fiscal Year</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table indicates for each of the NEOs the value on vesting of all awards during the 2018 financial year.</font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.85057471264368%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:24%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option-based Awards</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Share-based awards - Value vested during the year</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-equity incentive plan compensation - Value earned during the year </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of Securities Underlying Options Vested</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Value vested during the year</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Richard Glickman</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">373,611</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">661,079</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Dennis Bourgeault</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">100,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">156,067</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Neil Solomons</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">99,278</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">143,580</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Robert Huizinga</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">99,166</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">121,551</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Michael Martin</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,667</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">93,336</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Note:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The value reflected in the above chart relates to the in-the-money value of options at the date of the vesting and has been converted into US$ using the Bank of Canada closing rate on the date of granting of the options.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sBCC55C409ED852F480FD494B6D14342E"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;COMPENSATION OF DIRECTORS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As at December 31, 2018, the Board consisted of seven non-executive Directors (Mr. Jeff Randall, Dr. David Jayne, Dr. Joon Lee, Dr. George M. Milne, Jr., Dr. Benjamin Rovinski, Mr. Joseph Hagan and Dr. Michael Hayden) in addition to Dr. Richard Glickman, Chairman and CEO.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Summary Compensation Table:</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides details of the total compensation awarded to the Directors who were not NEOs of the Company during the 2018 financial year. </font></div><div style="line-height:120%;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:19%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:13%;"></td><td style="width:10%;"></td><td style="width:12%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Earned</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fees</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Share-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">based</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">awards</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Option-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">based </font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">awards</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Non-equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">incentive plan</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension </font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">All other compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Jeff Randall</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">85,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68,616</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">153,616</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Benjamin Rovinski</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">62,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68,616</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">131,116</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Joon Lee</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">65,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68,616</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">134,116</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. David Jayne</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">52,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68,616</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">121,616</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. George M. Milne, Jr.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">58,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">68,616</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">126,616</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Mr. Joseph Hagan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">53,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">112,096</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">165,096</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Dr. Michael Hayden</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">55,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">120,412</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">175,412</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculated as of the grant date using the Black-Scholes option pricing model.  The value shown is calculated by multiplying the number of stock options granted by the Canadian dollar exercise price at the time of grant by the Black-Scholes valuation factor and converting the value into US$ using the Bank of Canada closing rate</font><font style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">on the date of granting of the options.  The value is the same as the accounting fair value of the full grant but is not adjusted by the vesting schedule.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 30,000 options at an exercise price of CDN$6.42; Black-Scholes valuation factor = CDN$2.8314 &#8211; converted into US$ at a rate of US$1.00 = CDN$1.2379.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 50,000 options at an exercise price of CDN$6.40; Black-Scholes valuation factor = CDN$2.8214 &#8211; converted into US$ at a rate of US$1.00 = CDN$1.2585.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Calculation based on 50,000 options at an exercise price of CDN$6.92; Black-Scholes valuation factor = CDN$3.0515 &#8211; converted into US$ at a rate of US$1.00 = CDN$1.2671.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation for the Directors is determined by the Board of Directors. The Board has sought advice from third party advisors in respect to the compensation of the Directors, most recently Arnosti in 2018.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2018, non-management Directors (other than the Lead Director) earned an annual retainer fee of $40,000 for acting as a Board member.  The Lead Director earned an annual retainer fee of $65,000.  Directors were paid in US dollars at the end of each quarter.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annual committee compensation for 2018 was as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation Committee Chair Retainer:  $15,000  </font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation Committee Member Retainer:  $5,000</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Audit Committee Chair Retainer:  $15,000</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Audit Committee Member Retainer:  $7,500 </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Governance Committee Chair Retainer:  $10,000  </font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Governance Committee Member Retainer:  $5,000</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Committee Chair Retainer:  $15,000</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Committee Member Retainer:  $7,500</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 30, 2018, following consultation with Arnosti (including a review of compensation paid to the directors in the Company&#8217;s peer group) and upon recommendation of the Compensation Committee, the Board approved an annual grant of 30,000 stock options to non-management Board members and the grant of 50,000 stock options upon the election or appointment of a new Board member.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company granted 30,000 stock options on February 5, 2018 at a price of $5.19 (CDN$6.42) to each of the then non-management Directors, Dr. Rovinski, Mr. Randall, Dr. Jayne, Dr. Lee and Dr. Milne. On February 9, 2018, the Company granted Mr. Hagan 50,000 stock options at a price of $5.09 (CDN$6.40) related to his appointment as a new Board member in 2018.  On February 22, 2018, the Company granted Dr. Hayden 50,000 stock options at a price of $5.46 (CDN$6.92) related to his appointment as a new Board member in 2018.  All of the director options are exercisable for ten years and vest in equal amounts over 12 months.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Share-Based Awards and Option-Based Awards </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table indicates all awards outstanding at the end of the 2018 financial year for each of the Directors who were not NEOs.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:17%;"></td><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:16%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:12%;"></td><td style="width:12%;"></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option-based Awards</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Share-based Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of securities underlying unexercised options</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option exercise price</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option expiration date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Value of unexercised in-the-money options</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of shares or units of shares that have not vested </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Market or payout value of share-based awards that have not vested </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Market or payout value of vested share-based awards not paid out or distributed</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td rowspan="6" style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Benjamin Rovinski</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 5, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,891</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.95</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April 26, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.62</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 16, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,352</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.00</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March 23, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38,996</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.59</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 6, 2020</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">36,870</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.19</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 18, 2024</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">84,735</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. David Jayne</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 5, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,891</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.95</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April 26, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.62</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 16, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,352</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.00</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March 23, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38,996</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.47</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June 2, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,860</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Jeff Randall</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 5, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,891</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.95</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April 26, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.62</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 16, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,352</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">January 20, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">41,268</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.78</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">December 14, 2026</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">41,268</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Joon Lee</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 5, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,891</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.95</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">April 26, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.62</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 16, 2027</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,352</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.00</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">March 23, 2021</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38,996</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.47</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June 2, 2020</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,860</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #00000a;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. George M. Milne, Jr.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">30,000</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.19</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 5, 2028</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,891</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.40</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">June 23, 2027</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29,320</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #00000a;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Joseph Hagan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.09</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 9, 2028</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">105,552</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #00000a;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Michael Hayden</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.46</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February 22, 2028</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,494</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">(1)</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">Closing share price on TSX on December 31, 2018 was CDN$9.28 = US$6.80, converted to US$ at a rate of US$1.00 = CDN$1.3643.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">(2)&#160;&#160;&#160;&#160;Option exercise price has been converted into US$ using the Bank of Canada closing rate on the date of granting of the options.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Value Vested or Earned on Incentive Plan Awards During the Most Recently Completed Fiscal Year:</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table indicates the value on vesting of all awards during the 2018 financial year for each of the Directors who were not NEOs.</font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.65900383141762%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:24%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Option-based Awards</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Share-based awards - Value vested during the year</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-equity incentive plan compensation - Value earned during the year </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of Securities Underlying Options Vested</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Value vested during the year</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Jeff Randall</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">34,167</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">22,435</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Benjamin Rovinski</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,334</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,358</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. David Jayne</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,334</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,358</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Joon Lee</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">33,334</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20,358</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. George M. Milne, Jr.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">50,000</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17,974</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mr. Joseph Hagan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">41,667</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">28,771</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dr. Michael Hayden</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">41,667</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,326</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:8pt;text-indent:-24px;"><font style="font-family:Arial;font-size:8pt;">The value reflected in the above chart relates to the in-the-money value of options at the date of the vesting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The value vested during the year has been converted into US$ using the Bank of Canada closing rate on the date of granting of the options.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><a name="s207C9E6C928057F78768D98FA3A00AF8"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;EQUITY COMPENSATION PLAN</font></div><div><a name="s2ADDB679E0AA5313B25E8C23B83BA638"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.3.1&#160;&#160;&#160;&#160;Stock Option Plan</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of the material terms of the Stock Option Plan:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Administration</font><font style="font-family:Arial;font-size:10pt;">.  The Stock Option Plan is administered by the Board (or a committee thereof) which has the power to (i) grant options, (ii) reserve Common Shares for issuance upon the exercise of options, (iii) determine the terms, limitations, restrictions and conditions respecting option grants, (iv) interpret the Stock Option Plan and adopt, amend and rescind such administrative guidelines and other rules and regulations relating to the Stock Option Plan , and (v) make all other determinations and take all other actions in connection with the implementation and administration of the Stock Option Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Number of Securities Issuable</font><font style="font-family:Arial;font-size:10pt;">.  The Stock Option Plan is a rolling stock option plan that reserves, for issuance pursuant to stock options, a maximum number of Common Shares equal to 12.5% of the outstanding Common Shares of the Company at the time the Common Shares are reserved for issuance.  As at May 9, 2019, an aggregate of 8,184,969 Common Shares (or 8.92% of the total number of issued and outstanding Common Shares) are issuable under the Stock Option Plan pursuant to outstanding options leaving a total of 3,277,901 Common Shares (or 3.57% of the total number of issued and outstanding Common Shares) issuable under the Stock Option Plan. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Eligible Persons</font><font style="font-family:Arial;font-size:10pt;">.  "Service Providers" are eligible to receive grants of options under the Stock Option Plan.  "Service Providers" is defined as bona fide directors, officers, employees, management company employees and consultants and also includes a company of which 100% of the share capital is beneficially owned by one or more individual Service Providers.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Shareholder Approval</font><font style="font-family:Arial;font-size:10pt;">.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Arial;font-size:10pt;">The unallocated entitlements under the Stock Option Plan must be approved by the Shareholders every three years. The Shareholders last re-approved the unallocated entitlements under the Stock Option Plan on June 21, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Grants to One Person</font><font style="font-family:Arial;font-size:10pt;">.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Arial;font-size:10pt;">The number of Common Shares reserved for issue to any one person under the Stock Option Plan may not exceed 5% of the outstanding Common Shares at the time of grant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Insiders</font><font style="font-family:Arial;font-size:10pt;">.  Without the prior approval of the Shareholders, the number of Common Shares being issuable to insiders under the Stock Option Plan at any time, when combined with all of the Company&#8217;s other share compensation arrangements, shall not exceed 10% of the issued and outstanding Common Shares, and the number of Common Shares issued to insiders under the Stock Option Plan, when combined with all of the Company&#8217;s other share compensation arrangements, shall not exceed 10% of the issued and outstanding Common Shares in any 12 month period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exercise Price</font><font style="font-family:Arial;font-size:10pt;">.  The exercise price of options under the Stock Option Plan will be set by the Board at the time of grant and cannot be less than the Market Price (defined in the Stock Option Plan as the closing trading price for the Common Shares on the TSX on the day immediately prior to the date of grant).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Vesting</font><font style="font-family:Arial;font-size:10pt;">.  Vesting of options is at the discretion of the Board.  Options become exercisable only after they vest in accordance with the respective commitment and exercise form.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Term of Options</font><font style="font-family:Arial;font-size:10pt;">.  Options granted under the Stock Option Plan will have a maximum term of ten years from their date of grant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">No Assignment</font><font style="font-family:Arial;font-size:10pt;">.  All options will be exercisable only by the optionee to whom they are granted and are non-assignable and non-transferable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Termination of Exercise Right</font><font style="font-family:Arial;font-size:10pt;">.  No option may be exercised after an optionee has left the employ or service of the Company except as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">in the event of an optionee&#8217;s death, any vested option held by the optionee at the date of death will be exercisable by the optionee&#8217;s lawful personal representatives, heirs or executors until the earlier of 12 months after the date of death and the date of expiration of the term otherwise applicable to such option;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">in the event of an optionee&#8217;s disability, any vested option held by the optionee will be exercisable until the earlier of 12 months after the date the Board makes a determination of disability and the date of expiration of the term otherwise applicable to such option;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">generally speaking, vested options will expire 90 days after the date the optionee ceases to be employed by, provide services to, or be a Director or Officer of, the Company, and any unvested options shall immediately terminate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Change in Control.  </font><font style="font-family:Arial;font-size:10pt;">Upon a change in control or takeover bid, vesting can be accelerated in accordance with the provisions set out in the Stock Option Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Extension of Expiry Period.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;If an option which has been previously granted is set to expire during a period in which trading in securities of the Company by the option holder is restricted by a black-out, or within nine business days of the expiry of a black-out, the expiry date of the option will be extended to ten business days after the trading restrictions are lifted.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amendments Requiring Shareholder Approval.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Shareholder approval is required for the following amendments to the Stock Option Plan:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an increase to the aggregate percentage of securities issuable under the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a reduction in the exercise price of an outstanding option;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an extension of the term of any option beyond the expiry date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any amendment to permit assignments or exercises other than by the optionee other than as set out in the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">amendment to the individuals eligible to receive options under the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an amendment to the Stock Option Plan to provide for other types of compensation through equity issuance, other than an amendment in the nature of a substitution and/or adjustment made by the Board in response to a change to, event affecting, exchange of, or corporate change or transaction affecting the Common Shares; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an amendment which is required to be approved by Shareholders under applicable law (including, without limitation, applicable TSX policies).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amendments Without Shareholder Approval</font><font style="font-family:Arial;font-size:10pt;">.  Subject to the policies of the TSX, the Stock Option Plan may be amended without Shareholder approval for the following:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">amendments of a "housekeeping" nature;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">amendments necessary to comply with the provisions of applicable law;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">amendments respecting the administration of the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any amendment to the vesting provisions of the Stock Option Plan or any option;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any amendment to the early termination provisions of the Stock Option Plan or any option, whether or not such option is held by an insider, provided such amendment does not entail an extension beyond the original expiry date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any amendments necessary to suspend or terminate the Stock Option Plan; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:45px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any other amendment not requiring Shareholder approval under applicable law (including, without limitation, applicable TSX policies).</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has not provided any financial assistance to participants under the Stock Option Plan to facilitate the purchase of securities under the Stock Option Plan.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below shows the burn rate in respect of the Stock Option Plan for the last three fiscal years, calculated by dividing the number of options granted under the Stock Option Plan in the fiscal year by the weighted average number of securities outstanding for the year:</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(as at December 31)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options granted under the Stock Option Plan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,003,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,728,500</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,470,000</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average number of securities outstanding</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">84,782,436</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">76,918,394</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35,285,288</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Burn Rate (%)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.54%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.55%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.17%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8552D9A929C95BCF8ECEF34EA64EE976"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.3.2&#160;&#160;&#160;&#160;Pension Plan Benefits</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company does not provide retirement benefits for Directors or Officers.  </font></div><div><a name="s338F1CBD7F9E5FE59AD55A15A46D386C"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table indicates the number of Common Shares to be issued upon the exercise of outstanding options, the weighted average exercise price of such outstanding options and the number of Common Shares remaining for future issuance under the Stock Option Plan as at December 31, 2018. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:6px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.85057471264368%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:21%;"></td><td style="width:18%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Plan Category</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of common shares to be issued upon exercise of outstanding options, warrants and rights</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average exercise price of outstanding options, warrants and rights</font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#c9c9c9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of Common Shares remaining available for future issuance under the equity compensation plans <br>(excluding securities reflected in the first column)</font><font style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity Compensation plans approved by security holders</font></div><div style="padding-bottom:4px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stock Option Plan</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,426,826</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.07</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,260,702</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity compensation plans not approved by security holders</font></div><div style="padding-bottom:4px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Option Commitment</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">163,601</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.68</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total:</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,590,427</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.04</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,260,702</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Under the Stock Option Plan, any increase in the number of outstanding Common Shares will result in an increase in the number of Common Shares that are available to be issued under the plan in the future, and any exercise of an option previously granted under the Stock Option Plan will result in an additional option being available for grant under the Stock Option Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Weighted-average exercise price of CDN$5.55 converted into US$ at the Bank of Canada closing rate on December 31, 2018 of US$1.00 = CDN$1.3643.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">200,000 options to acquire Common Shares were issued under an option commitment to Bradley J. Dickerson on May 2, 2016 under section 613(c) of the TSX Company Manual which allows the Company to issue security based compensation without shareholder approval as an inducement to employment to a person not previously employed by the Company to enter into full time employment with the Company.  Mr. Dickerson&#8217;s options vest according to a vesting schedule specified in the option commitment, becoming fully vested on the third year anniversary of the grant date, for so long as he remains employed by the Company, and may be exercised up to five</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">years from the grant date at an exercise price of CDN$3.66</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">per Common Share. As at December 31, 2018, 163,601 options remain outstanding. On April 29, 2019, the Company issued an additional 1,600,000 options to purchase Common Shares under an option commitment to Peter Greenleaf under section 613(c) of the TSX Company Manual. Mr. Greenleaf&#8217;s options vest according to a vesting schedule specified in the option commitment, becoming fully vested on the fourth year anniversary of the grant date, for so long as he remains employed by the Company, and may be exercised up to ten</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">years from the grant date at an exercise price of CDN$8.45</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:8pt;">per Common Share. As these options were issued after December 31, 2018, they are not included in the above table. While options issued under option commitments are not issued pursuant to the Stock Option Plan, to the extent not otherwise specified in the relevant option commitment, the options will be governed by like terms and conditions as set out in the Stock Option Plan, and such terms are specifically incorporated into the option commitments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">(4) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Exercise price of CDN$3.66 converted into US$ at the Bank of Canada closing rate on December 31, 2018 of US$1.00 = CDN$1.3643.</font></div></td></tr></table><div style="line-height:150%;padding-top:8px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><a name="s937259000EC65177BAC0E6D393FE15A4"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.5&#160;&#160;&#160;&#160;INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No Directors, Officers and employees or former Directors, Officers and employees of the Company nor any proposed nominee for election as a Director of the Company is or was indebted to the Company at any time since the beginning of the fiscal year ended December 31, 2018.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s7E976D6249CA5C85B4E2405A7E46E0F7"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART 4 <br>REPORT ON CORPORATE GOVERNANCE AND OTHER ITEMS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate governance is the process and structure used to direct and manage the business and affairs of the Company to achieve the Shareholders&#8217; objectives.  The Canadian Securities Administrators (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CSA</font><font style="font-family:Arial;font-size:10pt;">") has adopted National Policy 58-201 - </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Corporate Governance Guidelines</font><font style="font-family:Arial;font-size:10pt;">&#32;("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NP 58-201</font><font style="font-family:Arial;font-size:10pt;">") to provide guidance to Canadian reporting issuers regarding corporate governance.  NP 58-201 relates to a number of significant governance issues, including the proper role of the Board, its structure and composition and its relationship with Shareholders and management.  The CSA has also adopted National Instrument 58-101 - </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure of Corporate Governance Practices</font><font style="font-family:Arial;font-size:10pt;">&#32;requiring that disclosure be </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">made by a listed corporation of its corporate governance practices.  A complete description of the Company&#8217;s corporate governance practices, with specific references to NP 58-201, is attached hereto as Appendix "A".  The Board has reviewed the disclosure set out in Appendix "A".</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board continues to periodically review corporate governance proposals made by the CSA.  As new standards become effective, the Board will review and amend, where necessary and appropriate, the Company&#8217;s corporate governance practices and eligibility of the members of the Board on each committee.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s63FC96CA064B5AFB9DC3423F4C5AFCD2"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;COMMITTEES OF THE BOARD </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board has four standing committees:  Audit Committee, Compensation Committee, Governance &amp; Nomination Committee and Research Committee.  The following are descriptions of the four standing committees of the Board:</font></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Audit Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Members: Mr. Jeff Randall (Chair), Dr. Benjamin Rovinski and Dr. Joon Lee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Audit Committee is presently composed of three Directors, all of whom are "financially literate" as that term is defined in National Instrument 52-110 - </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Audit Committees </font><font style="font-family:Arial;font-size:10pt;">("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NI 52-110</font><font style="font-family:Arial;font-size:10pt;">"). </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Mr. Randall, Dr. Rovinski and Dr. Lee are considered independent Directors. Please refer to the description of the Audit Committee set out in the Company&#8217;s annual information form for the year ended December 31, 2018 (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AIF</font><font style="font-family:Arial;font-size:10pt;">"), including the information required to be disclosed under NI 52-110, available on the SEDAR website at www.sedar.com. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As Mr. Randall and Dr. Rovinski are not standing for re-election, the membership of this committee will be determined at the board meeting immediately following the Meeting. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Compensation Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Members: Dr. Benjamin Rovinski (Chair), Mr. Jeff Randall and Dr. Joon Lee.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Compensation Committee is presently composed of three Directors, all of whom are independent.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Compensation Committee is responsible for ensuring that effective human resources and compensation policies and procedures are in place for the Company, including oversight of Director, Officer and employee remuneration and compensation, employment contracts, together with oversight of the evaluation of management of the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As Mr. Randall and Dr. Rovinski are not standing for re-election, the membership of this committee will be determined at the board meeting immediately following the Meeting.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Governance &amp; Nomination Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Members: Dr. George M. Milne, Jr. (Chair), Dr. David Jayne and Dr. Joon Lee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s corporate governance committee (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Governance &amp; Nomination Committee</font><font style="font-family:Arial;font-size:10pt;">") is presently composed of three Directors all of whom are independent.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Governance &amp; Nomination Committee assists the Board in fulfilling its responsibilities in relation to the monitoring and oversight of the quality and effectiveness of the Company&#8217;s governance practices and policies, considering nominees for the Board and considering any conflicts of interest.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Research Committee</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Members: Dr. Michael Hayden (Chair) and Dr. David Jayne</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s Research Committee consists of two independent Directors.  The mandate of the Research Committee is to support the Company&#8217;s research initiatives, provide independent review of internal and external programs, and review additional new opportunities, as required.</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Communications, Insider Trading, Confidential Information and Disclosure Policies</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board is committed to an effective communications policy with all stakeholders including Shareholders, suppliers, advertisers, employees, agents and members of the investment community.  The Company is committed to complying with all laws, regulations and policies which are applicable to it, as well as to best practices in the field.  This commitment is evidenced, notably, by the adoption by the Company of a corporate disclosure policy, fraud policy and insider trading policy.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Audit Committee reviews in advance all press releases which disclose financial results.  Other continuous disclosure documents, including, without limitation, proxy-related materials and the AIF are reviewed by the executive team and, where appropriate, the Board. Where required, these documents are also approved by the Board.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s72E448471D805CF8BA1E8D81AB7EF140"></a></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has had no material transaction with an "informed person" (as that term is defined under applicable securities laws).</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s7E467C75108355288D140D4695B4B334"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;SHAREHOLDER PROPOSALS</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Shareholders who comply with the applicable provisions of the ABCA are, subject to certain conditions in the ABCA, entitled to have the Company include in its information circular any matter that the person proposes to raise at an annual meeting.&#160; Any Shareholder who intends to make such a proposal to be considered by the Company for the next annual general meeting must have arranged for the Company to receive the proposal no later than March 27, 2020.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s7B8C40D83DDA5C918A52166A13D66D95"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;ADDITIONAL INFORMATION</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial information is provided in the Company&#8217;s audited financial statements and management&#8217;s discussion and analysis for its most recently completed financial year.  Copies of these documents and additional information relating to the Company are available on the Company&#8217;s website www.auriniapharma.com, on SEDAR at www.sedar.com or at EDGAR at www.sec.gov.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s04789c974623407d8ad8adc54f9bfd9e"></a></div><div style="line-height:150%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.5&#160;&#160;&#160;&#160;CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A statement is forward-looking when it uses what we know and expect today to make a statement about the future.  Forward-looking statements may include words such as "anticipate", "believe", "intend", "expect", "goal", "may", "plan", "seek", "project", "should", "target", "could", "continue", "potential" and "estimated", or the negative of such terms or comparable terminology.  You should not place undue reliance on the forward-looking statements as they are inherently risky and uncertain.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The statements made in this Circular, and the in accompanying Notice of Meeting and Letter to Shareholders, may include, without limitation: statements with respect to the Company&#8217;s plans and expectations and the timing of completion and release of results of clinical trials; statements with respect to increasing the Company&#8217;s breadth and bandwidth with respect to commercialization and hiring a significant number of additional employees in the future; statements concerning the anticipated commercial potential of voclosporin; our expectation that the Company will develop into a commercial enterprise; the Company&#8217;s intention to submit a rolling NDA to the U.S. FDA in 2020 for voclosporin, the anticipated timing of results for AURORA Phase 3; the Company&#8217;s belief that its current cash position is sufficient to fund its existing lupus nephritis program, its ongoing Phase 2a study in focal segmental glomerulosclerosis, commence further studies for dry eye syndrome, and fund supporting operations until approximately mid-2020; the Company&#8217;s expectations with respect to management&#8217;s director nominees and the Company&#8217;s plans to achieve upcoming milestones. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Such statements reflect the Company&#8217;s current views with respect to future events and are subject to risks and uncertainties and are necessarily based on a number of estimates and assumptions that, while considered reasonable by management, as at the date of such statements, are inherently subject to significant business, economic, competitive, political, regulatory, legal, scientific and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. The factors and assumptions used by management to develop such forward-looking statements include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that we will be able to obtain approval from regulatory agencies on executable development programs with parameters that are satisfactory to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that we will successfully complete our clinical programs on a timely basis, including conducting the required AURORA clinical trial and meet regulatory requirements for approval of marketing authorization applications and new drug approvals, as well as favourable product labeling;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that the planned studies will achieve positive results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumptions regarding the costs and expenses associated with the Company&#8217;s clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption the regulatory requirements and commitments will be maintained; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that we will be able to meet good manufacturing practices standards and manufacture and secure a sufficient supply of voclosporin on a timely basis to successfully complete the development and commercialization of voclosporin; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumptions on the market value for the lupus nephritis program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that the Company&#8217;s patent portfolio is sufficient and valid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that the United States Patent and Trademark Office will issue a new patent for its dosing protocol once applicable steps have been followed and fees paid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that the Company will be able to extend its patents to the fullest extent allowed by law, on terms most beneficial to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumptions on the market; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that the Company&#8217;s current good relationships with its suppliers, service providers and other third parties will be maintained;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:26px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the assumption that we will be able to attract and retain a sufficient amount of skilled staff; and/or</font></div></td></tr></table><div style="line-height:150%;text-align:justify;padding-left:50px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is important to know that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual results could be materially different from what the Company expect if known or unknown risks affect its business, or if its estimates or assumptions turn out to be inaccurate.  As a result, the Company cannot guarantee that any forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made may have on the Company&#8217;s business.  For example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges, and do not include the effect of activities by shareholder activists, including a proxy contest or any unsolicited takeover proposal, announced or occurring after the forward-looking statements are made.  The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depend on the facts particular to each of them.  Accordingly, the expected impact cannot be meaningfully described in the abstract or presented in the same manner as known risks affecting the Company&#8217;s business.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The factors discussed below and other considerations discussed in the "Risk Factors" section of the Company&#8217;s annual information form filed on SEDAR at www.sedar.com which can be retrieved under the Company&#8217;s profile on either of the SEDAR or EDGAR websites could cause the Company&#8217;s actual results to differ significantly from those contained in any forward-looking statements.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company&#8217;s actual results, performance, or achievements to differ materially from any assumptions, further results, performance or achievements expressed or implied by such forward-looking statements.  Important factors that could cause such differences include, among other things, the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the need for additional capital in the future to continue to fund the Company&#8217;s development programs and commercialization activities, and the effect of capital market conditions and other factors on capital availability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties, delays, or failures we may experience in the conduct of and reporting of results of the Company&#8217;s clinical trials for voclosporin;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties in meeting good manufacturing practices standards and the manufacturing and securing of a sufficient supply of voclosporin on a timely basis to successfully complete the development and commercialization of voclosporin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties in gaining alignment among the key regulatory jurisdictions, European Medicines Agency, Food and Drug Administration of the United States Government and Pharmaceutical and Medical Devices Agency, which may require further clinical activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties, delays or failures in obtaining regulatory approvals to market voclosporin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">not being able to extend the Company&#8217;s patent portfolio for voclosporin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the Company&#8217;s patent portfolio not covering all of its proposed uses of voclosporin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties we may experience in completing the development and commercialization of voclosporin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the market for the lupus nephritis business may not be as we have estimated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties obtaining adequate reimbursements from third party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties obtaining formulary acceptance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">product liability, patent infringement and other civil litigation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">injunctions, court orders, regulatory and other enforcement actions.</font></div></td></tr></table><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.  These forward-looking statements are made as of the date hereof.</font></div><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s8FEEBC0D1AEF5F08BFE791A755B71648"></a></div><div style="line-height:150%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.5&#160;&#160;&#160;&#160;APPROVAL BY DIRECTORS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The contents of this Circular and the sending thereof have been approved by resolution of a special committee of the board of directors.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DATED this 29</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;day of May, 2019.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ON BEHALF OF THE SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS OF AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.85057471264368%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Dr. George M. Milne, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Peter Greenleaf</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director and Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9C36BC0F6E0D519A933F3D285780F258"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">APPENDIX A</font></div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STATEMENT OF CORPORATE GOVERNANCE PRACTICES </font></div><div style="line-height:150%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is committed to the highest standards of corporate governance.  The Board and each of its committees have continued to refine the Company&#8217;s governance policies and procedures in light of recent regulatory initiatives that have been adopted to improve corporate governance.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective June 30, 2005, National Instrument 58-101 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure of Corporate Governance Practices</font><font style="font-family:Arial;font-size:10pt;">&#32;("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NI 58-101</font><font style="font-family:Arial;font-size:10pt;">") and National Policy 58-201 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Corporate Governance Guidelines</font><font style="font-family:Arial;font-size:10pt;">&#32;("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NP 58-201</font><font style="font-family:Arial;font-size:10pt;">") were adopted in Canada.  NI 58-101 requires issuers to disclose the corporate governance practices that they have adopted.  NP 58-201 provides guidance on corporate governance practices.  In addition, the Company is subject to National Instrument 52-110 &#8211; </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Audit Committees</font><font style="font-family:Arial;font-size:10pt;">, which has been adopted in various Canadian provinces and territories and which prescribes certain requirements in relation to audit committees.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board will continue to review the Company&#8217;s corporate governance practices on an ongoing basis in response to the evolving regulatory standards.</font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.&#160;&#160;&#160;&#160;Board of Directors &#8211; Disclose how the board of directors (the "Board") facilitates its exercise of independent supervision over management, including:</font></div></td><td colspan="2" rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board has reviewed the independence of each director of the Board ("Director") as defined in NI 58-101.  A Director who is independent has no direct or indirect material relationship with the Company, including a relationship which in the view of the Board could reasonably interfere with the Director&#8217;s exercise of independent judgment.  After having reviewed the role and relationships of each Director, the Board has determined that the following Directors nominated by management for election to the Board are independent, namely:</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br>Dr. George M. Milne, Jr.</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. David R.W. Jayne</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Lorin J. Randall</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Hyuek Joon Lee</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Joseph P. Hagan</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Michael Hayden</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. R. Hector MacKay-Dunn</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:16px;padding-top:4px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;the identity of directors that are independent.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;the identity of directors who are not independent, and the basis for that determination. </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Peter Greenleaf</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peter Greenleaf is considered to have a material relationship with the Company by virtue of being the CEO of the Company.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Daniel G. Billen</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Daniel G. Billen is considered to have a material relationship with the Company by virtue of having been a recent consultant to the Company.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;whether or not a majority of the directors are independent.  If a majority of directors are not independent, describe what the Board does to facilitate its exercise of independent judgment in carrying out its responsibilities.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A majority of the Board is independent.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:justify;padding-bottom:2px;padding-top:2px;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;If a director is presently a director of any other issuer that is a reporting issuer (or the equivalent) in a jurisdiction or a foreign jurisdiction, identify both the director and the other issuer.</font></div><div style="text-align:right;padding-bottom:2px;padding-top:2px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This information is disclosed in the Circular in Section 2.1.3.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Disclose whether or not the independent directors hold regularly scheduled meetings at which non-independent directors and members of management are not in attendance.  If the independent directors hold such meetings, disclose the number of meetings held since the beginning of the issuer&#8217;s most recently completed financial year.  If the independent directors do not hold such meetings, describe what the board does to facilitate open and candid discussion among its independent directors.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The independent Directors hold an independent Directors meeting a week prior to each scheduled Board meeting and hold </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:Arial;font-size:10pt;">&#160;meetings following every meeting of the Board.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Disclose whether or not the chair of the board is an independent director.  If the board has a chair or lead director who is an independent director, disclose the identity of the independent chair or lead director, and describe his or her role and responsibilities.  If the board has neither a chair that is independent nor a lead director that is independent, describe what the board does to provide leadership for its independent directors.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dr. Richard Glickman was the Chairman of the Board until April 29, 2019.  Dr. Glickman was not an independent Director.  The Chairman&#8217;s primary responsibility is managing the affairs of the Board including ensuring the Board is organized properly, functions effectively, and meets it obligations and responsibilities as set out in the by-laws of the Company and its mandate.  The Chairman works to ensure effective relations with the Board, shareholders, other stakeholders and the public.  </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 21, 2017, the Board appointed Mr. Jeff Randall, an independent director, as the Lead Director.  The Lead Director&#8217;s role was to ensure that the Board functions independent of management and to act as principal liaison between the independent directors and the CEO. The responsibilities of the Lead Director included presiding over meetings of independent directors, reviewing and making recommendations with respect to the agendas, and providing the leadership necessary to provide greater assurance that the Board operates and functions independent of management and that Board </font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">functions are effectively carried out.  However, upon the appointment of Dr. George Milne, an independent Director, as the Chairman of the Board on April 29, 2019, there is no longer a requirement for a Lead Director.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(g)&#160;&#160;&#160;&#160;Disclose the attendance record of each director for all board meetings held since the beginning of the issuer&#8217;s most recently completed financial year.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This information is disclosed in the Circular in Section 2.1.2.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Board Mandate &#8211; </font><font style="font-family:Arial;font-size:10pt;">Disclose the text of the board&#8217;s written mandate.  If the board does not have a written mandate, describe how the board delineates its role and responsibilities.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A copy of the mandate of the Board is attached to this Circular as Appendix "B". </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Position Descriptions</font><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8211;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Disclose whether or not the board has developed written position descriptions for the chair and the chair of each board committee.  If the board has not developed written position descriptions for the chair and/or the chair of each board committee, briefly describe how the board delineates the role and responsibilities of each such position.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board has developed written position descriptions for the Chairman of the Board and the Chair of each committee of the Board. </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Disclose whether or not the board and CEO have developed a written position description for the CEO.  If the board and CEO have not developed such a position description, briefly describe how the board delineates the role and responsibilities of the CEO.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board and the CEO have developed a written position description for the CEO.</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Orientation and continuing Education &#8211; </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Briefly describe what measures the board takes to orient new directors regarding:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;the role of the board, its committees and its directors;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;the nature and operation of the issuer&#8217;s business.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Briefly describe what measures, if any, the board takes to provide the continuing education for its directors.  If the board does not provide continuing education, describe how the board ensures that its directors maintain the skill and knowledge necessary to meet their obligations as directors.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has not implemented a "formal" orientation process for its new Directors; however new Directors are given the opportunity to individually meet with senior Management to improve their understanding of the Company&#8217;s business.  Newly appointed Directors receive an onboarding package and are also provided with reference materials describing the Company&#8217;s organizational structure, the structure of the Board and its committees, corporate policies, articles and by-laws, as well as other Board materials. In addition, regardless of whether a meeting of the Board is scheduled, all Directors regularly receive information on the Company&#8217;s operations, including a report on corporate development activities, operations reports, a financial overview and other pertinent information.  All Company executives are available for discussions with Directors concerning any questions or comments which may arise between meetings. </font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">3</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Ethical Business Conduct &#8211; </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Disclosure whether or not the board has adopted a written code for the directors, officers and employees.  If the board has adopted a written code:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;disclose how a person or company may obtain a copy of the code;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;describe how the board monitors compliance with its code, or if the board does not monitor compliance, explain whether and how the board satisfies itself regarding compliance with its code;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;provide a cross-reference to any material change report filed since the beginning of the issuer&#8217;s most recently completed financial year that pertains to any conduct of a director or executive officer that constitutes a departure from the code.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Describe any steps the board takes to ensure directors exercise independent judgment in considering transactions and agreements in respect of which a director or executive officer has a material interest.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Describe any other steps the board takes to encourage and promote a culture of ethical business conduct.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board believes that a culture of strong corporate governance and ethical business conduct must be endorsed by the Board and the executive officers.  The Code addresses many areas of business conduct and provides a procedure for employees to raise concerns or questions regarding questionable audit or accounting matters. The Code is available on the Company&#8217;s website at www.auriniapharma.com.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has adopted a Corporate Disclosure Policy, which is reviewed annually, as well as Fraud and Whistleblower policies.  Quarterly financial packages are reviewed and approved by the Audit Committee. The Annual financial package is reviewed by the Audit Committee prior to being recommended for Board approval and CEO/CFO certification of annual/interim filings.  </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For any transactions where a Director or executive officer has a material interest, the Board ensures the member discloses such interest and discusses the transaction only once the applicable person is not in attendance.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Nomination of Directors &#8211;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Describe the process by which the board identifies new candidates for board nomination.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Disclose whether or not the board has a nominating committee composed entirely of independent directors.  If the board does not have a nominating committee composed entirely of independent directors, describe what steps the board takes to encourage an objective nominating process</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;If the board has a nominating committee, describe the responsibilities, powers and operation of the nominating committee.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board reviews, on an annual basis, both the size and composition of the Board.  In considering nominees for election to the Board, the Board takes into account geographic diversity, and considers the primary markets in which the Company operates, the expertise and experience necessary to support the Company&#8217;s strategy and operations and requirements for its Board imposed by law.  The Board considers such matters as a candidate&#8217;s integrity, independence, and residency.  The Board then assesses each potential nominee against the criteria developed by the Board.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Governance &amp; Nomination Committee is responsible for identifying nominees for election to the Board.  The Governance &amp; Nomination Committee is comprised of three Directors who are independent.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">4</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Compensation &#8211; </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Describe the process by which the board determines the compensation for the issuer&#8217;s directors and officers.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Disclosure whether or not the board has a compensation committee composed entirely of independent directors.  If the board does not have a compensation committee composed entirely of independent directors, describe what steps the board takes to ensure an objective process for determining such compensation.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;If the board has a compensation committee, describe the responsibilities, powers and operation of the compensation committee.</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Compensation Committee is comprised of three independent Directors.  </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The remuneration paid to the Directors and officers is reviewed each year by the Compensation Committee.  The level of remuneration is designed to provide a competitive level of remuneration.  The mandate of this Committee in respect of compensation matters specifically sets out the following duties and responsibilities:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">In respect of Director Compensation and Protection:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Review periodically Director compensation and recommend compensation terms that adequately reflect the responsibilities being assumed by the Directors, the Chair of the Board, and Chairs of the committees of the Board and members;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Review periodically the Directors&#8217; and officers&#8217; insurance policy and make recommendations for its renewal or amendment or the replacement of the insurer; </font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Administer, review, and recommend on all policies of or agreements by the Company with respect to the indemnification by the Company of its Directors and officers, if any.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">In respect of the Company&#8217;s Officers and Employees and Compensation Plans:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Review and recommend to the Board the employment, appointment, and compensation arrangements of the CEO of the Company, and in conjunction with the CEO, the employment and appointment of the top executives of the Company and their compensation arrangements, and make changes in these arrangements upon annual reviews of their performance;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Review with the CEO the position descriptions for the executive employees, ensuring they remain current and accurate;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Oversee the evaluation of the Company&#8217;s CEO;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Review the CEO&#8217;s evaluation of the performance of the employees of the Company, and the CEO&#8217;s recommendations with respect to the amount of compensation to be provided to such employees;</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">5</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Review the equity compensation plans of the Company for the benefit of employees of the Company and its subsidiaries; review and approve corporate goals and objectives relevant to the CEO and senior management&#8217;s compensation, evaluate the CEO and senior management&#8217;s performance in light of those goals and objectives, and make recommendations with respect to the CEO and Senior Executives&#8217; compensation levels based on this evaluation; and make recommendations with respect to the CEO and senior executives&#8217; compensation, incentive-compensation plans and equity-based plans; and</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Administer, review and recommend the stock option plans and awards of the Company.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Other Board Committees &#8211; </font><font style="font-family:Arial;font-size:10pt;">If the board has standing committees other than the audit, compensation and governance and nominating committees, identify the committees and describe their function.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company created a standing Research Committee effective March 13, 2018. The committee consists of two independent Directors, Dr. Michael Hayden (Chair) and Dr. David Jayne. The mandate of the committee is to support the Company&#8217;s research initiatives, provide independent review of internal and external programs, and review additional new opportunities, as required.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assessments &#8211; </font><font style="font-family:Arial;font-size:10pt;">Disclose whether or not the board, its committees and individual directors are regularly assessed with respect to their effectiveness and contribution.  If assessments are regularly conducted, describe the process used for the assessments.  If assessments are not regularly conducted, describe how the board satisfies itself that the board, its committees, and its individual directors are performing effectively.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There is currently no formal assessment process.  Each of the directors are assessed annually informally as part of the process of determining nominations for election to the Board by each of the other directors.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Director Term Limits and Other Mechanisms of Board Renewal</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#160;(Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only)&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8211; </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Disclose whether or not the issuer has adopted term limits for the directors on its board or other mechanisms of board renewal and, if so, include a description of those director term limits or other mechanisms of board renewal. If the issuer has not adopted director term limits or other mechanisms of board renewal, disclose why it has not done so.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has not adopted term limits or other mechanisms for Board renewal.  The Board has recently gone through an extensive renewal process. Given this recent renewal of the Board, the Company does not consider it appropriate to implement term limits or other mechanisms of Board renewal at this time.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">6</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;font-weight:bold;">Policies Regarding the Representation of Women on the Board&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">(Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only)</font><font style="font-family:Arial;font-size:10pt;color:#333333;background-color:#ffffff;">&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;font-weight:bold;">&#8211;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">Disclose whether the issuer has adopted a written policy relating to the identification and nomination of women directors. If the issuer has not adopted such a policy, disclose why it has not done so.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">If an issuer has adopted a policy referred to in (a), disclose the following in respect of the policy:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">a short summary of its objectives and key provisions,</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">the measures taken to ensure that the policy has been effectively implemented,</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">annual and cumulative progress by the issuer in achieving the objectives of the policy, and</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">whether and, if so, how the board or its nominating committee measures the effectiveness of the policy.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has adopted a written policy with respect to the identification and nomination of female Directors (the "Diversity Policy").  The Diversity Policy requires that the Board consider diversity on the Board from a number of aspects, including but not limited to gender, age, ethnicity and cultural diversity.  In addition, when assessing and identifying potential new members to join the Board or the Company&#8217;s executive team, the Board shall consider the current level of diversity on the Board and the executive team.  The Board has followed the Diversity Policy in considering potential candidates for election and appointment of members of the Board and the executive team.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Consideration of the Representation of Women in the Director Identification and Selection Process</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-style:italic;">&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">(Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only) </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#160;Disclose whether and, if so, how the board or nominating committee considers the level of representation of women on the board in identifying and nominating candidates for election or re-election to the board. If the issuer does not consider the level of representation of women on the board in identifying and nominating candidates for election or re-election to the board, disclose the issuer's reasons for not doing so.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the Diversity Policy, the Board does consider and evaluate the representation of women on the Board when identifying and nominating candidates for election and re-election to the Board.  Women have served as Directors of the Company in the past.  However, the Company focuses its search for new Directors purely based on the qualification of potential candidates, not specifically based on gender.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Consideration Given to the Representation of Women in Executive Officer Appointments</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#160;(Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only) </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#160;Disclose whether and, if so, how the issuer considers the level of representation of women in executive officer positions when making executive officer appointments. If the issuer does not consider the level of representation of women in executive officer positions when making executive officer appointments, disclose the issuer's reasons for not doing so.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the Diversity Policy, the Board does consider and evaluate the representation of women on the Company&#8217;s executive officer positions when identifying and nominating candidates for appointment as executive officers.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;However, the Company focuses its search for new executive officers purely based on the qualification of potential candidates, not specifically based on gender.  </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Governance Disclosure Requirements</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Company&#8217;s Governance Procedures</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14.&#160;&#160;&#160;&#160;Issuer's Targets Regarding the Representation of Women on the Board and in Executive Officer Positions (Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only) &#8211;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;or purposes of this Item, a "target" means a number or percentage, or a range of numbers or percentages, adopted by the issuer of women on the issuer's board or in executive officer positions of the issuer by a specific date.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Disclose whether the issuer has adopted a target regarding women on the issuer's board. If the issuer has not adopted a target, disclose why it has not done so.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Disclose whether the issuer has adopted a target regarding women in executive officer positions of the issuer. If the issuer has not adopted a target, disclose why it has not done so.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;If the issuer has adopted a target referred to in either (b) or (c), disclose:</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;the target, and</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;the annual and cumulative progress of the issuer in achieving the target.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has not established a target for the representation of women on the Board or in executive officer positions of the Company by a specific date.  The Company does not think it is appropriate to set targets because the Company focuses its search for new Directors and executive officers purely based on the qualification of potential candidates, not specifically based on gender.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.&#160;&#160;&#160;&#160;Number of Women on the Board and in Executive Officer Positions&#160;(Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Qu&#233;bec and Saskatchewan only) &#8211;</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Disclose the number and proportion (in percentage terms) of directors on the issuer's board who are women.</font></div><div style="padding-bottom:8px;padding-top:2px;text-align:justify;padding-left:22px;text-indent:-23px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b) Disclose the number and proportion (in percentage terms) of executive officers of the issuer, including all major subsidiaries of the issuer, who are women.</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;As at the date of this Circular, none (0%) of the Company&#8217;s Directors are women.</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;As at the date of this Circular, none (0%) of the Company&#8217;s executive officers, including the Company&#8217;s major subsidiaries, is a woman.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A - </font><font style="font-family:Arial;font-size:10pt;">8</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFD30760A6A4D5E68B5E09FD9CC2C16BF"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">APPENDIX B</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AURINIA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">MANDATE OF THE BOARD OF DIRECTORS</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.&#160;&#160;&#160;&#160;Introduction</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The primary responsibility of the board of directors ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:10pt;">") of Aurinia Pharmaceuticals Inc. (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:Arial;font-size:10pt;">") is to oversee the management of the business and to pursue the best interests of the Company.  The Board has plenary power and exercises overall responsibility for the management and supervision of the affairs of the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.&#160;&#160;&#160;&#160;Board Size and Criteria</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board must consist of such a number of directors within the limits as set out in the company&#8217;s articles of incorporation.  The By-laws of the Company require that at least one quarter (1/4) of the Company's directors be resident Canadians, and that at least two (2) of the Company's directors must not be officers or employees of the Company or a subsidiary of the Company.  A majority of the directors of the Board shall be independent within the meaning of National Instrument 52-110 Audit Committees.  </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">C.&#160;&#160;&#160;&#160;Board Meetings</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order for the Board to transact business, a majority of the directors must be present.  The Board shall meet on a regular basis and shall schedule a sufficient number of meetings (whether in person, by teleconference or other means permitted by applicable law) to carry out its mandate, which shall occur at least once each quarter.  </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">D.&#160;&#160;&#160;&#160;Reports from Committees/Subsidiaries</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unless waived by the Board, each committee chair shall provide a report to the Board on material matters considered by the committee at the first Board meeting after the committee's meeting.  Each board of a material subsidiary that does not have the same directors as the Board shall provide a report to the Board on material matters considered by the subsidiary board at the first Board meeting after the subsidiary's meeting.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">E.&#160;&#160;&#160;&#160;Chairman</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board shall appoint a Chairman of the Board who shall have responsibility to ensure that the Board discharges its duties and responsibilities.  Where it is not appropriate for the chair to be an independent director, the Board should consider whether it should appoint an independent director to act as a lead director.  The Board shall develop a written position description delineating the chair&#8217;s role. </font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">F.&#160;&#160;&#160;&#160;Outside Advisors</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board shall have the authority to retain, at the Company's expense, independent advisors and consultants to advise the Board as it determines necessary to carry out its duties and to fix the remuneration of such advisors and consultants.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B - </font><font style="font-family:Arial;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board may request any officer or employee of the Company, or the Company's internal or external auditors or legal counsel to attend a meeting of the Board or to meet with any directors of, or consultants to, the Board.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">G.&#160;&#160;&#160;&#160;Governance</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board has responsibility for developing the Company's approach to governance issues although the Corporate Governance Committee plays a key role by recommending and reporting on governance issues, including ethical conduct, to the Board.  The Board may delegate specific governance issues to other committees of the Board.  The Board is responsible for establishing the appropriate procedures to ensure that the Board, Board committees and individual directors can function independently of management.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H.&#160;&#160;&#160;&#160;General Duties</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is the duty of the directors of the Company to manage, or supervise the management of, the business and affairs of the Company.  In exercising his or her duties, every director shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill that a reasonably prudent person would exercise in similar circumstances.  Each director is expected to attend all regularly scheduled meetings of the Board and all of the committees on which they serve and to be prepared for such meetings by reviewing materials provided in advance of meetings.  Each director shall also comply with the provisions of the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:Arial;font-size:10pt;">&#32;(Alberta), and the By-laws of the Company.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">I.&#160;&#160;&#160;&#160;Directors' Duties and Responsibilities</font></div><div style="line-height:150%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board has responsibility for stewardship of the Company, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to the extent feasible, satisfying itself as to the integrity of the Chief Executive Officer (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CEO"</font><font style="font-family:Arial;font-size:10pt;">) and other executive officers (as defined in National Instrument 51-102 Continuous Disclosure Obligations) and that the CEO and other executive officers create a culture of integrity throughout the organization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">adopting a strategic planning process and approving, on at least an annual basis, a strategic plan which takes into account, among other things, the opportunities and risks of the business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the identification of the principal risks of the Company's business, and ensuring the implementation of appropriate systems to manage these risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">overseeing succession planning (including appointing, training and monitoring senior management);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">adopting a communication and disclosure policy for the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">overseeing the Company's internal control and management information systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">developing the Company's approach to corporate governance, including developing a set of corporate governance principles and guidelines that are specifically applicable to the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">reviewing and disclosing, no less than annually, measures for receiving feedback from stakeholders.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the above, the Board shall:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Compensation Committee, review and ratify the employment, appointment, grade levels and compensation of the top five executive employees of the Company, or any additional employees directly reporting to the CEO, and approve all senior officer appointments;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B - </font><font style="font-family:Arial;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Compensation Committee, develop a position description for the CEO, which together with other board approved policies and practices, should provide for a definition of the limits to management's responsibilities, and approve the objectives of the Company to be met by the CEO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Compensation Committee, ensure the performance of the CEO is evaluated at least annually;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Compensation Committee, develop a process to evaluate the effectiveness of each director and the Board as a whole on no less than an annual basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review and approve the strategic plan, the annual business plan and accompanying capital plan and financial operations budget, including all material capital expenditures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approve material divestitures, acquisition and financial commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Audit Committee, approve the annual audited financial statements, Management's Discussion and Analysis ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">MD&amp;A"</font><font style="font-family:Arial;font-size:10pt;">), Annual Information Form, management information circular and other annual public documents of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the assistance of the Audit Committee, approve the quarterly reports to the shareholders, including the unaudited interim quarterly statements and the quarterly MD&amp;A;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">determine the content and frequency of management reports;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review any recommendations from regulators or the external auditors respecting their assessment of the effectiveness of the internal controls that come to their attention in the conduct of their work; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ensure an independent audit/inspection function is in place to monitor the effectiveness of organizational and procedural controls.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further the Board will also consider periodically or annually as the case may be:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:150%;text-align:justify;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;">In Respect of Operations of the Board:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">assess the needs of the Board with respect to the conduct of the affairs of the Board, including:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the size of the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the frequency and location of Board and committee meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">procedures for establishing meeting agendas and the conduct of meetings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the availability, relevance and timeliness of discussion papers, reports and other information required by the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">recommend at the first meeting of the Board following each annual meeting, the allocation of directors to each of the Board committees and thereafter, where a vacancy occurs at any time in the membership of any Board committee, recommend a particular director to the Board to fill such vacancy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">oversee continuing education for all directors in respect to the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">oversee the relationship between the Board on the one hand and officers of the Company on the other hand and, if appropriate, make recommendations with a view to ensuring that the Board is able to function independently of management.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.&#160;&#160;&#160;&#160;In Respect of Governance:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review periodically the Company's approach to governance issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review periodically the mandate for the Board and the positions description for the Chairman of the Board, the President and CEO, and the Chief Financial Officer ("</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CFO"</font><font style="font-family:Arial;font-size:10pt;">)</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">of the Company;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B - </font><font style="font-family:Arial;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review periodically the charters of the committees of the Board and, where appropriate, make recommendations thereon including changes in the role, size, composition and structure of the committees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">conduct periodic surveys of directors with respect to their views on the effectiveness of the Board, the Chairman of the Board, each committee of the Board and its Chair and individual directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">evaluate periodically the performance of the Chairman of the Board and the Chair of each committee and the performance and contribution of individual directors, having regard for the mandate for the Board and position description for the Chairman of the Board and the results of surveys of the directors, attendance at Board and Board committee meetings and overall contribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">assess the effectiveness and review the performance of the Board as a whole and each committee of the Board, including the Committee and the Chairman of the Board, President and CEO, and CFO of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review the Company's director qualification criteria including the number of boards on which directors may sit, director tenure, retirement and succession; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review the procedure to enable an individual director to engage an outside advisor at the expense of the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">recommend policies regarding succession in the event of an emergency or the retirement of the Chairman of the Board, CEO, and/or CFO of the Company.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.&#160;&#160;&#160;&#160;In Respect of Board Composition and Director Nominations:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review periodically the competencies, skills and personal qualities required of directors in order to add value to the Company, in light of</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the activities of the Company and the nature of its investments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the need to ensure that a majority of the Board is comprised of independent directors within the meaning of applicable laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the constating documents of the Company; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">the Company's governance guidelines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review the competencies, skills and personal qualities of each existing director, and the contributions made by the director to the effective operation of the Board and any significant change in the primary occupation of the director;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ensure candidates understand the demands and expectations of a director of the Company and the role of the Board and its committees; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">oversee an orientation program to familiarise new directors with the business and operations of the Company, including the reporting structure, strategic plans, significant financial, accounting and risk issues and compliance policies, management and the external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:150%;text-align:justify;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;">In Respect of Reporting and Disclosure Requirements:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review and approve the annual corporate governance report to be made in the proxy circular prepared in connection with the Company's annual meeting describing the corporate governance practices of the Company with reference to the reporting requirements of the Toronto Stock Exchange or other applicable securities law requirements;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B - </font><font style="font-family:Arial;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review and approve the statement of executive compensation to be made in the proxy circular prepared in connection with the Company's annual meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Corporate Disclosure Policy" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Code of Ethics &amp; Conduct" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Whistleblower Policy" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Fraud Policy" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Diversity Policy" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Indemnity Policy" of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Terms of Reference for the Chairman of the Board";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Mandate of the Board of Directors";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the position description for the CEO of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the position description for the CFO of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xiii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Audit Committee Charter";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xiv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Compensation Committee Charter";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xv)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Governance &amp; Nomination Committee Charter";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xvi)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Disclosure Committee Charter";</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xvii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Insider Trading Policy"; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(xviii)</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">review at least annually the "Majority Voting Policy".</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B - </font><font style="font-family:Arial;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">YOUR VOTE IS IMPORTANT - SUBMIT YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;PROXY TODAY.</font></div><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FOR ASSISTANCE VOTING YOUR </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:8pt;">&#160;PROXY, PLEASE CONTACT LAUREL HILL ADVISORY GROUP AT:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1-877-452-7184 TOLL FREE (1-416-304-0211 COLLECT), OR BY EMAIL AT ASSISTANCE@LAURELHILL.COM</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s39E67739E705587591D856C58C524FB2"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(This page intentionally left blank)</font></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vote the </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">&#32;proxy well in advance of the Proxy Voting Cut-Off of 10:00 A.M. (Mountain time) on June 24, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.65900383141762%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:8%;"></td><td style="width:37%;"></td><td style="width:36%;"></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #ffffff;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ffffff;font-weight:bold;">Voting Method</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #548dd4;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #000000;"><div style="padding-top:8px;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;font-weight:bold;">Registered Shareholders</font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#ffffff;">If your shares are held in your name and represented by a physical certificate or in a direct registration system.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #548dd4;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;font-weight:bold;">Non-Registered Shareholders</font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#ffffff;">If your shares are held with a broker, bank or other intermediary.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Internet</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="interneta01.jpg" alt="interneta01.jpg" style="height:55px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not available</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">www.proxyvote.com</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Facsimile</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="faxa01.jpg" alt="faxa01.jpg" style="height:52px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">North American toll free:</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1-866-249-7775</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outside North America:</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">416-263-9524</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date, and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">voting instruction form and fax it to the number listed therein.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Telephone</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="phone.jpg" alt="phone.jpg" style="height:47px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not available</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Call the toll-free number listed on your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#160;voting instruction form and vote using the control number provided therein.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mail</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="maila01.jpg" alt="maila01.jpg" style="height:50px;width:52px;"></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">proxy and return in the enclosed postage paid envelope to: </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Computershare Investor Services Inc. </font><font style="font-family:Arial;font-size:10pt;">100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#160;voting instruction form and return it in the enclosed postage paid envelope.</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUESTIONS OR REQUESTS FOR ASSISTANCE WITH VOTING MAY BE DIRECTED TO AURINIA&#8217;S </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROXY SOLICITATION AGENT:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:176px;"><img src="laurelhill.jpg" alt="laurelhill.jpg" style="height:68px;width:268px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NORTH AMERICAN TOLL FREE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1-877-452-7184</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COLLECT CALLS OUTSIDE NORTH AMERICA</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1-416-304-0211</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EMAIL</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ASSISTANCE@LAURELHILL.COM</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>a9932019formofproxy.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1EC93AF7A50B588F952E52700AFBBE00"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exhibit 99.3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="a2019proxy1a01.jpg" alt="a2019proxy1a01.jpg" style="height:882px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="a2019proxy2.jpg" alt="a2019proxy2.jpg" style="height:882px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>a9942019shareholderletter.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb4174280c9c34dd689d8e9c0fec7d290"></a></div><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exhibit 99.4</font></div><div style="line-height:150%;padding-bottom:0px;text-align:left;"><img src="aurinialogoweb700pxa05.jpg" alt="aurinialogoweb700pxa05.jpg" style="height:42px;width:112px;"></div><div style="line-height:120%;padding-bottom:10px;text-align:right;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;text-decoration:underline;">Letter to Shareholders &#8211; Your Vote is Crucial</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Dear Shareholders,</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">You have a decision to make at Aurinia&#8217;s 2019 Annual General Meeting of Shareholders being held on Wednesday, June 26, 2019 at 10:00 a.m. MT in Calgary, Alberta. Your vote will determine the direction of Aurinia&#8217;s future. The Company is moving in the right direction but a dissident shareholder is trying to impede this positive momentum. We ask you to support Aurinia&#8217;s plan and proposed director nominees after reading this letter and the accompanying Notice of Meeting and Management Information Circular.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Over the past year, Aurinia has achieved a number of goals and implemented positive actions including the advancement of voclosporin, maintaining a robust balance sheet, and undertaking board refreshment and improved governance initiatives. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Voclosporin, a potentially best-in-class calcineurin inhibitor (&#8220;CNI&#8221;)</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The past two years were a critical time in Aurinia&#8217;s growth, driven primarily by the potential of voclosporin, a next-generation CNI, being investigated for the treatment of lupus nephritis (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LN</font><font style="font-family:Arial;font-size:10pt;">&#8221;), focal segmental glomerulosclerosis (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FSGS</font><font style="font-family:Arial;font-size:10pt;">&#8221;), and for the management of dry eye syndrome (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DES</font><font style="font-family:Arial;font-size:10pt;">&#8221;).</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the leadership of Dr. Richard Glickman, Aurinia's former Chairman and CEO, the Company rapidly matured from an early stage clinical company pursuing a single indication for voclosporin into a late stage clinical company advancing this novel compound for multiple indications and preparing for commercialization. In addition to diligently executing on clinical development, the Company succeeded in strengthening its intellectual property portfolio and began expanding across critical functional areas including medical affairs, regulatory affairs, and commercial. This growth being necessary to support the planned submission of a rolling New Drug Application to the U.S. FDA in 2020 for voclosporin, assuming positive AURORA Phase 3 results which are anticipated by the end of this year. We believe that a robust balance sheet is critical to achieving our goals, and we have made significant efforts in this area over the past few years.  We believe our current cash position is sufficient to fund our existing LN program, our ongoing Phase 2a study in FSGS, commence further studies for DES, and fund supporting operations until approximately mid-2020.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent Highlights</font></div></td></tr><tr><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#9679;</font></div></td><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-style:italic;">AURORA Phase 3 trial in LN fully enrolled in September 2018 with results anticipated in late 2019.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#9679;</font></div></td><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-style:italic;">Reported results from a Phase 2a Dry Eye study with voclosporin ophthalmic solution ("VOS") that achieved statistically superior efficacy in secondary objective endpoints compared to cyclosporin ophthalmic emulsion 0.05% (Restasis</font><font style="font-family:Arial;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:9pt;font-style:italic;">), the current DES market leader. VOS did not meet the primary endpoint as both drugs were well tolerated and demonstrated less than anticipated drop discomfort.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#9679;</font></div></td><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-style:italic;">Received a Notice of Allowance from the United States Patent and Trademark Office for claims which have the potential to cover voclosporin's method of use and dosing protocol for LN until December 2037.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#9679;</font></div></td><td style="vertical-align:top;background-color:#ffe93b;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-style:italic;">Robust balance sheet of approximately $144.3 M USD as of March 31, 2019.</font></div></td></tr></table></div></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New CEO and Continued Good Governance</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As previously announced last November 2018, Dr. Glickman retired as Chairman and CEO of Aurinia, effective April 29, 2019. The Board initiated a global search through its Governance and Nominating Committee in order to identify the right individual to lead Aurinia through its next phase of growth. After a diligent and extensive executive search </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">and evaluation of several highly qualified individuals, the Board unanimously approved the appointment of Peter Greenleaf as Chief Executive Officer. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In conjunction with Dr. Glickman&#8217;s retirement as the Chairman and CEO, the Board took the opportunity to split the roles of CEO and Chairman, elevating independent director Dr. George M. Milne, Jr., PhD, to the position of Chairman of the Board.  </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are very thankful for Dr. Glickman&#8217;s efforts over the past few years and are looking forward to the future as we build upon our successes. While we previously had a lead director in order to retain the independence of our Board, one of our key goals in insuring Aurinia follows good corporate governance practices was to separate the role of Chairman and Chief Executive Officer on a go forward basis, and we have successfully accomplished that goal.</font></div><div style="line-height:174%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">An Experienced Approach</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For Aurinia&#8217;s current stage of development, the Company has attracted and assembled a very accomplished and experienced Board of Directors. Aurinia&#8217;s Board includes a diverse group of members with a wealth of drug discovery, development, and commercialization experiences, from across a range of backgrounds including pharmaceutical, biotechnology, finance, corporate and legal. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While providing continuity (in that seven of the eight nominees are current directors, with two of those seven having been appointed as directors on April 29, 2019), we have also sought out new experiences and skill sets in our directors as the Company&#8217;s focus on moving towards commercialization grows.  That&#8217;s why we are pleased to include Dr. Daniel Billen (appointed as a director April 29, 2019) and R. Hector MacKay-Dunn as nominee directors, each of whom will provide significant experience and fresh perspective to our board of directors.  We are also proud to have a group of returning directors, including Dr. George Milne, Dr. David Jayne, Dr. Michael Hayden, Joseph Hagan and Dr. Joon Lee, (Managing Director with ILJIN SNT (&#8220;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ILJIN</font><font style="font-family:Arial;font-size:10pt;">&#8221;)).  Peter Greenleaf, our newly appointed CEO, is also included as a nominee director. We believe that these proposed nominees provide the Company with a robust and qualified board of directors, who will be properly placed to help guide Aurinia towards future success.  We would like to thank Dr. Benjamin Rovinski and L. Jeffry Randall, two of our current directors who are not running for re-election, for their years of service on the Board, and the strong stewardship they have provided to Aurinia.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, the management team at Aurinia is tenured and passionate about their work bringing a successful track record to the table in the area of immunosuppressant drug development and the commercialization of drugs in general. People are what make companies and drugs succeed, and Aurinia has been fortunate to have great individuals throughout the organization.  We are very proud of the many achievements we have been able to make as an organization, particularly when operationally we have a very lean team.  </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our key priority is ensuring we remain focused on our strategic objectives for voclosporin, its clinical development programs, pre-commercial and regulatory activities, in order to address the unmet medical needs of patients suffering from disease. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe management&#8217;s proposed nominees have a wealth of relevant experience and are well qualified, and the Board strongly recommends that shareholders vote in favour of management&#8217;s nominees for election to the Board.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Dissident Nominees</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On May 24, 2019, ILJIN, a holder of approximately 14.94% of the outstanding shares of Aurinia, provided us with notice of their intention to solicit proxies on behalf of a dissident group of four nominee directors handpicked by ILJIN.  We have been in continuous discussions in respect of various matters with ILJIN over the past few years, and in particular in the past few months with respect to the proposed director nominees for Aurinia.  The Board is always open to considering shareholder proposals that are in the best interests of Aurinia and all of its shareholders and the Board </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">will give ILJIN&#8217;s nominees careful and due consideration. We intend on providing our views on the dissident nominees to shareholders of Aurinia in due course.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is worth noting that the impact of electing ILJIN's slate of four nominees to Aurinia's eight person Board would be to grant ILJIN, one shareholder, effective control of Aurinia without paying Aurinia's shareholders a premium.  </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have made numerous attempts to come to a mutually satisfactory resolution on matters with ILJIN, in particular in respect of ILJIN&#8217;s proposed group of nominees for election as directors.  We believe it is unfortunate that they decided to abruptly cease those negotiations, and instead decided to pursue poorly planned aggressive action which will force Aurinia to unduly incur substantial cost and place an undue burden on the time of management that would be better spent executing Aurinia's strategic plan.  This is particularly the case as we move towards completing our critical Phase 3 AURORA study of voclosporin in LN, with results expected in late 2019.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Your Vote Matters</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ILJIN should not be allowed to take effective control of Aurinia without paying Aurinia's shareholders a premium by replacing half of the Board with its hand-picked nominees. You, as a shareholder, have the ability to stop this. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We encourage you to read the enclosed Notice of Meeting and Management Information Circular (also available on Aurinia&#8217;s SEDAR profile at www.sedar.com and on our website at </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">https://www.auriniapharma.com/agm-materials</font><font style="font-family:Arial;font-size:10pt;">) prior to casting your vote. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Your participation at the 2019 Annual General Meeting of Shareholders is important to us and we urge you to vote your shares by using only the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">proxy </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;management&#8217;s nominees for directors of Aurinia and the other matters proposed by Aurinia. </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia has a bright future and the right team behind it to continue the ongoing development programs with voclosporin and achieve upcoming planned milestones. Your support will allow this to happen.  </font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Aurinia thanks you for your continued support and we look forward to sharing with you a year of success and growth.</font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:150%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sincerely,</font></div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Peter Greenleaf</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ George Milne</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peter Greenleaf</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">George Milne, Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chairman of the Board</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vote the </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">&#32;proxy well in advance of the Proxy Voting Cut-Off of 10:00 A.M. (Mountain time) on June 24, 2019.</font></div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:8%;"></td><td style="width:37%;"></td><td style="width:36%;"></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #ffffff;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ffffff;font-weight:bold;">Voting Method</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #548dd4;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #000000;"><div style="padding-top:8px;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;font-weight:bold;">Registered Shareholders</font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#ffffff;">If your shares are held in your name and represented by a physical certificate or in a direct registration system.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #548dd4;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;font-weight:bold;">Non-Registered Shareholders</font></div><div style="padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#ffffff;">If your shares are held with a broker, bank or other intermediary.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Internet</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="interneta01.jpg" alt="interneta01.jpg" style="height:55px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not available</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">www.proxyvote.com</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Facsimile</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="faxa01.jpg" alt="faxa01.jpg" style="height:52px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">North American toll free:</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1-866-249-7775</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outside North America:</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">416-263-9524</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date, and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">voting instruction form and fax it to the number listed therein.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Telephone</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="phone.jpg" alt="phone.jpg" style="height:47px;width:52px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not available</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Call the toll-free number listed on your </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#160;voting instruction form and vote using the control number provided therein.</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mail</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div><img src="maila01.jpg" alt="maila01.jpg" style="height:50px;width:52px;"></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">proxy and return in the enclosed postage paid envelope to: </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Computershare Investor Services Inc. </font><font style="font-family:Arial;font-size:10pt;">100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Complete, date and sign the </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">YELLOW</font><font style="font-family:Arial;font-size:10pt;">&#160;voting instruction form and return it in the enclosed postage paid envelope.</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:150%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUESTIONS OR REQUESTS FOR ASSISTANCE WITH VOTING MAY BE DIRECTED TO AURINIA&#8217;S </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROXY SOLICITATION AGENT:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:176px;"><img src="laurelhill.jpg" alt="laurelhill.jpg" style="height:68px;width:268px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NORTH AMERICAN TOLL FREE</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1-877-452-7184</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COLLECT CALLS OUTSIDE NORTH AMERICA</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1-416-304-0211</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EMAIL</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ASSISTANCE@LAURELHILL.COM</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a2019proxy1a01.jpg
<TEXT>
begin 644 a2019proxy1a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#:17AI9@  34T *@    @ ! $[  (
M   %   (2H=I  0    !   (4)R=  $    *   0R.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI;F$    %
MD ,  @   !0  !">D 0  @   !0  !"RDI$  @    ,S,P  DI(  @    ,S
M,P  ZAP !P  " P   B2     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4-0^PZ=XA%R]J%9K"&\BD,<B*(_,( +AL *>=O/3/-7:E*[5Q:HZ+5M7;3]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** .)\9Z7\0[W68I/!.NZ?IU@+<+)
M%<QAF,NYLMS$_&TJ.O8\5SW_  C_ ,:_^AOT7_ORO_R/6A\3]2ALO$7AJ'4M
M=O\ 1M,G-S]IFLKEX2<(I7)7KS[=ZMV?BRVTRQLM.\++J'BEY+:2]\ZXN_G$
M(<@DNXR3G(5<=NU=T7)4TTE]WKN_D0UK8Q/^$?\ C7_T-^B_]^5_^1Z/^$?^
M-?\ T-^B_P#?E?\ Y'KH?^%BM>ZMI-GH&BRZDNIV2WJR?:%B\E-^UMP(_AYZ
M$DGC'>J5M\4+RY:R,?A>9H[ZZFLK=UO$^>9"1C! PI R6[8/!ZEWJ_R1^Y$^
M[W_K<R_^$?\ C7_T-^B_]^5_^1Z/^$?^-?\ T-^B_P#?E?\ Y'KN-#\6V^K>
M$Y=<NH&L4MO-%S$S!_*:(D.,CJ.#S6$WQ!O+BPE5=#FLKJ[T^2]TSSKA2)T4
M9.< [& (;:<\=ZGVE2[7)'3R12BG;4Q/^$?^-?\ T-^B_P#?E?\ Y'H_X1_X
MU_\ 0WZ+_P!^5_\ D>NI^&LM_<?#^RO-5>X>YND\XR3W1G+A@#N!/W0?[O:O
M._"NMSQKX7N[3Q9?ZCJ]_J)@OM+GU#SU$.Y\L8R24P #FM5S.4HVCIIMZ_Y$
M:<O-J;?_  C_ ,:_^AOT7_ORO_R/1_PC_P :_P#H;]%_[\K_ /(];%M\3KB>
MWGN'\.3K#]L-A:,MTC?:K@2%0@! (&!N+'@<CG%3W/Q(^P:;-=:AH\L!T^]2
MTU6/S@QM%8 K*"!^\4Y'H>:CFJ_R1^Y?UU15E>U_Z_I&!_PC_P :_P#H;]%_
M[\K_ /(]'_"/_&O_ *&_1?\ ORO_ ,CUTNG>/I+E]*?4M).GVNJV\]Q!*]QN
M(6/# ,NT8+)ENO&.];OAO67UWPS9:O/:_8OM<8E$)DW[5/W><#J,'IWJ95*D
M5=P7W+S_ ,F"2>S//?\ A'_C7_T-^B_]^5_^1Z/^$?\ C7_T-^B_]^5_^1Z]
M0O+R&RT^>]G<"&")I7;/15&3_*O-/AEXEU<MJ\7B&>6YFN+9=9M$ED)VPR9^
M09Z 8' X&:(U)2C*7+'3R0W&UO/^O\OO(O\ A'_C7_T-^B_]^5_^1Z/^$?\
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M'T-'-5?V(_<@T75G._\ "/\ QK_Z&_1?^_*__(]'_"/_ !K_ .AOT7_ORO\
M\CUU7@:]NKN\\4K=W,TX@UJ:*(2R%O+0*F%7/0<G@5YC:>*=<'@_Q%8-JUXU
M_=7J&RG:X<R11M*Z,%;.0 (6Z>M.+DWM'IT74;27WM?=?_(Z3_A'_C7_ -#?
MHO\ WY7_ .1Z/^$?^-?_ $-^B_\ ?E?_ )'K0T[X@7&F^&-+7^SKC5GM='@O
MM3N3< -%&R_>^;)D8X8XR.!UK4N?B)%#JDBP:9)/I-O/#;W.HK,H$<DH4KA.
MK*-ZY.>,]#1+VJE907W+T)3C:]_ZW.;_ .$?^-?_ $-^B_\ ?E?_ )'H_P"$
M?^-?_0WZ+_WY7_Y'IEOXLUJ\CN&UJ.YA2/Q5%9PM9WPC*C=CRFPGS(,#(_BW
M'D8KH(/B2\E^J3:'+'8_VN^DO=BX4@2[L*0N 2#W],]Z;]ITC'[EY?YE.RO=
M_P!:_P"3,+_A'_C7_P!#?HO_ 'Y7_P"1Z/\ A'_C7_T-^B_]^5_^1ZW[CXC/
M'<HT&BR2Z?)JJZ5'=FX"[I-^UVVX)"CG![X[5-XRUW6M,\5>%[+28%DM[ZZ=
M9P9@GF (3MY4X 'S>^,=ZA2J-I<L=?)=K@TE?78YK_A'_C7_ -#?HO\ WY7_
M .1Z/^$?^-?_ $-^B_\ ?E?_ )'KIK;XA1W&I09TN=-)NKUK"WU(R*0\P)'*
M=0I*D!O7L*K^,=8U73?'_AF+28;B\,\-WNLDN/*CF(5<%R>,#GD@X[4*<VTG
M&.M^BZ*X-)7U_K8P?^$?^-?_ $-^B_\ ?E?_ )'H_P"$?^-?_0WZ+_WY7_Y'
MKH%^(YO;#3FT719KR_O$F>2S>=8C (6VR98@@G=P!W]J3QGXB-]\'+S7M$N+
MBV,UM'+#)&Y21,NN1D'@]1Q1S5+I.*WMLO0:2;M<P/\ A'_C7_T-^B_]^5_^
M1Z/^$?\ C7_T-^B_]^5_^1ZWX_B-]DMM576-&N;.YTV&&5(#,DC7"RG:F".%
M8MP1SCUK-U[Q??WL%C:R07&BZG::[90W=O'<[@T<G(PZXW*PZ@CL151=1RMR
MQ^Y>7^9.EKW_ *M<I?\ "/\ QK_Z&_1?^_*__(]'_"/_ !K_ .AOT7_ORO\
M\CU8\2^-K_4;BP72K.[M=.3Q#!9?VA'<;?/*OB1"@YV'IGD''(%=GXB\2-HM
MQ8V5G8OJ&HZ@[+;VRR",$*-S,S'H /8]:ESFDGRQU\EY,=E>U_ZU_P CA/\
MA'_C7_T-^B_]^5_^1Z/^$?\ C7_T-^B_]^5_^1ZZ _$?SETA-/T::XNM1GN+
M5K9IE1H)H1\RDX((SWSTYYZ5HV6LR>,/ -Y<V:3Z==R13VY1)?G@F7<IPXQT
M8<$8I2J5(KF<5;T0TDVE<X[_ (1_XU_]#?HO_?E?_D>C_A'_ (U_]#?HO_?E
M?_D>LVS\9:I=^(?"-Z+^?^S[:TMHM23S6VR33AT!<9PQ!0'GN:UO#OCN_LO#
MZ2&QNM:N)H[C5KDM<X^S6IE8*%W9R<#A!@<=:VDJD?LQ^Y>?Z*Y"L^_3\?\
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M'D<Y(JIK_AO5Y?$BZYX;NK.&ZDLFL9TO$8J4+;E=2O.X$GCH?:L+XB?%S_A
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M[U!>^ -8U2RO8;^^M%?7+Y)M6:W+KM@10%BBR#DG R3COQ7'_P##2G_4J?\
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MA^UNI[1+6"2T@9/,PZLSR/MR"=H^4 C/>M;Q#\/;G7]0UF26XMTAOK&VAAW
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M7PYOQ9VY6WT.PG75;:\>+3XFCC$41.1NVY=CDD9  SC-<G_PTI_U*G_E1_\
MM5'_  TI_P!2I_Y4?_M5.-'%Q5DOR_S\A7I_UZ6.NN/A_KHFBL[._L/[)AUM
M=5C617$V"^YD) (XR<>O&<5T?B;P_?ZAJFE:QHD]O%J.F-)L2Z5C'*DBX925
MY'0$'GI7EW_#2G_4J?\ E1_^U4?\-*?]2I_Y4?\ [54_5\5I[NWIVL/FAK_7
MF=QIW@&]L-2T"\-W;S26=[=WM^^&7S))U(_=K@\ D#DC@5N^#=!N?#VBSV=\
M\,DDE[/< Q$D;9)"P'('.#S7E7_#2G_4J?\ E1_^U4?\-*?]2I_Y4?\ [51+
M#XJ2LX_D'-#O_6O^9T5O\*+V#P7XETD7-J+K4KP3V4@=ML2(P:,,=N01ST!Z
MU+J/PMF8:9)8Q:/=RV^EQZ?*NI0M(D93I+'QR>3P<9]17,?\-*?]2I_Y4?\
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MJ/\ ]JH>'Q+5G'\O/_-A>'1_U_2L=GKGAOQK<?$(:]I3:!-;6\0ALXM1:8M
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M3_RH_P#VJC_AI3_J5/\ RH__ &JCZEB/Y?Q0>TCW/=**\+_X:4_ZE3_RH_\
MVJC_ (:4_P"I4_\ *C_]JH^I8C^7\4'M(]SW2BO"_P#AI3_J5/\ RH__ &JC
M_AI3_J5/_*C_ /:J/J6(_E_%![2/<]THKPO_ (:4_P"I4_\ *C_]JH_X:4_Z
ME3_RH_\ VJCZEB/Y?Q0>TCW/=**\+_X:4_ZE3_RH_P#VJC_AI3_J5/\ RH__
M &JCZEB/Y?Q0>TCW/=**PO!?B7_A+_"%EKGV3[']J\S]QYGF;=LC)][ SG;G
MIWK=KEE%Q;B^A>X4445(!1110!GZEX@T;1I$CU?5[&P>0;D6ZN4B+#U 8C-+
M::]H^H&$6&JV-R;C<(1#<H_F;?O;<'G&1G'2N5^+UC:3?#S4+F:UADN(O*"2
MM&"Z RID ]15#Q1IDL/C[PG9^''MM)D:WO2LJ6RLL>43)"< GZ_K71"G&44W
MY_@KDR;1Z%)>VL-W#:RW,*7$X8Q0M( \@7[Q5>IQWQTJ:O)+/Q5KFJMX7NXX
M;6YU22SU(#=;I^\EB&U<,1N0$@9"D ]ZZ#X>^*+O6KR[M-4U*>2\BB222QO;
M 6T\#$D-C;PR9QCJ?4\TY8>45?M_FU^@N;N=->^*O#VFW;6NHZ[IEI<)C=#/
M>1HZY&1E2<CBM56#*&4@J1D$'K7E)%PWQ7\4+!X2A\0J3:!WEEA3[./*]).N
M?;TJW=^+]=B34=>@N($TK3=7&FG3?(!,B!U1GW]0V6R .,#O1["_*H[M+\;?
MYA*5K_UY_H>ET5Y2_B/Q8/"_B[7?[:C6'3;BYMK2W%I'N4K(NURV.< E<8]R
M346J^(_&6FR:XG]NV[_V;IT.I@_84&XMG,/7[G!Y^]TYH6'D^J_KY#YOZ_#\
MSUNH;N\MK"U>YOKB*V@C&7EF<(JCW)X%<WXH\0WUEH>D?V88X;W6+J"U261-
MZP;QDMCO@ X![UPGBZ]UG5-/FT34-3#3:5KUG ;F.V0"X63:R,RD$!E)Z#@]
MQ2IT'-V\[?BE^J$YI*_E?\_\CUR?4K&UT[[?=7MO#9[0WVF255CP>AW$XP<C
M\Z9IVKZ;J\32Z3J%K?1J<,]M.L@!]RI-<G\5(S!\)=0B<^:8T@4D(!OQ*G8<
M#/I7+S/?Z?)XD\5Z#H5QX9MX=%$4:W%M'&TLX;=O\L$C@<9/6G"E&4'*_5_I
M^=QMO0]@HKS>#4O%]QJ<.B#7;=+O^SCJDMU]A7'S$!(0N<;00<MU/M61J7C[
MQ));>&[JPO+:U7Q- MNB2*G^ASB0!I5R,LI!. <C.*%AY-V37]7_ ,F+G5K_
M -=/T=SU^H9[RUMI88KFYAADN'V0I)(%,C8SA0>IP,X%>=ZOXGUW3=;U#PXF
MH%]0N+RS739VACW+#)_K#C;@X\N3D@]:W?&%U+;>(O"<<2POYVHLC&2%'/\
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MM+VWBN+.ZAN(9L^5)%(&5\=<$<'H>GI7%:'JGB37;J?5X]2M$TQ;ZXM#ILL
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M'[Q>>2=PSWJYX5Q=D^E_S_1"C*^_E_7WGK]%>;Z7XHUVVU,0ZSJUH\5WX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YWQ9;>:^CSF>9
M1#J4&(D?".2X&6'?'..W.<9QC+^)]Q;77PWOV2:!XEN88Y&D^:-2MP@8,,]
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M3*]D+Q+CRV"L"Q7;R.",'.<>G4'%C2M=T/4]9OX-,N/,O8@/M&8W7(4E1M+
M!E!##Y<C.>YK.H_=:Y+/?]/N+7Q7O_6YY#>>,?$GBGP_JT-ZQ@LVM3>IF)/]
M4TB1Q*>,\,LC=<].<<5NWOC#7[)9[2YUHVR6ES>1)J!M(V:YDC"&* KMV@MO
M;H 3MX.<UVL/Q$\+7%O+-%JF4C4,<V\H+@ML&P%<N=W&%R<\4L_Q$\+VS1++
MJ9)F@6=-EM*^48D _*IP25(QUSQC-:N;>BIZ?UY$VMNS)\6:WKL%GH0L[MM*
MN+NUN)KE5A1RKI!YFWYP<?,,5RLOQ&\6?VB_V2!YI?L(F2R$46QE-J)/.'/F
M$^8<8 VXXZUZ-)XY\.PQ6LDNH>6MUDQ[H) 5 ;:2XVYC&[C+X&:FL/%NB:IK
M$FEV-Z9+R,R*T9A=03&VUP&*A202,@$]0>E9QERIWI]_Z^0=M3R/4O&NN:IX
M5N[>^U*2#3YK>[6*^>&!FO6$28@/E[D4Y:3[N#A1W!KK?%6MZQI>F:-'HVHM
M9+_8UQ=OMACDWM#'&RCY@<#D@X['Z&NHN/'7ANUGO(I]35&LE=ISY3E0$(#[
M3MPY4D9"Y([U/=>+M%LM'MM3NKMX[6Z.(2;>3>^ 2<)MW< $GC@#/2FZC=K0
M_P"#H_+^K#2L]7M_P#SV^\6>(+ZZNK2*_>*XF62+^S8K9=T<!M=XN5;&[[_&
M<[><8S3]2O47P+X!NCK36Z+<)NU'8C&+%O("<$;>.1DCMDUW-QXY\-VMR8)M
M40,(O.++&[)MV;P-P!7<5&X+G<1T%16GQ"\,7LZPV^I$R-G :VE7HF_J5'5>
M1Z@'&:?-*VD.WX7\A6VN^_XG#Z7X[\47/B/0[2[$@%RD'[KR8D6[C8N'F^8A
MP0H5@$&!SGJ*VI/%VH+\8(-%BO2;)Y6@EM)(HUVX@\P.O5SDC[Q(!Y '&:WH
M?B#X9N+&2[AU%GBC\O(%M+O8/]PJFW<P.#R 1P?0T^/QYX;EO(+6+4M\LZQM
M'M@D*D.NY/FVX!(!P"<GIUI-N[?L^_X_+H'3?^D<++K&LZ'XRUN;293.EUJL
MT)L#$I$CK8B12&QNSE0, XZU5;Q'JNI3Z6WVW^VDM]0MY8;CR%C_ '[6\Q>#
M"@ [2%]QNP37J%AXFT?4U9K*]61$M4NV8HRJL3YVL20 /NMP>1CD5CW'Q(T)
M5LC8R2WGVJ[2UPL$BF/<I8.05SM('! P>QP"::F]N35)+[ANV]^_XGEZ>,=6
MM=2N=3@U::YDN[:R6]O8[>!3:G;.QCP^V,8<!<MSU&2U=WX/\3ZKJ7B21?$&
MI"VS#;1PZ<(D >:2 2.0P&[C#$#/<^U:FB?$G0M5\/\ ]HW,WV.2.-'GMRDC
MLA=BJA?E!DR1CY0>>*OVGB?P[K>KVMI:77VJ[6,74(6&3:JLK#<3C:#C<,$Y
MZCK55)/5.G;]/P)MUN<+J>N7^C^-]>B_MN6P@GO[99KEXD<6<!@)#C<I !<!
M,G(Y]>:TM:\6ZQ:_#72=1ENGT_4;QMIF6! &PKE2?,!";@H/0G)P!SD7(OBO
MI)DM'N;>>VM)Y+N-YY(Y,QF!E&=H3)!#9)Z+@YZ'&Y+XY\.0SWD4FH@-90M/
M,?)D*A%QN*MMP^-PR%)(S42YK).';\-"].:]SR>YUB_O=6AU*]UVXM3<-I%U
M)"B)L",OS-RI^4.?7&6YSQC2T[QSXJU.<6YO);5IKZW@E=H+<M:,\CJT2J-Q
MQM"D;QNR#V(KT.[\;Z3%X4U+7K)Y+R#3PPEC6)T?> /E(8 C.0<XQ@YZ54T?
MXBZ3J6J75A<DV,L3XA\Y7 E3R5E+$E0$(#'Y2<_*36G.Y)_N]OPV\OZ]#/ET
MWWT_,\[U;Q5J^L:-9VVKZEY2D6S1QBW0?;W%X4=B<<;0B'"X'S<\$5U_C[Q;
MJ&A^)]*M-.OF@#M"TL#Q1[)U>8(?F8%B0,\+C'4GH*ZFU\7:'>Z'=ZO;WVZR
MLU+7$AB=3& N[)0C=]T@CCD'C-53X_\ #(L&O#J6(EE\D@V\N_=MW?<V[L;?
MFW8QCG.*SYFY+W-F]/7Y%6T>N_Z' 1>-?$\5B99M5,BW-MYS3&UC_P!"47GD
MM( %Y 3).[(R,]*T=%UF32OA?JU_;ZC(7.KSJM\L*$G=.!YA#8100<DD8'7!
MZ5U<_P 1?"\%S);MJ3O+&VPK#:329.W=@;4.[Y>>,\<U;/C+0%U)+ ZBOVAT
M#J!&Y7E=X&[&T,5Y"YR1VH<GR_!Y_+?L/=[_ -6L>>:'XWUO56T^+4=<^P-)
M&%A\NR68Z@_GR1MT48*JJG*X SN(QQ6AHVM7VG_!K2[FWU)_-\](;N^DC5VL
MU,N)&(Q@E?5@<=3FNHB^(GA>>S:YAU%WC!C 5;68N^\$KM39N8$*W(!'!]#6
MC>>)]'T^PMKV\O1';74;2PR&-B&54,AZ#CY03@\\43D]N2VM_P!;;=@2N]SS
M.X\:>)_LIGBU4B*ULY+A'^RQ@7R+="-'.5X#(<_+CU&*M_$Z21-:U%9+Z2.*
M;PU<".W(&R1PX+ <9SC!X/8=JZ6^^)V@V6J6D'G&2TFC=Y;I8Y"(<)&X&T(<
MY60$G^$=:U9?&GAZ#4)+*74XUFC0NY*ML ";R-^-N[;\VW.<<XI\THN,N3O_
M %MT_JPEJWKO;]#S+4_'/BG1YY=.CO))_LMS)%%=>1 OGN(X7CA?=M4 ^8WW
M?G( QG!K9\,:IJ]Y\2+W38KW[%:"YNKF>".WB/FE6A7:6VY_C/(.>*ZYO'OA
MN/3TO9=0:.%Y#$/,MI58$+N)*%=P4*02Q& .<U:UKQ9HOA_R/[6O##]H1I(M
MD+R;E7&YOD4X # Y/;GL:.=Z+V>MFO5_=\Q<MU9,\W/B'5-%\6Z\FB7#75Q)
MJD[-I(@#;T%J&\W=C=PRJO7'.,9(K,C\1Z]KLFFW;:C+'-:-=/;WS0VY8D6F
MYT*H63ALCGG!YYKU.Z\=^&[*ZN(+G4@CV\1ED/DR%=H )PP7#$!E) )(STJ.
M#X@^&+EI535 IBCDD?S8)(]HC^_G<HY&0<=<$'&#0IR4?@Z6O\K7V*T;O?K^
M9YKKWCO5=0$UD][_ */>:3(+BT:*- K&R,N]>KD%OXB0.H XS76_#:R9==\0
MWDUPTTF^VA7>B95/L\; !@,X&[&,XXSU))Z!/'GAR3[,([]F-RQ5%%M+E2&"
MG>-N8_F('SXZUT-*=6T6E"UU;\?3Y"2O97O8****XS0**** "BBB@ K+\1Z1
M-KFARV%M?/8R.R-YJJ6!"L"58 J2IQ@@$<'K6I6#XUU671?"ES>07#VL@:-!
M.D:OY>YPN3O^4#GEFR!UP>E5&_,K 9GA/P%)X5U"*XCU19T6U>WDB%KL#9F>
M52#N.W&\C'.<#I5"3X7R2Q7L+:V/*N(+V"(?9.8EN)%D.3O^;:0?3.>V.>5L
MO''BR]TF[OHM39S86"R/%#;0MYC&XEB,A)4?=50W897L,UT#^+M8_P"%4G6#
M>M!<#4$ACO7BB<O 9U7>53<A.TD';QD<5W2C7C._,KWM]_R\S.\?Z\E<VM$^
M'\>B^*Y-8&HS3Q[I7AMW+XB>7&\_?*X..R ^I.!5&Z^&'VF"YC_M?;]HBO(\
M_9L[?M$RRY^_SMVX]\YXZ5R]YXD\0:M8ZA;#6O-L(=-OYTG^QPD:A'&RJI(*
MXP=Q'R@ XJ23Q'XAD\ZUBU1UMI))+".WCMXQL'V 2AE(7=N#=.<<_3"Y:R][
MFU2_#;L'NWMY_BM3:G^#\$\]W(=:N0&D:6SP9,VSM*)3TDP1N4?="'WSS4J_
M"LQV<\$.M%1=6?V>Y+V[2;W\XR[P6D)'+'@DYZYKE-+\=>([1=.LM)>74%CL
M(O)@:.';<+Y#,SYR)"5<!?E&,*<\FN@\"7S:E=>*;N35#JCRV=JS7)B6/+>4
M^5PH X.1^&#R#55/;TXMN6B_X;^O\R8\LK*VY/JOPUG327:RNVN[F&.Y,,2Q
MB,L\MRLZG+-CY2@&#PWJM7]!\)ZA>^"]9L/$K-;W.KW<L[% FZ/=MVG"LRYR
MN<9/'&:X;2_%FO:#X2M+..^E>U6ST^3[1'!"'LXI5DW ;\(1^[49<_Q'GI5Q
M/&GBZ32[[4KB_E@2V^Q1RPPVT!\I95!>;<W';(W-M&_G@<.5.JKQNM'^J_4$
MXNS^?X?Y';:9X&FL_$MOKU]JPN[Y9)9)RMMY:R;HTC4*-QVX"#UR2>E0:_\
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M-O%UE5+D;\#C(/3&:QV^(_B1?#L,D=Y-(_VB5&OECMGCD<1JT<8<[$*LQ.<
M/Q@#(HC3K+1-?\/KV_K8.:+L=?)\+(UT<V5EJ\ML\=\+NWE57'ECR1#L)616
M;Y0>0PZ]QG,L?PRBMS%;VVJ/'IV;:2>V,.YI)(% 0ARV57Y5RN#TZBJ/A[Q/
MK]WXPMX]0O";:YOKJU:R,,8$(CA6088#<2"2.21C\ZS-7\;:[:Z]K,%EJ_F2
M6MU<1)8?9D/E0K;>8)MVW/RO@<G'.#U%+]^W;FZ7_K^O,(\KV]/S.XTCPO=:
M;X4?09M36XMQ8K:0L+;88_D*LQ^8[LY!QQC'6G>&/"O_  C<MT_VS[3]HAMH
M\>5LV^3$(\]3G.,^WO7#MXJ\26-Q917>N-)/)#:2P0-9QK]N69OWQR%X$:^F
M,8RV<U6LO'GB"+P_?:Q<:D]X--NXP;86B(;FT=66.<<9^=BK<$#Y<8ZT2I57
MS:K7?SU]._\ 6XHN+2M\OZ^1M:/\/KQI;S5=[:-J+:HUW9+,%N!!'AQL95;!
M!,LAP&XW#WJR/A=Y$UK]CUIHX8_LQN$DM@[3-#,9000PVY+-Q@]O3!YVQU'Q
M%H?BBZF:]-U<W%[;6UW;&% +B0V6[.0 0=R@ # ]<U$/$FJZNFFBXO?[51+_
M $^=G^SB+[/<LS[[?@#[N!P<L,\GFKM5NFI+I_7]?F#<;-M;IO\ K^OP.M\9
M?#*W\7:N^H/J,EG(UJL "1[MKJ^1)]X<[2R?1OPJ#6_A8NJWMS/!JJ6JS2HZ
M+]C#-!MB6,%'#*RL-N00<<X*FN*A\6ZO'>7>L+J,EQ>R:?:)>21V\2MIX,[^
M8@#83Y.F7Z9Y-=EX U[Q!XBUJ5M5OFCM[:RAD^S"&+$Q<R 2%ESC(16P#CGT
MI.-:G"ZEHOZ_R!RCS;&M;^!?(UZ/4CJ32;-2-_L:'ELVWD[2V[KQNSCVQWJ"
M[\!73Z]=ZMI^MBUGEN_M4 >T$@B9H1%(#\PW J 1TP1WKBH_$^N:?9W!TV_6
MUAM5N[IH4M8MLK"_,>#\N0"IY(P<\YS5[XJ22KKMPC7\D,<VB$10%04=Q.A.
M,C.<8/7L.U)0J.:3EO=?)?\ # W%77;]7_P3KM2\"_:O!^FZ!8:G);0V("LT
MD?F+.NPJ0ZAESR=PYQD#@]*YK3OAKJL"WUI<WH-A;RPR6T0A4&[>*U6-7W;S
ML&X'*GT'..N=K'CGQ1I0-I'>23/;WMU;I=>1 OVAT\LQQ/NVJ =[9V?,<#'>
MNB\=>*=5T/7=%6UNC!!<!3-:QHADE8NH(&]2'X)&U&5AG/(H4:VR:]__ (>X
M<T;:_9_X8AT;X;Z@-+TV[U'5?)UFSM[5+;%LK):^4K?(P#XD^^P)!';'O:M_
MA@EOJ%G=KJS,UN\4L@:W_P!:ZS23,?O?*&,A&,'&.]<S;>/]:^SW<KZT]SMB
MNO/6.SC)T\I<".)LX Y!.2Q(^7/8YET7QWK5[)8IJ.MBT3<ZQ2):)/\ VBXN
M2GE_*!T3:?DV_>W=!BJDJ[?-=;_UT_K<'RJ+3]#LO#?@B3PYJL-W'J?GHMHU
MM+$;?;OS,\BL#N.,;R,<Y]J3P[X(FT+Q+>:Q<:L;Y[F%H</"5?!D+@LY<Y(S
MMX & .!BL?P#XLUS7;S54U0R%8(/,*R)$IM9M[#R@$);&T _. W![$5S6F^.
M/$NH:?8+;>(#</>"S6XN!9Q V<LDVQHP-N#E?FYYXR.#6?LZTI.-UT7WW\OZ
MZ=!R<4G?^K6_X!JZ9\*K^_T'3CKNJ26E]8(19QQ)C[*3+O.YXY 7S@="I'KG
MFMJW^&26VFWEK'J2M]JL8[5C-;>:NY97D9B'8Y#%R,9R.S9Y'/R>*_%8N;N&
MUU)KB]M3<M<V!M(P;>.!@4;.W_EJH/7KO^7&*KS^*=;^T1ZSYRP->Z=YZ3&V
MC+6=J]XJAON\[8SNYR,\G.*T:K2TYE9_\'_@B;BKNVO_  5^6AT4?PM>+3Q:
M)KTFR:V:TO-T&X20&0N$CW.3'C<0"2W!K6TGP0-*UNVU!;_S!!->2B+R<9^T
M,K8SN_AVXSWSVKS:S\7:UHMM%%I-S)<1W&HWDB3"*$"^E^T !&WE< J2<)\W
M((X!KH?"FKWFL_$^VFU.],MVEE>I)9&)4^Q8G0!,@9.5"G))/.>A%*4*UKN6
MFOY:A>.JMU7^1JZA\,/M\-U;-K++:,;E[2+[,"8'G;+EFW?..3@<8SR370^(
M?#MQJ[:?<:=J/]GWM@SF*9H!*N'0HP*Y'8Y!SP1WKSO5?%.K:&5NK:\,!NM5
MO#=0HB&68I,L:*N]2K810-BLKG.0>*BN_B'XICOM92))PL#NLJ>3!FP03JBN
MH+;CF,LQ,@"YP1\N:GV=62B[K^MRFTF[_P!?U8ZO5?AJ^J?:X9-<D^R7C+/-
M&]LK.UPL/E"3>"/EX#%0.HZ@<4V;X</&K30ZCYLD<B3+'Y&W>4M#;A<[N,YW
M9[=/>H#XDUVZ^'.E7L=XUK>WFIQ6HN_*B<O$TVP/M&Y,E<'CC/3BN>_X3OQ9
M;:GJ)DFFFATEWEOH'A@4K#'*J_*!\_SQEF)8#D#;Q0HUFG'F7;[K>7H*Z5G;
M^G?_ "-O3?AKJ<WA^T_M+63!?"TM;=HA;@QI%&#F%PKCS/F<\@@?*.#SF[IO
MPS.F06ZC5?.-O+92 "VV[OLP88^_QNW=>WO7-S^-O%UGJEA;7,DGG3VL4XA\
MF!5D$@=G.20Q,8V@;01\IW=13M/\7^)+76/#::CK;W\>IV]M,]O';1(Y,N<C
M;L&]1Q\R-E<98$5;C7;;NM_ZZ>1'N6[Z?@=1X1\&M;^'=<MM6MY;7^V9YOW!
ME5WMX&RJ1[E)' )/!(&:8OPYN3-;WD^N^9J%O-;LDWV,!/*A5U5"F[J1(V6S
MUQQVKE=/\6Z[K(D>_P#,:6TOK1T5TB4VTS7/EM" A+8,;$?. W7L17KMC?VV
MI6:75C,L\#DA77H<$@_J"*QJ>TA[U]_TL::-\OK^._\ 7^1PC?"D-86\ UJ1
M);:T@@BECA9"'BE9P_RN#@[\8!!&,AJV?"'@E/"5Q<RQWK7/VF"*-@R,"&0N
MS-EF8G)D/!Z8ZFNIHK)UJDDXMZ,?*KW.#;X:R/#-"VL@Q,FH)$/LO*+=$$Y.
M_P";:<GMG/;%59OA3-/->/-X@,OVBSFM$:2U+.BR!1U\S!"[.  .#^->C44U
M7J+9C:3_ #.6D\$K+HOB/3WOSC7&+;Q%_J<Q+'TS\WW,]NN/>LR3X9F[5QJ.
MK^:9KI[B8Q6WE[MUK]G('S''][//I[UWE%2JTUL_Z_I!RI'!CP'<Z3X!\0Z=
M:W3ZGJ&I6S1JSLR[B(]B+^\D;'UR![ "JUQ\+KG48!=7NNR)JK%<S10M&JQB
M+R_+*QR*2<$\AL$]L<5Z+15>WJ:N^XN5:>1Y_/\ "R-O#\^E6^HQK&]X+E#/
M:>;L A6,+G>&R-N0RLI^HZSQ?#=HYD0ZW-+9^9%<RQ30AI);B.(1AS)GH0 2
MN.HZUW-%+V]1]0Y4CSR7X5>9IJVO]K1/ML[2U_?6(=3Y <;L;P1G?D;64C'4
MY(K7U;P)%J_@W3M!N]0FD-D\1-U*N]Y0HPX//\2EEZ\9[UUE%#KU&[M];_,.
M5?A8\^MOA3%::4ME!JI 6WO8"[6^21.%53][^!448[X[58_X5L3-Y?\ ;#?8
M?--RMO\ 948BX,/E%]S$@KCG85//?'%=S11[>H]V/E1YI_PI_P#XEJ0#7I(Y
M%DDP(8I(X5CD15=%C64$9VY^]MR3\N.*Z/7?!2:Q';1Q7IMDMM.N+!08O,)$
MJ*H;.X=-O3OZBNHHH=:H]V"23NCSC4OA/-J5U+++X@)5H'ACWVI9HU:-4QGS
M,;1MR  .IR3UJUJ/POCU.2X\_575)I[J;$<."IF1% SN_A,>??..*[VBG]8J
M=R5"*/.?^%3,?LLAUQOM,=PT\MSY#M*6)7F.1I2Z'"@'<S@]<9KT:BBHG4G-
M)28U%)W04445F4%%%% !1110 45E:QK\6C,GG6=U/'L,DTL*J5@C! +L68<<
M]%R>O%6M2U&'2[+[5<*[)YL<6$ )R[J@ZD<989]JKE>GF'6Q;JKJ.F6FK6HM
MM0B\Z$2)*%W%?F1@RG((Z$ UE1>,M*E\/7VMB0KI]E*\33%XR'*G:2N&/!/
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M'<QK*+N/:S#&5!SC/(X]Q1RM]!W-2BL[_A(=%\F*;^U[#RII3!&_VE-KR#^
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MD#Q5HLEU906^I6MPU[,\$+03HZET7<RY!Z]..N2*M2:SI<5\UG+J5HET@4M
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MM!EMX9O;77K:^C-J8HYD9DWLI"BV\HD?+R<C@<<=QTJKJOA#4M0FN(HY+2.
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M,=1OKO38)8+96U8++;JL;9BC5G\Y'R?OJH0=OF;IQ5;Q;XFU6UN-4L89(+>
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M6-S+IJ,D@N7:-&#1,F5PK=-W3TXS6/%\/=0L_-2UE@G*H6AN+F\G;<Q15*F
M@Q+P#\^&/3Y>,UZ)135::OY@XI[G)>%O#&H:5K5UJ&IM;LTX? 2=YF4L5.-S
M*N?N]>.W [5K[P=J5V^I /9A9X+^*!C(Q.;@QLI8;?EP58'!/8]\#MJ*2JR4
MN9>@TK??<Y'PYX1N-&UN:YGV-'B<1S"]GD=_-D#G]TQ\N/&,';G<0#QT.>GA
M'7X418O[-S:V\%M"PG97G6-V.YF,1\MCN!X#8.>><COJ*?MI7NQ<JM8\ZB\
MZO':HLCV\K121S*L>H3P%V4S J9$7>HQ*#N&3D8(QS6^_A^]M='T6/3DM)+G
M2SGR)II!$^8V0X<AVXW9!(.>G&>.FHI2JREN"BD<7H7@N\TB6S+3V[K;WZW#
M,N02@L_)P!C^]T&?N]\\5#?^ [V[\62:DEW"MJUTCB(E@1#C?(O3&6E5#] :
M[JBFZTV^;Y#M<\[G^'>HSVMC!]IM(U@L(+:0@L<ND-PA(&WD$S+Z9&[VSI77
MA?5=2:[N+F/3+6>YM)(0ENS$*Q:,@E]@+<1\G [#'&:[*BFZ\V^9BE%25G_5
MCG-7T&]N_$UIJEJUN4MS#E)'920K/NZ*>SY'J1CCK6;K_A'5;_6KF^TY[-&G
M8!9'F='C78BG*[661<IS&PP>/F7%=K141J2C:W0;5W<YOQ%X9FUN6Z*R1J);
M#[,I+,K;O,#]5Y"G&"0<UFV/A+4[&5IHH-/+7>4N8[F\GNO)&X'<KR M(W'0
M[!POISVU%"J22L)Q3//+/X<W"6Z6MUY)ACVQ-(;ZXF::,+("VU_EC/S@[%&!
MS\W:EC^'^HFXMKB]GAN[F9$%](+VXA5764R;E2/ DX( #D8V@\\BO0J*OV\Q
MM)[G+>'/#VI:7>,;T6?DPV$=C"\,C,\H1F.]P5&TG=T!;G/-<[-X1U:VT.U@
MG\J+4 EI86[:>'E553>LDKL479E)9.O P.22!7I=%)5I)W_K0#$U'3+Z"^L;
M_0HK622U@>U-O<RM$C1L4((958@@H.,<Y/2L>\\+:U>F1+BXLIOM;037%R2R
M/&\1R%10I!4],D@C)X.:[.BI51K^OG^>H62V."O_  =?1:%*L7V=WCMX1LBW
M%F\NV>,@#;R26X%,_P"$4UZ:,WT<6FPW5Q9O:/;&>18XD:*- ^?+R6&SE<#C
M W<9/H%%5[:6K[BC%1M;H>>77@'4KA0K_995!GBV_;[B!?+E*,6(C +8*D&,
MG##!W#I5N7P;J<<-DMBUFDL4\[23><ZD))/Y@RNUEE&,95@.>0U=Q13]O/1=
MA<B.&G\'ZO'':O8O9&2 2[E:0IOW7'F##^6VTX_B )SP.N:KVW@'48M%EAGD
MMY+G[1%.@CO)HM^QG.TRJ-Z_?X(SR*]!HI>VE:WS_4.17O\ UV,KP[IUQI.D
MQV4\<*+&,KY4\DO+$LV6D^8\GJ3SUP.E:M%%92;D[LI*RL%%%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!R_B?4;^QU:T>.74;?2X86ENYK)+=@OS*!O\ -!.W&[.P;JUO
M$"W3:!=OI]])8SQQ&1)XD1R-HSC#J1@XQTIVH:%IVJW,4]]"SR1# VS.@89S
MM<*0'7(SM;(]J+YM.TS2;@ZA)Y=I(Q$ADD9LF1L8!R3R6P .F<"M&TXI+<%I
M*[V/.D\:>(-"LM$O[RXDUJ&YT634KR.010%0/*Y4K'SM#-@=\\FNET;XB6>L
M^,)=#BAC7!E2*07*M(S18W;HL90<G:<G.T]*D?3/"-]H4LAMWFL=-MIM+<)Y
MY9(E($D8 ^9N4'(R>.#6O8^'-(L=3DU.QM3%<3 [CYC[><9(0G:"<#) !/>N
MB<Z3WCW\NNGW(S2DE:_]=?Q.1?XK1P+J*W>FQ6L]K.D$<-Q>>46+.5#2;T'E
MK@;MPWC'?-7=*^(CZ[-;#1](^TQ^2DMX_P!L1?(W2-'\N1B3!1CG(XQC).*U
M!X"\- 7 &FX^T$%CY\F4PV\>6=W[OYN?DV\U*W@KP^\]E,^GAI+)56$F9SPI
MW+N&[Y\-R-V<'FHYJ%MM?^!Z]Q^]=G-'XI2O:V3VVAB6:\@MI8XC>;1NFF:(
M+G9V*YS[]*Q;OX@^(XC>#RQ''!;ZA))B:,R1M#(J@*?*VD+D 9!SNR<XY[FV
M\ >&;282V^F['5XW7_2)2%*/O3 +8 #$G X[8Q3KKP%X;O=WVG3BVXSEL7$J
M[O.YDSAAD$\XZ#MBKC4H)_#W_P"!U&U+\O\ @G-R_%F&.^O;2WTW[9);+(L:
MQ70:61XRH??&JED7YB0<-D*W%:[^.B? </B*UL(KF26=(!;17>5+-*(_O[??
M."H/8@4S5](\%V-Y<C5;9XGNO+$G^OV%I) JE=ORJY=5^9<-P"3WJ:"/PB?"
MNF00C.E7]W&UIDS$S3E_,4EC\^2RYRQ[<TOW32:B]U_P2?>5]>_Y&!<_&".T
MGN[>7286N;<F,01Z@K.94=$=2-N5&7.UC][:>!5J7XFW-O?/93Z"JSVOVAKX
M"]!6!(5C8LIV?/E9 <<<C'O6MK_P^TC6;/4$A3[)<7Y4RRAG=?OJS$1[@H+;
M0"1@GWJ]:>#= LF5H-/&Y4EC)DE>0NLN/,W;B=V=J]<\# I<U#E^'7_@>NQ5
MG?Y_@<?_ ,+B0V*SII,+[9@D\B7X>"(%%9<RJA 8[B,,% *L"U6=4^+=GIVI
M:C:I9Q3BS27R\7JB25XXQ(04 )5""0'YR0>*UK[P;X/M;>UM+ZU9%FG\J -=
MS%Y&9<&/=NW%2J_=)VX7IQ5^Z\%>'KF2[FGT_P#X^HFBG59I%1E*A3\@8 $@
M ;@ <#K3YL/>_*[?\-YBM/17.5NOB1J,>JVJR:;':P6T]RFHQ_:/,)2.W$H*
MML'\+9QQR,9QS4?_  MB34]-G@T?3H7U012R;8K])(XHUB$F\/MPS#<!LQU!
M&<#-:E]'X$_LVSUR[A:6WU"Z\VWD2.XD::5H]F-B@M@HF"I&#CD53O8_AQ:Z
M?:VFH"6.*4&=%F-T)(T(\LER?GC0@;</A<"JM3:MR.^WSZB5TTV_^&);WQ5K
MMK#X1ELHTOI+_3Y9[N!W6$3%84?.[:=N"2< <Y]*N:1\0X]9UBST^VTYEDO-
MDR;IN1;-#YGFD;?[WR8]>_:H-7E\!75Y::)JGFE]-"6L&Q;E4@\Q5"J9D^7Y
MEVCEN_N:V]/\*PV/BN76O,B(6S2QM((X-@MX5.2"<G<2?88 Q[TI.G:[C;>W
MWW7YKY?(24DDKZ_U_P $X^_\;>)K?Q//;V]O;RP0:P]K' )0OG1K:F3:S%"5
MYPV1D\XZ#F23XH301W.HPZ?-<6KQ6DB)+)LCMEEB9R69(V8#( R<C)'W178R
M>#]"EUB35'LB;N27S6<32 %_+,>[;NVYV,1T_D*R[?PCX.OI;K3K:S8RZ?Y,
M,P2>=&BVQ8C ?<#]QR#@\@\YI*=%K6.R7_!*:?-?IK_P!^L>,[BR71QI>EQZ
MC)JEO+<(/M@C5%1%<_,%8-D'J/Z\9=K\3IK^.:>PT+S+;S+>WMG>["-+-,B.
MJE=OR@!SELG[O .:V=8\"Z9K-SHXF'E6&EQ2Q):1%DW*ZA0 ZL"H 7WSG%69
M_"WAZ'2[Z*:RCBLYRDUQB1E"F-0%8$'*;51<%<8QFI4J*6J_J_KV"TG9?U_5
MS M_B1<W&LZ?I::$!=7TDL*[KT;4DA9A,"=O0  J0/FST&*T-!\;2>(;._FL
M],P]C:J\D9N,_P"D$-N@SMXV[1\W^T.*9IWASP9>74']EP1M=6\$-U"XEEW1
MH69HWR6S\S%B>[<[LUJ>%_#B^';&ZC>=+FYO;J2[N9DA\I7=SSA<G   '4T3
M]DHM)68*][]#A[KXPI?Z;J"Z1921S0V[SK*LZY6,1;C( R$<.=F"",\^U:/A
MGQ1J^H_$";3;N[\RS4WFV+RT&-A@V<@ \;V^N?I701^ /#$,$L46E(B2VSVC
MA9'&8G<NRYW<98DYZ]NE7++POH^G:JVI6=GY=VWF9D\USG?MW<$XYV+V[?6J
M=2@OACT?W]!.,K6OU_ XJU^)5YI%I>2^(;/S[<7-\MK<I*H+^3(0(R@4!1C
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MQHZ;\19_$$$D^@Z,)K>. &6>2[5/*E:,N%VX^91@ L#GG@&MT>"O#XL);-;
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MGLYCI^Z2S $3-/(<X;<-^6_>88DC=G!YJY2P^J2_K[_Z_ 3YNAC:/XSU+_A
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]>\OK6RT]42S=1)<?:@&YG,0PIC8'.WGT!]:S;7Q_J=K#;+?6+7E]<V\+)#
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M8L8D25R,[#G B/USVJSK?BV32+FY*Z>L]G9F..XF,^UP\GW J;3N'*Y.1C/
M.*EL_#?A[1]6M3;PNEXP)M_,N)9,*BL,#<Q 4"5@!T&[@=*2XL_#FLZX!,#-
M>,LBE!)*J/Y1"L64$(Q4N,$Y(SQTJ9>S<O=6@U=;D=WXJN--\-6>K:CIJ1_:
M0Q:**YW^7^[9T&[8,EMH7&."W?O@7OCW4+UK&31K80B=HUVRRC:V9+8,#^[)
M!'G,F0>,,<$XQV.JV.D_V*EOJD2FQ@>(JK%OE977R^G/W@O]:@;PAH;0I$+'
M8D;.R;)G4J7E65B"&R#O53GMCC IPE23NX]16E;<YBU\7^()K73(#:6[7L\D
M3JQN0%N8V\P'?B/]V<H#\H;C\JGE^(<TRK'9Z1<_-;*\LR1RR""1U)'(C*$#
MC)9EX[&NFB\-Z5#+;21VN'M%583YCG:%W8[\_?;KZU2OO#GAVPLVO;RW:*VL
MX#OQ-*4"*"<L@.'(!."02.U+FIO2Q5G?0H:;XEU/4=5T>,1(EC,SQ2S^8"\T
MB0EFRFWY1NZ$-SCH!UI6/C#6;>YU 7UE%=(EQ.5Q=!1$B3>2B*!$"26QDL3U
M)ST6NGMO#.D6VI1:A;6[I/&/W?[^38N5VYV%MN2N 3C)QS3_ /A'-)Q< V@(
MN5D64%V.X.Y=N_&6)/'3M0YT[[$14N6U];K[CG[CQS?VUS/:MHL+7-GDWBK?
M':@S'C8WE_/D2J>0O?\ '5C\22C0VO[NR2)X+S[+<QI/O6/$FQG#%1N SGD#
MC-07^F^&-!M0VHJ\:3*Z&226:5Y !YC;FR6)Q&#DG/RX]JV'T>PFTV[L9+<-
M:WID,\98_/O^]SG(SGM2DX65E_7WC5[N[_K_ (<Y.[\?7CZ->7MCID:019B2
M=[GYA*R;XCLV<J59"3G@MC!QFHU\<ZE9M=)/IZ74EO$UQ/F["K&D<,#N$Q%E
MCF8X!QR.H! &K=V/A5()-1GA<Q0/]C9(_.92X_= >4O#OSM#;2<=#5Y/"&B+
M'*OV1V\^!H)"]Q(S.C(B,"2V<E8D&>O'J3FXRI+>.G]>8];JY7TOQ/<:CJZ0
M-IR0V4\<\EO<_:-SL(9%1MT>T;<ELCYCP.W2J \;WKI:^3H\32:@(Y+%6O2!
M)&YQN<^7\A&0< -UZ]JO:1X2&F>)KC5FNQ(KK(D,*(ZB,2.&;(,C+G*C[BIG
MDG)YJY;^%]&LI/.AM6#*ZR+NFD81[22 H+$*H))VKA?:HO236G]:_P# #WK-
M=2EKWC!/#\\L5U9EV2))DVR?ZQ<.9,<=46,GWR.F:R;_ ,;ZGI^J+'>Z;#"E
MK;37%W##<F4NH0-'L/EC)SD$<?4]^BGAT35K2WUZ: 7426CF&7RW8F&106 0
M#)R .,9K.MM(\+2VEU)'%-)#9/*EQ+/).V?DVNI9S^\4*,8R5!7 P1PX\B7O
M1U_K^O4=G=6,J_\ '>K3>'K\V.CO9ZA;VL\S-<&2)8T15PZ"6%2YRXX*J/E;
MGIG;\1^*W\/FVQ:Q7"NGF2[K@HX7(!VH%8L><\[5_P!JHH/#'A?6+"6"&*>>
M))&CF<W<XD<LJ[E=RVYP5V<$D<#TXNZ_HVAW48N];20)&JPDI/*@92P"JRH1
MN&XC&0<'GBFW2NER_P!=.I'O-.S,J3QO=H-_]E6ZPSQF2SDEO]OF*) GSCRR
M5/S9PN\].,YQ4M_'M[=2@V6F+-)-&I$$UUY:1%5E+X;RBQ_U9ZCTX7FKUKX!
MM1J5S<ZC<O<*Y/D) \T#09?=D,)3M.?^>80<GCFI[/2O"UI:VM[:0E8I9/(A
M<O*<LQ=,8)SR7<9/K]*+TN6R5V#YN:]]#)O/'E_<6]PFFV$-M-LADM_M-P5>
M16>,$[3&1M(DX92_O@\5KZSXN?2_$%OI<.EW%XS)')</#'*_E*[E1C9&PZJQ
M.XH,#@GI5A?!6@HDB)9R!'C\O:+J7"#Y>4&[Y&)5267!)&2:FN-,T?6-5+3(
M\MU8%%<"61!V=0X!"R <$!L@'WI<U*ZLM!I2L[[F(OCN>35)-/ATR"2XD;;:
M;;PE9#O*GS&$>$QC/RE_3KQ4EEXFU7_A(WMKZPC6UDN(K?BY!:WD:'>5 "X=
M<@_,6!Y''IH#P5H2L[+;3AG& PO)LQ#<&Q&=_P"[P1D;<8[=35NV\.:5:;/L
M]KL\N1)5_>,?G5=H/)Y."?KU/-+FI6V_K[QVE=F#XD\8WVG6NIM8V$1CM_,M
MX[EY\$3K"9>8]I^3'&<YSVQS4^J:GK.F:;H"QR1RSW+E+N21QDXMY')!$8!Y
M7/"KG '&3C3N_"VCWUY/<W5JTDEPC+(/.D"-N386V!MH;:=N_&['&:GU6PT^
M>SB;4(I&BLV\V/RB^Y3M*\;.3PQ&.<@TN:'*DEK_ , KK?U_X!R$/Q"U"UTZ
MTAO='-SJ<L,4H6W>659$:/<7/EPL5;C&T*0"1\V.:V];\53Z786ES;:89_/M
M9+N2.>8P-$D:JS C:WS8.,<<CJ.HCMM,\,:Y)-;VL%R6M D+2H;B  1[HPJR
M_+N ^93M)SWS6GJ=AH[16MOJ$("2(UC BE@-LBX*#;TRJ]>V.M7-T^;X3.FI
M)+F>VYSMS\09[-I4N-*@62WEVW""]+$(51@4 CRQVR#.0J@@C=5!?'.MV-R\
ME_9PW,&ZYCBC@=V=W%V(H^%B+8 ..-Q(YP3Q74W7@O0;RZFN)[23S)\><4NI
M4$N%50&"L P 48!Z'GJ2:BU'P[X=MHS/?0R1K+-L#+<3#$DTJGC:WRDR;2",
M;3R,<FG&5'1<O]>6HVI6>O;_ ()F_P#"=:C)"SV_AV0F&V6>=)9)8W3,KQ\(
M8=Y7Y-V=H.WG;GBM0>)I9M$TZZLK6WGN]1E,,,(NOW6X!F;,@4G "-_#G. 0
M#G%@>%-&%K) +1@DD:QLWGR;R%<R []V[=O8MNSNR<YI8M$TF[T&"SBAF6T5
MO-B/FRQRJV22V_(D#$DY).3DYZU$G2>RZ_UU_KN5K?\ KM_F<SI7CZ]>.RMI
M=(N[Z8P(US-!%(=LC@D ;8S'CIDLZ]> :N:=XWO-4VQ6>D0272AI+B$7Q7RH
MUV9^_&I$GSCY651P?FQ@G67P;H2"!19'9!$(EC,\A1E&0-R[L.1DX+ D9X-4
MK[PYX7TFS66_AG6)2S/*UQ<2$J$RRR-N)*;8Q\K';P!CH*KFI-[?U]Y+4NAD
M77C#6YYK)K.RBMS<R*(83=!EE3STC.\F+*$Y/3=@>IZ6[?XA&XU2.U71[DHA
M\N[EC2600298$!EC*%05Y+,IP<@&M1?#_A[6+14BA=H[5VA5HYY8FC99 Q 8
M,#D. <C\ZLQ^%='BN;>>.T97MU"H!-)M;&<%EW;789)#,"<GK2YJ7+9K45I<
MS=S#M?$FK7BZW/+%'9QQ:1%>6<:2"4KO$Q#,2HPV%7*\@8X)S5>3XA7UDD=I
M<Z(T^I8WO%;/+,IC$:-NS'"2&/F 8*A<_P 6,&NDLO"VD:>EVEK;2!;R(03!
M[B1P8QNPB[F.U1O; 7 &:2[\*:->DF>U?<V-S1W$D9("A-I*L"5*@ KT..0:
M.>ES/30K7^OD8=[X]O+9W$6A/,&N&A@57E=WV*&<LD<+LF,J!UY)SM S4:^.
MKM)KDIICRQ1%IY?M,_E/#$!%E0@CY8>9]UB.A^;I6[>:'H<K1:?<1-&\\CSQ
MK#-)&Q; #D,A! P0",X(.,4VWT#P_<M>I;6JGEK:X57< 9"$KC/'"IT]/K3C
M*EUC_7_#D24[:/K_ %^!<UW5&TC2S<Q112R;U15FF\I22<<MAC^ 4D]A6%H_
MCA]5U2QM9--6UCNT.)))V!9QNR$!0!P"A'W@W?9CFMN70;2ZTT65ZT\R+,TZ
MR"=XY$8L6&UU8,,;L#!Z<5!9>$=%TZZAN+.U>-X22@^T2%-W/S%"VTM\Q&X@
MD XS6<7346I+4M\U]#)UWQXVB:I<VW]G1W$<*2;66Z^=G6$RX*A"%!"D9+;N
M^W'-,N/'-_;3S6\FB0^?9Q33WBK?$K''&L3Y0^7\Y*RC@A>01GO6CK?@C2M8
MCO7*R0W5TD@$OG2,D;O&8RXBW!<[3@\#/K4;^ ]*DO;25O.,$$<JO$UQ*6G9
MS'R[E\L,1XVMD$8'08K2+HV5UZ^OW_UY#=S(TOQEJ4]^UG#"-0NIBWD)-*L$
M8 FN1DE8R1A(5'?)QTY)?K?CJ[MX=0MX+2.VF6SF>&9;@2O'*D/F890I0#K_
M !D\?=Q6F-&\*W>H2V42,+LLY813S1NI1BS8=2".;DYP>0^.1P+#>!_#[%\V
M+A'1X_*6YE$:ATV-M0-M7*GD@#/7KS3<J7-=Q)7-=:_UU,"\\>7VGZF8KNQ(
MF@B:.2S@9IEDE9H/+8.L>_&V7D!2>O#<5UVAZF^L:/%>36<UG(Y96AF1U*E6
M(R ZJV#C()4'!' K.M?#/AVZ@E6W@>78[PO*UQ*9 P92?G+;MP,:8;.1M&",
M5HZ;HUMI+O\ 8C(L3(JB)I&< AF8MEB268N<D\G'-1-TW"R6H)23-"BBBL"P
MHHHH **** "L?Q18W.HZ.D%G'YD@N[:0KN ^5)D9CSZ $UL5E>)=6GT71Q>6
ML'VB3[3!%Y0&2P>54('(&<,<9.,XS50OS*W= 8'A3PW>Z%93QQV$=NTNDVR,
M@D"B2Z42"0L5.<\H"W?C!XK T_PGJ,+2->>&?/L&*L=,W6\8:785\S"R%>#C
MYBQ?D'DC Z?_ (61H:ZI::?,9(;FX<1O'*\2M YD,85EWY8[E(^0,!U) (-:
M&K>+++1=4BM+Z"X2.3 -UA!&I.<#!8,W3^%2!WQ72YU>9MK?]/Z_R(:3^1RL
M?AB^2%EN?#BSR+,7OY!<HW]IIYA98QN;Y]H(_P!;M^[M'!-,M/!=U%#<W5]H
ML=T3-&5M"T3,UMN8_9P6;;A<IP2%.P#)&*V;WQ\MA+;2W>DWUI8O%++++<K&
MI5552K#]YC#;L>H/4"HY_B/:7.ARW>A6LMW/&K&15:*1+?! R[))@@Y_@+'\
MC3O5>B7]?>2^5*[, >$]:!TL1Z%Y36LD31R*\+&W3[2SNFXOE?D(XC'S=">
M*EM/!=Y80V2RZ EY9+9VOVW3T>+_ $BX"2J[$,P5F4M&22>< @DJ!7;ZGXDM
MM+OA;RV]Q-L19+B6(*5MD9BJL^6!P2#]T$\$GBFZ'XFM]=F>.&SN[8B)9HS<
M*@$J$E=R[6/=2.<'\*7MJG*]-&5RI:>ASGA_POJ-CXR_M"\@ND.&S,)X&A\L
MH L6[;Y[[3V8A>-W4XJB/!VN?\)#*[QJ=.,LD87S%YA0F: @9X/F.R_116_J
MOBR_L/$,MA!I4ES''-;H#'LW2^8LA(7+@ _(/O8'!]J6R^(NAW^M6NEPNZW%
MRJX#O&"C,NX(4W[\X[A2O;-'-5>J73^F%DOS.8M? 5PUD\%WH4.Y8IG#-Y1#
M2M;Q*AX.=P=6Y/0\Y[UM>(_#-SJEW:R'3$NF.GK;RRL8\H1-$Q4DD'!4/TSW
M]:TKOQWI=C+J8N8YTCTT[99B8PK-E0%^_E22PP7"@]0<#--L/'NG:I'&^FVE
MY>*1F<VWERBV!8H"Y5R""5/*;A@$G YH<ZK:G;^K?U^ E!*/+_6Z?YG-/X(U
M!->A>*TN$LH+@_8H[1[9([1?/9RWSJS("I'^JYXP<"MC7_"\^L>-(;BXL([K
M3-L(E$I0JVV.Z!RI/.&DC[=_8XO/XXL_.LH+:POKB:]AAFB2-(^%D61AG+@#
M B8GGTQFL>P^)&;,WFK0_9[1&7]]Y2CS0;99>/WIV'+=\C! SU(?[YIZ;(JZ
MNWW,5/!FLO93Q7.B^=--IJQSO<202>8ZQH BON#?>7[K@H#R&&:V8O#=YID8
MO;+0MUS+=WAEBA>%9"DA<1$DL%P 1P"2 >!6II_Q$TG5+BT@L89YI+ARC".2
M%Q$00.2LA#_>!/E[\ Y.*MZGXSTS2-0-G?">.0.RYVKMP(C+NZ_=P"O^]Q[T
MISJRT:%%1OIWN<>?!UZVGV\-YX:2\O(9;>66\>6(^9$C1GR0"WS$!6&&PO&0
M<FIAX3U8%E;2]UTTV^WOO-C_ -$C$K,\?WMPW@_P@@[OFQBM6U\:WEUXH@T]
M(8EMY)UC;S(BLBY^T9'#D9'DKS[GCIBU/XXATS5-5AUJ"2"SLYS''>*H\LXM
MUE*'YMV_&_'R@8 &<U4I57I;S_(2@HO0Y>[\#ZA!9PQ6.B*X6&!A&C0&/[0(
MBKNZ,PSSMRZL''5<\UTGB[1;S4VMRNF#40+26&-1(JBUN&V[)\N1]W!^9<L.
MP.35[3?&NEZIX?NM7M0[06C[)T22*0Q\ D[D=D( 8$X8]^XQ3/\ A-[%KN>&
M"SO)8[>X^S27*JGE+*6VJN2V3N;@$# XSC-3*=5RNUJOZ_X8(QC&*2?];E"'
MPM/%\/==TD64(NKU[QE0! )F=FV,<<<C;UZ<=,5D7O@J^ECN)],TU;"YN)I
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MGTJBI5>:ES$J*2L>67/A#5KO4;^6?0$9)DD\Y<P%;IA<1NG)<LYV*V#)@ \
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MRNIR&!Z$'N*=5.K4N[LFR.=F\&PW36S7VK:E=&&43.)GC83,&#*2-F$P0/\
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M*F](@%+.VY@,#<O ).3P#1IOB>WU73KR_M;.\-K:LX638I^T;20?+56+'IW
MZBIYYJ.JV_S_ *0<JEJGO_E_3.=UZSU>Z\0:B(6U6.V6*62$VLLL:LX@38 5
M(S\^>.YR.>15O7+;6KJ1I["2^CN8='9H1&[K&;@\?,H(5FP3@&G_ /"Q=/\
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MHM)IW?\ 7]?H1I==V=5!X(L(%(-U>2L;9K8L[)DJ8UCSPH&=J#\:K:-X7O\
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M67+I+9_J'-=V:_IZF^_@NTED\R?4-0F=EC$C22(3*4D:16/R\'+L,# P< #
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MT..2*XG1U,))+RM+Y0/FYX92X^7'R\"G!O>7]?U^ 62=E_7]?F=0?"6GK/\
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MV?M-VPNGWE2R83]\9L+\N<;R>N>#5K2M'M])O9$AU"YE!0F*TED79 A8D[5
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MWW>G:H]8\-2:GJ$DT-ZL$-U#'!>1M#O,D:,S (VX;#\S DAN#T!YK-<C2O\
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MX\8Z':7-W!<7<B/9Y$Q-M+M! !*AMN&;# X4DX-(?&6AJ7\RYFCV)O8R6DR
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M)(!C 3,@.UN4R.">U96H> 9KZ\DD_M9?L\EQYYADMB^QO-\SY/G !/W22"2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%"^E2Z:8U7+ .RG?N)ZC;TQSGK6)8?#&ZTR9;VP\121:FWF)/=M TOF1N$&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(P^$+I;MII)8<B[AF
M79(X$FR9W9W&,%RKA<'/W1SZ==151DX[":35F<'%\/9OL$_GSQ?:\H8@A 0@
M0K&P9BF[!PW'*]"5/2KGA+PMJVA:@UW?75J_GHT4L,)8A$4_N0&( .!G.%49
M<^U=A16CK3:LP:3"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a2019proxy2.jpg
<TEXT>
begin 644 a2019proxy2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#:17AI9@  34T *@    @ ! $[  (
M   %   (2H=I  0    !   (4)R=  $    *   0R.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI;F$    %
MD ,  @   !0  !">D 0  @   !0  !"RDI$  @    ,P-@  DI(  @    ,P
M-@  ZAP !P  " P   B2     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,&$7_Q5'LY]@NC=HK"_X3GPG_T-&B_^#"+_ .*H_P"$Y\)_]#1HO_@PB_\
MBJ/9S[!=&[16%_PG/A/_ *&C1?\ P81?_%4?\)SX3_Z&C1?_  81?_%4>SGV
M"Z-VBL+_ (3GPG_T-&B_^#"+_P"*H_X3GPG_ -#1HO\ X,(O_BJ/9S[!=&[1
M6%_PG/A/_H:-%_\ !A%_\51_PG/A/_H:-%_\&$7_ ,51[.?8+HW:*PO^$Y\)
M_P#0T:+_ .#"+_XJC_A.?"?_ $-&B_\ @PB_^*H]G/L%T;M%87_"<^$_^AHT
M7_P81?\ Q5'_  G/A/\ Z&C1?_!A%_\ %4>SGV"Z-VBL+_A.?"?_ $-&B_\
M@PB_^*H_X3GPG_T-&B_^#"+_ .*H]G/L%T;M%87_  G/A/\ Z&C1?_!A%_\
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M(6U"_-U<9#[HP43S0Z#>ZQX!.\@%VR2!R:9;>%O#&KR3:?9WNJ.ZQNCMY!"
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MBBB@ HHHH **** "BBB@#"\0?\ASPO\ ]A1__2*YK=K"\0?\ASPO_P!A1_\
MTBN:W:N6R_KJQ(****@84444 %%%% !7#>+_ .U[+7)=1T:.\>7[&D,;0VXD
M"G,C'GRG/)"9 '<9Q]X=S151ERNX=+'F%O'XC.M)-#;7-D]S<!);B+3T!1#<
M29(W(0,J<DXYSDYZUJ^&=;UJ\URSMM8GNEEDM)6FM7M D:E5AP0VT'=\[97<
M<$XP,"NZJ".PLX;V2\BM($N9AB2=8P'<>A;J>@K9U5*]UN0HV_KU/-[*/Q3:
M1Z/:0&^1([3:9S81EX 8XCY88Q\#((P>3CG) QUNB7M])I\]IK#SR7K*SQ>;
M!L+IY<9/10.&DQZ\=\$UT5&.<]ZF=3G336Y7VD^QY?:Q:AH^G6[>%-*N-.C:
MVMX[W;8O%F4(Y+",Q,6;.P,P0Y! SQD7EN_&;I&);B^B>:25I/+LXR(0OG;5
M7,?W3MCY;).1@\UZ%152K<VK0E&RL<1X=O-?_M^*&]@N([.5IV>,68B13YDA
M#D[.<_+_ ! \@[6R6&%IMOJFD7P;3[.YLH;B-OMD]EI#I(K@R%=P96$K,2,N
M!P!SC((]4HI>VU;L'*>?1:IXNNGMH)1>6DRR.;EA9J(^/.95#LA7:0L8)![]
M0352U\0^*9[\I8S7EY!'*@9I[+RV+%(6*$+#PN&<@G;_ +Q Y],(!!!&0>HJ
M"SL;33X/)L+6&UBSN\N",(N?7 I^UCK[J!IGGUKKGBR6!TNK?4")9ECC)L&)
M*EH-VX^4N!M:89( X."2 :U/"BW4'AN]TVXDOH[XQ%XUE@*LB^2@&PE0#@\=
M^:[2C'.>]3*HG%Q2M<.75/L>8Z>_B?2])B%D=1:*X8M*9K3:\.&09 $+-ELG
M(*MZ@#!-;>H127'V.;Q%I4^H.^G*(X[:%V\NYSEL$#]TQ^7#G;C!Y%=G13=:
M[O82A8\U8^)M.4I907,RK++-%YEH"8"[W ;:P0G[H0C[Q.X=0V#K^'K75)AK
M-]JZRO<W%LL<9>';N4>9M S&C9Q@D8')Z"NSHI2J<R:MN.,>5IGGEKHNIZ+'
MI=OI%M!IYGM\W$^FZ4D3*?DX?<'^8X.2<9].*2WU7Q??:@D#C4+..2-#(XLQ
M^[; SC=%M&>?XG_X">*]$HINM?5JY*A;9GG4FI^)9(;:>:WU![I69Y(1IJE(
M/W#[61BA.XDC.-V"2O&=IFTL:YJ.CZO/J-M="YEBC0AHFC:6-)I<@91,DQX_
MA7[PX&:[^BAUDU910^7;78\NUCPZ^IZA&=*L[RTTE908K9;$(N[="'/ER1DH
M"-W89VL>A.;-MJ'BBVT>VBCBOH)%2)'ACTY4B@CV)\R[8F.XMN!4*V.>%P#7
MI%%'MM+-7*L<?9W/B(>'3=:G<7B7,ERBRK!:*S6\? 8QIY>YLG^\&^G%5+*R
MU:3PCXFN+I;M-2O$RI$ 61L6Z8V@+D\Y&.<'('.:[NBE[2U[+^M/\A)'F<<_
MBS3+'R-.^W/"[M*'FM,-&6DN#MPL+'!Q$3E<C=U4$8WM3AW:\TNH:3<7MP8K
M<V+PQL5B<,2^)!Q'@X))(W# YQBNNHHE5N[V!1L>>)?^+KB>!$GU*.+RE:61
MK!%(F+Q*Z#=']U0SD'O@\D"FR:WXF69XXI-0FGBC1985L1M53&V9-PC/S[MO
MR\\$X0UZ+35BC21Y$C57DQO8+@MC@9/>G[5?RH$CSC^VO%T&E_VI</>*MN2\
MMO)9JH>.-6=CDQJP+!0N?E'S= :[[23=G1[1M1;==M$K3$ ##$9(P/3I4]Q;
M07<)ANX8YXB02DJ!E)!R.#Z$ _A4E3.:DM%8(Q:ZA1116104444 %%%% !5#
M79+R+0+Y]+)%XL#F B/S"'QQ\O?Z<_0U?K'\77USIG@W5[ZPD\JZM[.22%]H
M.U@I(.#D'GUIQ5W8:W.%;7?'3:?$\=OJ*7/V5C&AL0XF8>;N=SY2E6&V(JI5
M"=V"I[/DU+QU;6]QB34+C(8;VL5#1JLT8W*%B.6*,_&UONY"G!RNE?$S4%BO
MFU*Q\Z:WF<30LXB\A88HO."G:=YWN2H.,@]1Q3]0^*-VNGW3#2/LZA'\N>*\
M#.IV3,IVM%C/[A\YSC*]>0/0Y)\VD$8Z-)7(_P"U_'K[4D6[BN&$*R"&P!BC
MC/E9E5F3ER6D!4_= SM&,F_H^I^,I/$^G6U^DYL0KK,\MKM$H#RC>Q$>%;"Q
M$#<H(8X4YX==_$N>SN)8#HOF,9I(;8I<LQE,<OEL6"QDKUR,!O3BH7^*SM%-
M);>'[ET55,9D,BY^[O# 1D@C=T7>3@D@5%IR6D%^ :+1LJ7USXLO=<@6X.J+
M:0ZC^_CALP$0;I515(3,D9786;)P3U':GI=UXYTG3M'TZUBNS;QQ6XS-9XVD
MQ1_N6VQ'"#YP6."".7'0]/J_BJX@U[2/LLS&RO+>*79&4PVZ11G<RGC!]OJ*
MR%^*=Y)/%+_94,<8AD$MH9I#*)=\*Q@_NLX_? G .0203@9<.=QLHK_AK@VG
M+?\ IDVJ0^(KGP+HLUY<ZI->R7(>\CBM5#A6C<;&14^Z&*CD9&<D\ C*CU3Q
MMI-MI^GV\.IRI#+ OF&P!#1&.#<C;8C]TM(,Y3[IRQ(P=[3/'5YKOB32K:VL
MS8VK3-%="5_WC/\ 9S)MV% 0H.,-D$XZ52C^)-_IT,T%_IOVZX:ZG6U>.0CS
M$6:9<,J1G:56+ P&SQDCDT)36CBM=;?U_5BFTW?M^NI)')XJO?A_JR:E-J37
MWV:WEB=;58YMS1JTB*JH,X.X8P3R16;;3>+M(TBZCTY=0\F6>692]C\\ :[E
MR5 B8DLI5L%6X.0 *UC\3IS-&/["D$,TTB(Z3,TBHDBQERGEX4[G!P3C /.<
M VO#?CN?4;G3K2ZL@(KB*)3=O<@N9&MEGY0(JXP2,@CGMSP6J6;Y5;?I_70G
M2UK_ -?TSFO'^D^)=5NM'N+:RF>YFTLV=\8(F*IYV%D[=NN#V%+I&H>-%FL=
M*ACU2QLU@MH2YL ?)P(PQ!:+ X+=6?I_#C%>MT5BJ_N\KBOZ=_U&X7UO_6G^
M1Y/<>*/&T3VS30W]M$;*'[4[6(PCL(][H#%C>,N I8Y(QLZ99:>)/'5W:3S6
MC75Q&MI<&%S9#,A4R!6PL6WS-RH-FX<9^4]:]6NK6WOK62VO8(KB"0;7BE0.
MKCT(/!I;:V@L[:.WLX8X((EVQQ1(%5!Z #@"G[:%O@0^5WW/+[O5/'UK#(L3
MW\X,CJ96L%W1JLLBJ0$A.=P6,GY3P<C:.0^2X\9W&H6)U"74UMS?[YHK>S7;
M&J7"JH!$>2I5B><Y"YZ UZC1259)I\J"4>9-7"BBBN8LPO!__(#N/^PIJ/\
MZ6S5NURFD7>K:+;7-G)X8U.Y_P!/O)DF@FM=CI)<R2*1NF5ONN.H%7O^$@U+
M_H4-:_[_ %E_\D5K.+<FU^:$GH;M%87_  D&I?\ 0H:U_P!_K+_Y(H_X2#4O
M^A0UK_O]9?\ R14\C_IH+F[16%_PD&I?]"AK7_?ZR_\ DBC_ (2#4O\ H4-:
M_P"_UE_\D4<C_IH+F[16%_PD&I?]"AK7_?ZR_P#DBC_A(-2_Z%#6O^_UE_\
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MVWM=1N[DVZ2M-?V=K:>=(%BB91+N3:50R-G: =K#W-7!-M-)=_Z_ :33M?\
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MCJOQ O4M]0M;33#'>6L<B/,CM)'%*!)@AO+VD?)_%CDXP<&AJ<K)1V)NN_\
M6Y%J.D7Z>#_#-I;&_B=(U69(+8$JY4'+KL(&#GD@<]<U?T>_\42>)(;>_6;[
M&K.C-+ 5\Q!O D)$6T,2$XWJ,<A>0:CF\?7=E;0>;I:3%H6G+_;.3$BR%F($
M?W_W1PH&#GJ,&G:WXMU4>$FO]/M%L[I9I8I!-N&W;"[AEWQ@GH.JCN/>AJ<G
MJEK?\0BD]G_6_P"1GQR^)KC5HKN7[?YEH)@K_9 %D5I(/W>#&,# ;H3TX<X-
M1Q:MXTN1.R?VA"(DDD56LP-_^J 4DP#IND("AB2N,N!SNVGC6:76(=,GTMA,
M'6.X>)WD6,L[*I!$8!'R9.XKC/&:P)/B5-:^-]?M-\%W:6D)6TM5E57\V+8)
M-Q + ,9#C.?]6<=Z<5)NW*MOZ_,;DDKO^KCX)_%D#27O^F;KB=8Y@EINQ" ?
MWH!B5MX4#C: 3QMR<56NG\1W&J3>?#J/V:>*$)*ECEKADN6V"0;/D'EG<<!<
M$]NE:L7Q*N&O)()=$C06[F*=EO2VV3=,H"CRQN7,!Y.#\W3BH[GXI+&\<<>F
MJ3)+%&Q6X+,@D2%@^!&1P9@/F*@XZY(%.U2^D%^ K+9LL^&KSQ7?:U;#69+B
MWMEBDDF46X4&0;!Y99HEPHW,1M)S@_.V*F\-2Z\-9N!?"X2R^U7"1P&T2.-4
M&UE<$("22S<DX//>LZ?Q)JDVA:"[ZQ)I[3Z,VH7-U%9K,TL@$8 V!&^7+EFV
M@' Z@5*/B5+)>?9++2?M1:1(H+AI'ACE8[0228SM&7! &XD YQ2E"3NE%=5^
M-KAS*UW_ %U(;'6O%<TK?:8]2BC#DQ8L S.^(]L;9C4*G+Y/;'^L/&5;5O%0
MA8P-JLDHCB,0ETQ5620G]\K83A4'*D[<G(R_<_X6JTJ(;30I)/,B@*%YF5?-
MD$9V%A&0 !*/FR22/NC@U+:>/;O5/&5EHZ6R6BK=F.9HY#*DZ>5/P"T:]'AZ
MKD=L]13Y)_R+_AAW2U*,\_B6VU*.:675KNZ@MI8_,-@H5 SP$$,D)!) ;("L
M1CH,$U8L]3\7M#;S7K:A&DZ+]H5+!2UN +?<47R\EB7EX(;H<#Y:YD?$_7['
MQ&\-[(TUI:7]ZTRK"@,L"JXA0$+Q\T3\CGCG-;NI_%>\CT^Z6ST*2*[AMW9W
MF,FR*0>9@\QC*_NB<G:>0,=<7[.=E[J8M+V;_K^OZW-G1[WQ3>W5_%<F>!?L
MLGDM/;A&1\+Y; >7MR<L2-[X/&!C%8,EWXPUC3I)-2M+RU4.6C6.R!E16C>3
MCY"00&2,XY)##J:TV^(5U87L\-SIXN8XK@":07(S$I>.,! (QO&Z3/)!QGGH
M*T-)\<3ZGID]P=,BBE62V2&,7FY7\\*4+-L&W <9&&]LUFE)+F45T%=2TN4K
M2WUB/P;J-G)+J'RVT<D#?9@)5)9BR* G/ '!!/S>XJC'<>+=,L+>UT_[6\6P
M2(\UK@JYWXC(6%CMX&<@$=V&170:;XCOKMM8OI85^SVELIBM5F7F0;]_S%!U
M*X!SC&#@5GQ>/+L7DDTUG']E:-4$9F96AF G)4@QAN?*P<@$'&%-)<UW[J!6
MTU$UM=:LO%5_>Z<+P":U58VAM%E#2JOR1$["0A);<<C''(K*T0>)K*]O+>&&
M]LUFFMS!BSW)(2J+*79E.T(HR.1DY'.,5JK\1KF0*8M$W L8L>=+N\P-*"-@
MA+8Q QR0#D@$#DA=,\<:A,%BDT^.66YFG:V:6X\K]VKR\.-GRD"/ ^]GN1S3
MM.,;.*_K7]"M+?U_7D9<.H^.+^6*2\M;FTV2?NRMDC,@=&&02AP5QC/^W@YK
M3TO6=<_X2:TLM2NKL9NY8/*:T54FB6)V5V<(,.64< CC!VX.:I1_$.]-G#>B
M#?:I>3B4E@)'7;.T<80*> $3YLYR.AYJV?%S?;+C45\+VXN;=%BDN'=UFR6<
M8 \GS"F(R>F>1\N 2'*,MG%$Z+9_U_2,^-O$DNK-<(-02ZF%O%-<-IR@VY,F
M)%C+1X*J&;YN<CDDXJW::GXM:X*:@U]%!DC?;V0DD$N6PF#$J^61CY@2,_QC
M-:?B7Q==6.GWATVWB.V ;+@SC*R/&SJ0NTAE 7KG\.M4?B#XRNO"=OHB17D,
M4TDHFN_.9,RP1@>8JY ^8[AC !XXQ27--J/*M1Z):>IG:/<>)K&VDB1=15@R
M>46TX9N'VQ!A*WEC@#=AN,XZG %;$<VLOX5D367GFD^UVBL]Q"L9='$)=2%4
M#&YG4\<#(/2F+\1I;F^L[33]*BFENYWB0O>;5 665-V0AZB+=CWQVS62WQ%N
M;C0A%<Z>7CD18S<M<(SM(8A+RABV8P2,XZ]O1\LY?973MT82:5VS;T&Z\1WF
MO6B7MQ?I9+;-+.9K)(MT^$!BR4'R L2".3S\QQ46E6FJV>C>(+V*.>'4)446
M^+1%*XC&-B[.<$G@Y&<^],N?'4]_X?\ $<EC$UE-IBJ8;B+,N]68@, \8!/R
MGH&7T)JC:^,M;TK4H_[26XN]/)8;[Z);6;RVN$C24IY8Y^?IA!@9ZU/+)NUD
MOZN%TD;&EWWB+^VDM[Y[UXTNGB&^S41RP!I!YC.$ #<)@ @'@X.<UBZH_B.7
MQ!YULM_]H$_E&3^SE9+9-TP!C8QD'Y=A+9/7&>2*EB^*T]Q'=/;Z%&XM+>>Y
ME+7C(#'&D; KNB!);S5[ <9!88S9_P"%E7"6MV]QHT4<T.1%&MX[B5EE:)A\
ML1;JA(PIR.N*?)4B^9Q_+^OZ[#=FFKC8]1\6*\\=Y)?) LY1YH+(23(H\W:5
M7R0K XBR1O R>5SQGZ9<>*;*?8J:EC[*"LLFG+OGN/.?]W(P3A-ISD$ 9X;G
MG2_X6<TFGB\M](5UF9$MHS=_O)'(4MN14+!1NX8!L^V15>]^)MW,NGII6F1Q
M275VL;F[G*F--\"G*[#@GS\>V">>E.,:C?*H+\"&XO6Y/9:AXMCFTP73W\ZR
M-$UP&LU4_,L>Y21'@!26X.T]?FR "[49=?TO5=4DT];YH+J=V"QVP8(0+<!E
M(C=N09!T;[IP.#19_$*1;.9IK:-UMU<-+<7BH[R9<JBHL?S#"]5!/^R>35&T
M^)]R9WN9[ _99)(HVC9V M!\X=B1'N(RH^\J@=RM)1FW=17_  XW*.G]='_F
M+_:_CEK. O%=1[8XFFD%I\S&2/=@ 1.<HZE2 AX<9QU'HEFTSV,#7859S&IE
M"] V.<?C7&:[XVOM \0:E MHM]!#"LJ1M,(O+58GD<@A"6)"\ ]^XK:\.>)Q
MX@DG_P!'BMXU8^0/M*O)(H=T):/ *<H<=01WR"!G4C)QYN5)#35[W-^BBBN8
MT"BBB@ HHHH **** "BBB@ KEO$VK:5I6II/=Z/%?74<('G^3ODC#E@JY"DA
M3B3VX]ZZFL+6/#:ZOJ#R23O##+ B2-$0'#(Y9,;E(P0[@_ABKA;FU#HRC97O
M@^[ALD33[2-G!CCB;3BODE\ J<H-@8N!S@-GC.:S_$\DVJ,^@Q>'69R\MSL$
M\*":)<*7 9'4LQ<8! Y&=PQ6I<>#M%M;S^V+J1Q]G*S.TJQLH"!<<E"5QL!^
M4@]?;%_6_#=OKLD4KWEY9R)&\)DM) C21/@LA)!X.T<C##'!%;*4%)/^OZN0
MN:VIE2:OX,LH;FSGAMP+<+!-&;%I-_[P#:,(?,Q(W.W=ACSR:A/BKP+)#$JO
M&J,RLA2PE7&T(0V0GRJ%\OYCA< <\<6W\ :7)>/.T]YCSA-%'O7;"?-69@OR
MYPSH"<D^V*S)OAA:F^LEM[ZZ2QCM6MKE3(N^5-D:*OW,8(0[NA],4XND]V[A
M9IZ$%_JNAQWFH-)XNU:U\Z5OM$*:7"1@*>N;4LR!5(WDD87[QQ5=-+@B,-EX
M2U2ZNY(WD22!+6QME@C+%)&_X],<LH&/XNO(%:3_  UT#3X]0NY[Z]2.>*7S
MW9HP%5D=6.0F20'/+9/ SFK6CZ?!H7B+699)K<7^K2QK;0J[L JQ-LW';\I;
MRY&.!CW-5S0M[NNG9!:77N U3P_#!H45]9?:/,L=]K,]B)&4#8NT"-,!CNZ*
M ..@XI9;CPG9W6GVYTFP6TNX'FAG2R&Q-Q1"" F$#;P"6QTP:N'PC#):Z2'O
M;F&XTR#RXY8-G)^4EB&4]T_4T7WA+3YK2V2>ZNDMK2W,,D89<3Q[E<[R5)ZH
M#\I'>L^:%]^_ZV_0+/IY#+O7-#;1A>0VB7EM]JCC=/LK;@9<+O";-S963L/F
M!Z\U4O-;\)))#>1VME/*&C(G:UV[$<KEA(5QD+(&*@YYYQFKFA^&M)AT.%-.
M>;[-++%=([0I$QV;2@("+Q\HZC)]:ICX9Z%Y?EMY[(41#D1[CM"C[X3=R$&1
MG')P!37LT[-O?_+_ ((>\U_7G_P!]C-X7EL;B^&B6\$%I<F",C33YA^1.1'Y
M>\<8'3HH[4S5M3L=2T'5+VQTFWO6TI&5'N,P_NS"KEHG,;8.UN,#L,XJ]-X.
MM;K1I].N[Z\G6>X^T232B)F9MH7!79L(P!P5Z\]>:L6_ABTMM'OM-6>Y:WO8
MA$^XKN4")8LJ0O7:H/.>?RI<T-V^WZ7_ %'&Z:N8>EW^@61:PU71[&PN=+(6
M(0P&9<LD9S&XB7+DNHV@;B>W-.U?4]#T72XKBP\/VEU!-;N\")"L1=PP01;2
MO!/FOUZ?-D<FM34O!NFZHTQNGG/G2B8CY" P6-0<%2#_ *I3@Y'7.1Q4W_"*
MZ<;32[<A]FF3>="%"J&;# [@H QELX '(%-SAO\ ?_7J"5E8Q4U?P=/%.U]I
M]A&GGM+DV?F*Y&[YR0F Y*O@9W'!QFI7\5>'9-2E>XL\$2I$9I+"4RR-\C(%
M7RR3AMO!P00#3H_ASHL*PK"TZ>3#Y2L1&S'[V&W,A.?G/0@'N#4MKX"TRSDM
MVBN;O;;S+.D>8PH9<=@@P/E P,  < 4-TKZ-B]X?=W-G-=17&BZ+9ZE<7EO]
MK:5]L1DC4H5^8J26)V[0< ;>2,"J.I7_ (9M(9],CLX[,7JM:7C0VWE,B>5)
MRIV8DQL*@+GG\CK2>%;8V5G;P7M[;?9+4V@DA=0TD1 !5B5(_A'( ([$5E7G
MP[L'ENKNTGN#=R,98Q(Z*H?#A<L$+'&\X+%B, <@8HBZ>S?]="M5JA_]K>"8
MM-:)K2!+3:RO&^ENJ_NR[%2IC^\"LAV]>I YI;N;P[>Z7)+8P[#:*UX]NEK]
MG9_);?L?>F5&_:<<$GGD9JK:_#B&XVW6MWUQ+?%YF8QM&P'F&3@,8P>DAZ;5
M) .WBMF#PVAU#7KBZ 3^U@L1\J0DB,)MSR,!CDG R.G6B3@G=-W_ %$M[=#'
MM/$'A&\MGTV9[/4K2,B;>%%XK.Y+.S;%(7#/R3@?-VIPUOPMJ.C)C2;>4NJM
M]DGLMJC<P.TEDV[OGWXZX.>AS6M>>$+&]U![QKBZC>2!;>58V7;+$,?(<J>#
M@<C!]"*IP?#W2;>8RI+<,Y PS+$6!  !W;-WW5 QG&.V3FCFI[ZDKFMJ2^)3
M86=WI[W.@65^)66V6641[TW,%"(I!+<,Q(X 56YK-_MZ"6\BM+[PU9AK*X4R
M8D61;<NT?S(=@R^Z7Y@,8VGDG&>AO-".I6MI'?:A=%X53S#$559G4JP8J5(!
MW*",8].G%4[?P9:P1VJ/J%],+9L_O&C!E&]7PY5!N^=0Q/4DG)P2*4)02M+]
M2I)]"C?ZIH&FZK<:0-"@DB7RO.,5J"I>9U0J5"G)P5)]MHJ?3M<T:?P5<ZC:
M:;''$EL))[$0; 6\L$)RH# C:H;&",8JW<^#].N-0>]26[@GD97;R[@E=PD6
M3.ULJ#E .G2G)X1T]-+_ +.9YI+9O(#I(5/F+%MVJWR\@[1D=^>E+F@X:WN/
M6[[&6FK^$M2TR";5-.M5FF95DM9++SF24_,4P$.XAI",CJ6/<FI8K[P3?71B
M2SLI))'7);3B!(S%2/F*8)S*I//!?G'-#?#C0C-/(BRQB7[D0"&.']YYGRH5
M*_>[$$8XJ5/ FFPQ1+;7%U T)W1O'Y8V-F(Y V;>L*\8QR>.F*YJ?=D^]L6+
M&_\ #>HWL3Z?!!-<QQM/"XM"I&X!VVL5 W'>"0#GYN>M<^OB;36L[B]E\.Z>
MQG9O,6*5'=Y1$[B.4% RR<,"&'&[@G)K<T?P3I>B77GVIE=_(\G,BQ[L;54G
M>%#9(0<9QUP!2#P18NH^V7E[>.LL#I).Z;E6%BR)E5&5^9@2<L03DTKTTWJ_
MZW&[[_UY%32=2T@Z#=:C8Z#;6T<:I"D44:*9#*B,8^%&!ND"GW!-3W4VE16_
ME>)=#LX)7D*)&(?M$4F2@!W[/E!8JOSA>1WP#5NT\+6UKIM]IRSS&TNI&E5<
M@/$[.7)5@.Q(QG.-HJI>^!;+49H)KZ_OKB:*83^9(8B68%2.-F$QL4?(%R,Y
MSDTN:#EN"7<S+/4?#%QH=Y:/)<+_ &I#YL\<5H[[5V(ACC*1[6"#:N #C'/>
MM&+5/!L\3V,=O:F#"CRSI["*3#+@*2FU\-*O S@M6;'\.?-N#;7=Y(NEP1NE
MM$CI(?F96)96BQU7)!W\G(VX J_=>"@+;2[33KAHXK&=K@7$K!I%?850!=NU
MANPQS_<'!SQHW3;W?]?\ A<Q'>1Z'H^OII;Z+;W0U0237$TD:$(0-T:,-O(.
MQMN>FVF:#<6?C#3)4:PLK01>5(?[/G69'5L/Y3.8QM.5&Y0/3FMC4?">FZI>
MR7MT'-VQB,=P N^$1G("$C@$DY]<FC2/#?\ 8]XDT.H7-PHMTMV6=8\E$_U8
M^55Z9;GJ<^PJ%*/)Y_U_PWR*:=]-C'NM3NY[&[U+5_"^E3&Q:2$O]L\TA%5M
MXRT(// "C.=W..[M(O(+R8VLGAC3X8)(;A[5(75V=8G,95T,:A,^8<<L/F89
M]=B[\-PW4:*E]=VX6[-W^[\LAG/0$,A! /(&.H![5-8^'[+3;2XBL5\F6X,A
MDND1!*Q=BV2P7D@MQD&ESQY?^'_K<=GS?UW_ ,CF1KMK'<RV4_AW38'O)C!=
M[IU6.Y;Y<HK&,"5_G.5;;R"!FK6E7OA^^L;F\ETC3(;.S_<Q20K',=C%AL**
MN48Y^X <[QU)(JY_PAD'V.&T;5=1:!$\N2,F+$Z9SM?]WZY.X88Y/S5-#X2L
M8+2Y@CFN0)C'L;<N8!&Y>,)\N,*Q)&X'WS5.4+:?K_6PDG?4BT_4/"UYJ;06
M%O!]KF+,Y^PLFY\,&#,4 WXWY4G=C.1UK!/BC0T@_LRZ\/V<5E$$=HR%,2/Y
MFV4!=G5 0W3G=CBNET_PK9:;=)<137,DHG:X9I&7YY&5E8G"CKO)XQS[<53N
MOA_HMYYGG+,?,N)[AOG'WIEVMVZ="!Z@=:2E34M;V#WK,K7OB?PM:W]I<"TB
MDE663S)_L+A[7"2.Q)V9#'RR-G#'.<5//J_@UK=%N8;4Q(TDP62P;$;DOOR"
MGRN2K\'#$@\&F#X=:4B[(KF[BC9VDECB6&-99"CIO(6,8.UR.,#@<&I)O &D
MS7TMT9)Q+*TC,VV)CEV=L@LA(P9&X!P1C(--NEI9L-?Z^9%)K/AB'4H$M]-B
M=[AS)-(NGNK(0KR#/R9+Y9OE^]\Y..>7Z?;>"+V2""PTG3"XE)CC_LT(4?;D
MG!0;3A0,\<KCJ,4T?#O3%MQ!'>7T<&2QA4Q;&<KLW8V8^[@;1\F!C;BG:3X,
M&D:]!=V<^R"UM_LZ9*EI5+N[!E"A5Y9<;>P[=*&Z=M&P][=_UM_P274I_#JW
M;:-K.FV36MC;)<0)+;"1$7Y@=J;2%VA!T]>.E,75O!^^6_%O;B4R*'E_LYA(
MY0,5;[FYE4(Q#<@!3S4EUX)M+R:>:;4=1\R;<K-YB$B,EB8AE#\N6/\ M#@9
MP*;=^ ]*O(D29YCL554LL;X #CHR$<B0]O3&*5X=6PUOY%37KG2?#]Q'<2>&
M]/DM?($<=PHC5R$5I%0+M^XI1>20 2,"KVF6MA+IKZY8>'],_M%V>13:&)O.
M<%E#"8*,Y!/)&<,>.HJQ?>%K;4+N26:[NA%):_93;KY?EJG/W<H64DX)(/.U
M?2GQ>'VBTZ\L$U*[6&Z1LR)L659'9F>0,%P"=P[8&.!2<H\NCU^8];ZG.VNK
M:9<WV'\*V1_>O#++"J.S2_OS\F4&]6VR?,<<R'CDFETZ_P!$O+K2K=O#&G6Z
M7%LD2!ECW0B5)'\I5"\IB-@<$#)Z'DUNVGA6UM;RVN?M5U(;95"QMY:HQ565
M255!R%=@,8'3.2 :6#PI8P7UA<^;/(=/C$<".5(& PW9VYSACP"!T.,@53G#
M7_@^?]?TPU*)O?# U6#3+;3(6GFF$+!; J$P&96R4P1NAX(XRN<\5A6"6'AB
MTUBQM]'EOE:Z83)?-$@F1(1(6"H@7IP,C+$Y)YS71V7@BPL-:?5(+JZ^T/.)
MFSY>"0)!@X0$\2MR26X'/%6=1\+VFI/.\D]S$UQ)O=HG4'!C\IEY!X*]>^>0
M10IP6E]+?B%M3*U/Q'I^C+/'#HR/8QVZBX(019!\Q40(5^9?D(SD !AC(S5B
M&?1(M#DDU71K2T6"5H)8(;;SU4@-TVIDC:S'.T8#-[U:U#PE9:I,SWD]RZ/'
MY<D0955U&[8#A<_+O;!!!Z9SBH[[P;9:EH?]F7=U=2(TS3R3-Y;/(Y!&6!0K
MT/'R\8!&",U/-"W]?UW_  \PL[HKVMYX.NI/[(M;*U97DV>3_9K")F5FQR4V
M'Y@^#GKG'-9,WBKP^\AM;_0K41KJL]E+YD:LJ)&&<S8V<@GM_>8\DUT5EX1L
M+&6*2*:Y9HGWC>R\G>[\X7UD;\ *J7'P^T>ZNKBXE>Z+S[]V)  -SNYQQQR^
M/HJ^G-*5-/5O^NH-.SM_6_\ P!)-1\&'S;J>VM!):HQD:73R)(@_F%@04W#.
M)"1WR?[W, UKPB1+9?V8@M%A61Q_9;[>&?Y2GEY!4ACR.,D^M6+GP%8W;SO/
MJ&H,]T"+EMT8,QPR@GY, @.<;<#IG-&I^ =-U5I3/=7:K,271?*96.6/1D/3
M><>G!Z@&E>GW?]?\&X,?;ZKX;U?55@FM[6:^;? C?96<% 9%V^8R #(C?Y<]
MCC(Y-:;75BN]1F\1:3IEO;6C_8GN1.\[R(R"0KM\D':5(RN<9!]B=#3_  ?8
M:;<Q3PS7+/%-YPWLI!;][UPHX_?-^0]\R:EX6LM4ANXKB6X5;NX6XDV,H(81
MB, 9!XPH_&B]/F\O^#_D&MG_ %Z?H9=KJ/@>VD>ZM+&UMYD<$LFEM'(& <9Q
MY8;@)(">VU@<<U:U&7PEI($-]8VD:;/-&W3RZ8"'H50C=L1L#K@<"F7O@'2;
MZ0O.\Y8DGYA&X&7E8\,A'69ATSP,<\F35O ^FZQJ45[<37$;Q1>4BQ^7@#8R
M\$H6'#G@$#(!QQ1>G?=B=];%:+4?"T=Q%:Z9IELSZI.$N$2Q,>3N?F7Y.NY'
MX?!)S5J_UC0IM7@L[BS^UW4DZV^7LF;;RS [BN"H:/J#@$#IBI(_"5I#J:7L
M-W=H1.;AX@R;)6+R.-V5S@&5L8([9SBHX/!5A;ZY)JL5S="XDG$YXCP3EC@G
M9EA\Y')) P 1@4KT[[L;OK;^M_\ @%62Y\$Z0\]M_9MI;D[H98XM*;]X&!W#
MY8_G7]T<D9'R<]!5H'PEJ-M<C[%8W,4:-+,ALMW D;)(V\G>K''4G)&>M1_\
M('IG]K3Z@;BZ,T[N[#]V.65UZA-QP)&QN)Q@#H,4ZP\)QPPZW'<,8QJCA 89
M-Q2)4"+R5QD_,Q&",L>O=WA;=W&]]#(U'5_!MO$$@TC3YUNLQ7/FV)C1$B1V
M"R'RC]TQ8"$9'4#BM 7'@FY::[:QL&=HMTDDFG89XU"L#RF67 4@\@[1CI5*
M\^&EHNBR66FW4^&+GR)6C2)V<.I8A(\C"RMA5P.!]:TG\"V3VXB-_?Y$8A\S
M='N\D+M$7W,;<=\;O>K;I]),A\W1%3^U_ MQ-,)+*WW1PNCO-I+JIBP[LH9H
M\,IV2' )S@]:='>^!O("QZ=:HL,BLD7]DLK!P6P53R\DKASP/EYSBKL_@K3K
MBW,+S704Q^7D.N<;)4_N^DS?B![Y9?>!-+U YGDGW"1I%)$;A2S,3\K(5/WV
M'(/;OS4<U/NRK:$4NN^%]1U".-+.._GNI_LKR&Q8A@0ZD[BF&7Y64D$CGTJ1
M-2\)6>JCR;6!+V6ZVJ\.G,7DFPR%E94^; #@L"0!D$C-3VO@[3[*2U>UFN(_
MLLADC *8Y=V*XV]/WC#Z8[\TZ'PG9PZM!?\ VBZ=[:626"-F79%OW;P,+D@E
MR>23P,''%%Z?1NP.YNT445SE!1110 4444 %%%% !1110 5PWBKPQ?>(/$EP
M+..*W_T*!4U"0L'C(>4LB84YW @-R, ]Z[FBKA-P=T#U37<\ZNOA]J%S-<.D
M6EP)/#*BVZN6CA#(P"+F/@;B&RNWJV5; (KV/@;49XFG_L_3K5";B,VCNX5V
M:23;.W[O[RAAMXY!ZCC'IM%:>WG:Q'*KW_K^OZV/.9_ASJ!A*03VH#DM, VW
MSI"TY\QB8V&X"5.<9RO48!ITGPYO/+D-M-:17$@?=<*2';<+@-D[>I\V+/\
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M2ZZ9+<,91-NVI*O$#'^^V1@UZ5YJ>OZ4>:GK^E"]LFGR/2_3O\@?*[Z[_P#
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MWR3R6UMY8_B0DH-^"!G/%?0/_"!>"?\ H4M!_P#!9#_\31_P@7@G_H4M!_\
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M3_E#V*[E;:W]T_E1M;^Z?RJS11_:4_Y0]BNY6VM_=/Y4;6_NG\JLT4?VE/\
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MW_!^\MT445S%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYP !T%$/A6U@TNZL4O+PI=3"X>1G5F$H8,7&5P,L 2,8] *T_=V)]Z_]>?\
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M.L5CGFWR-N>1%QL5V=G8J< ]6QSV X'-9RY.16W'K<T****R*"BBB@ HHHH
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M2OJ:?11]:K_S![./89Y*^IH\E?4T^BCZU7_F#V<>PSR5]31Y*^II]%'UJO\
MS![./89Y*^II]%%9U*LZGQNXU%1V"BJ]_J%EI5C)>ZI=P65K%CS)[B58T3)
M&68@#)('U-8W_"PO!G_0W:#_ .#.'_XJH49/9#NCH:*IZ7K.F:W:M<Z+J-IJ
M,"N8VEM)UE4, "5)4D9P0<>XHI--;C+E%%%( HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#-\1ZC+H_A75=3ME1IK.RFN(UD!*ED0L <$'
M&1ZUYE;?$7QO?>%=,U/3M.M+NYU(.8XHM+D%O%L<J1).UP G"D\K_C7J.N:;
M_;7A[4=+\WR?MUK+;^;MW;-Z%=V,C.,YQD5YW8?"'4M..D>3XEM6728IH8U?
M2V(E24L75_W_ #]XCC%==%TE!\^]_P +/];&<N:^ASNJ_%7XE:)I[WNJ:%H=
MO DOD[BQ)9L _*HG)888'(!&#UKW2O+/$OP@U'Q3:V]O?^);6*.WD9XEM]+9
M=H*(FWF<\ 1KCOUR37J=*O*G)1Y+7ZVOY#BFMS'\3>(8_#.G17UQ")+<S".5
MB^WRP5)#=#GD 8XZURUM\6+:33Q>7&F21(J*)(T=I)%EVDM&%5/X<#))'!]L
M'KO$6@67B?1)=*U/S/L\K(S>60&^5@PZ@]Q6--\.-%DCNT22[A^U74UTYC=0
M0\JA3C*G@8R!Z^M13=+E]]:_U_P0ES77*0O\2=.C\Q)+>99XKXVKQ".0G8)"
MGF+A/G/3*+DC(!JW>>/M%CL9IM/G%[+'"LR1A719 0IP'*[=VUU)7J 1D4O_
M  @>FF^@NVN;QI8)WG&73#,\HD.?EZ;A^558/AGH]O:_9DNK\P",(L9D3"MM
M5#(/ESN*H >W7 &:I>PMK<4N>[M_7]?UYZFD>*K36]?OM.L%9X[.%'-P590[
M,[J0H91D#9]X$@Y]JW*P]"\*6F@7US=6MU=3>?&L2QSLI6%%=V"KA0<9D;J2
M>E;E8SY;^Z7K<****@84444 %%%% !1110 4444 %%%% !1110 4444 %>.Z
M7\2_&>K>$;?5[/3[:YN+JX>WBM[3299(T==H'F2FX 0$MC.#T->Q5Y3IWP;U
M+2[?28K3Q3 O]DW4EU QTLDLS[0P;]]@C"]L=3S750=))\_D9RYKJQB:C\3_
M (FZ3IT]_J&@Z##:P%0TIDR&W#*[,3_/D?W<]_0U[C7F.O\ PEU'Q#H\>EW/
MB&RM[2&1)(H[;2G'EA$*!1NG/&"3SDY/6O3J5>5.27);Y7\O^"5%-&;K^L#0
M=)-^\/FQI-$DGS[=B/(JE\X/W0V<>W:N-M/B[:W-C]KDTQXHXT+S)YC.Z_ZT
MJH4)R2L6[G: #UXY[;6](M]?T.\TJ^+BWNXC%(8R P![C((S^%8#_#?0V%T%
M-S&+IT>0(ZC[L#0@#Y>FUB?K^533=+E?.M2NI7'Q,T\V-W*;:99[>5 +=TD4
MO&6C4N"4ZCS1E!D].F:N:C\0]#M-+FNK2<W4R6SSQPF.2/>5#'86*X1OD;Y3
M\WRGCBFK\/=,VQ>9>7\KQL6WNZ98EHF).$ ZP+T]6]L0W'PRT:YBFB>ZOQ#.
M9&DB$B;3(^\>9]S.X"1@.W3()&:O_9]-R%S=34LO%=GJ/BAM&LE:5HH'EEFV
ML%5E=5* E<-RQR03@C!K=K"TOPG9Z3KDVIVUS=,TBR*MO(RF.+S'#OMPH;EA
MGDGJ:W:PGRZ<HU>[N%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:R7%E*SQQ'Y]\3H1\H8?*P!P000<<@U'8>(M*U.2S2QNQ,U[;&[@ 1AOB!
M+<CCE@,'!_(T^6785T:5%9FI>(=.TF[CM[Z299)%W9CM99%1<XR[*I5!GNQ
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MF17 CBW1;C&5*LRM_>.6.4ZYW]2\$:A=Z;H\5O=0QW&GPRQ^8[$[/,9 P4A
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M2;W8LQ"K(%&68G@#K1%JS3 W:PO W_)//#O_ &"[;_T4M'_"'Z;_ ,_.M?\
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M._\ 2V&MVL:#P=X8M;B.XMO#FDPS1.'CDCL8E9&!R""%R"#WK9HDU:R *PO
MW_)//#O_ &"[;_T4M;M87_"#>$_^A7T7_P %\7_Q-$6K-, \<_\ )//$7_8+
MN?\ T4U;M87_  @WA/\ Z%?1?_!?%_\ $UNT2:LD@"L76_#[:O=PRK=^0BJ$
MF3R@YD42*X )/RG*8S@\$\=#6U14IM.Z&8.A>''T2UGMTGM1#,.8[:T\E%.U
M5!50Q Z$GU)'3'.-8?#A=/NH)X]3WF!E**]OP &B?;][IOC=O^VGMSV]%:*K
M-.Z9/*FK?UJ<]X@\-76OF!)=36*"+;(8A;9!E4-A@=V0#NY4YR ,$<DY<_P_
MEN;B>>35@DEP6>7R8&C#.6)' D^Z"1_M=<.,D5VM%)5))60VD]SA(? -RSW=
MM->(EJS&5'\IG:25T=6;+2,=H\QOE.3GO6Z_A6.6*WBFNI"D-Y<71\LM$6\T
MR';E6! 'F>O..G-;U%.56<MV+E1S>J^"[#6K:VAOX;.5;:QDM8D:T#)&S! )
M$5B=NW9P,YYZUAZGX*U2TNI-1TZ[-_<L72.%HLB-660<AY0O\>/EV^I#'.?0
M**%5FM+_ -,=D</9?#VXBG2>ZU;S"J$"/R6(7,<BX&7P,>;_  JN=O(R2:[2
MVA^SVL4.[=Y:!,XQG Q4E%*=24]P44@HHHK,84444 %%%% !6%X&_P"2>>'?
M^P7;?^BEK=K"_P"$&\)_]"OHO_@OB_\ B:N+5FF(/'/_ "3SQ%_V"[G_ -%-
M6[6%_P (-X3_ .A7T7_P7Q?_ !-;M$FK)( K"\'_ /(#N/\ L*:C_P"ELU;M
M8T_@[PQ=7$EQ<^'-)FFE<O)))8Q,SL3DDDKDDGO1%JUF!'XY_P"2>>(O^P7<
M_P#HIJW:PO\ A!O"?_0KZ+_X+XO_ (FMVB35DD 5C:[X?.LS0NMUY"K&T,R^
M7N\R-F1F .1M/R#GGJ>/39HJ4VG=#,'PUX9_X1JW-O;7$30L5!5;?9D*NT$X
M;&\]6;'S>@JG_P (?=M]E,VIPN;''V7%F0%_>K(=_P"\.X_(HXV]_P .JHJ_
M:3YN:^HN56L<OX@\%KK^J+>R7QA/E1Q.BQ9#JOF'!YZ%G4X_V/?BO!X$EMXW
MB35$\F67S90UH"Q(D=P 2WRCY\'OQU&2#V%%-59I6N#2>YQ5S\/9+FXD,FL-
MY#B;$0B8;3('])-O&_KMW'IN X%RU\%)#IFIVD]VLPU) LNZ-F7.YV/#NQ(.
M_&">WO74T4>UFU:XN2/]?<<7-\/8(=0,^G316UB+A;C^S;>VV(=H7*@*ZKR5
MZL"!GC')-2S^'4\FB16]SJ#0&XB'VQ7B$DI;$@&'# # EP>#G:,5W]%/VTTK
M7#E5[G*Z7X*_L^^^UO?^;*TD4C_NW.2AD[O(S<AQW/W??CJJ**B4Y2W'9(**
M**@84444 %%%% !6%X/_ .0'<?\ 84U'_P!+9JW:QI_!WABZN)+BY\.:3--*
MY>222QB9G8G)))7))/>KBU:S$1^.?^2>>(O^P7<_^BFK=K"_X0;PG_T*^B_^
M"^+_ .)K=HDU9) %87@__D!W'_84U'_TMFK=K&G\'>&+JXDN+GPYI,TTKEY)
M)+&)F=B<DDE<DD]Z(M6LP-FL+P-_R3SP[_V"[;_T4M'_  @WA/\ Z%?1?_!?
M%_\ $UM0016MO';VT20PQ($CCC4*J*!@  <  =J&XJ-D&H^BBBH&%%%% !11
M10 4444 %%%8FH^(9+'65LH[!KA L9D=90K!I"X154\')0Y)88R.O.&DV[(-
ME<VZ*QAXB63PK=ZU'93(MO',ZPSLJF3R\]U+#!*\'GCFHK+Q,?MZZ=K5JMIJ
M#LHCBM6DN4=6!(;>(UP.#DL !CK5<DA72-ZBN=N?$\]GJUTEQ8Q+IEK<);27
M0N"9 [1JX/E;,;?G SNS[5-)XQT=%&+B0.P;:)+:9 I!VX<[/D^88YY/8&CD
MEO8>SL;E%8</BRPN[JSM[)O/>XG\IR RA/DD;<I91O&8BN1W^F*QH_B%FTOI
MI;2SS;1F54@OC*2/G^1\1_(_[OIR/?BG[*;=K"NCM:*YZU\;:5+;2/=2-!)$
MTBR(L4D@!5B, JN"Q&&VCG!Z=ZVK*]@U"S2YM'+Q/G!*E3P<$$$ @@@C!J7&
M4=T"DGL3T445(PHHHH **** "BBB@ HK"\<_\D\\1?\ 8+N?_134?\(-X3_Z
M%?1?_!?%_P#$U:BK7;$;M%<9XC\*^'M-T^TN].T'3+2YCU33]DT%G&CKF\A!
MPP&1P2/QKLZ&DE= %%%<3X-\'>&+KP+H-Q<^'-)FFETVW>222QB9G8Q*222N
M22>]$4FKL#MJ*XGQEX.\,6O@77KBV\.:3#-%IMP\<D=C$K(PB8@@A<@@]Z[:
MB44E= %%%8NM>(&TB\@B2S-PC*'F82;3&ID6,8&#N.7Z9' /L*E)MV0S:HK#
M\.>)1X@T>>^%NL7DMC$<WF*WR*_WL#D;L$8X((YK&T[XEV%V---S:36ZWEC]
MJDV*\S1/YJQ"(*J98EB>@'3IS6GLIMV2_K?]">96N=K17/>(?%7]A7D</DVT
MFZ!IL377E.^& V1KM.]CG@9%7=:U^ST'[$^I306UO<SF%I[B81)'\C,"2>.=
MN,9'6IY)63[CNKV-2BN>L_&VCW%C!/-/Y3RQ))L1'D&6 (165<,Q#*0H^8@@
MXHMO'&C3W$\323Q>3($#/;2@$%4.X_+\HRX'S8YI^SGV"Z.AHKFKGQO80W&D
M&.*5[/5(IY4N71XM@C4-DHR@X;/!..V,YIVF^-M.NM)L[N_$MC+<VXG,+12/
MMR,[-P7!;_9'S>U'LYVO;^M?\F%T='17,VWC>SO-7N;&VBW"TS).S%E9(1&K
M;_+V[MVYMNW&>"?:M&T\3:3?3I#;73-+))Y8C:%U;=\_!! (_P!6_7H5QUI.
MG-:V"Z-6BN:M/%DINT&JV45I:7$LD5K/%<-*7991%AUV#:22,8+#KDC%6&\:
MZ"K2+]KE)C*@[;29LDE0%!"_,WSKP,GFCV<NP7N;M%0VEW#?6<5U:OOAE4,C
M%2N1]#R/H:FJ=AA1112 ***XGP;X.\,77@70;BY\.:3--+IMN\DDEC$S.QB4
MDDE<DD]ZN*35V([:BN)\9>#O#%KX%UZXMO#FDPS1:;</')'8Q*R,(F(((7((
M/>NVHE%)70!117&>'/"OA[4M/N[O4=!TR[N9-4U#?-/9QN[8O)@,L1D\ #\*
M$DU=@=G17$^,O!WABU\"Z]<6WAS289HM-N'CDCL8E9&$3$$$+D$'O7;42BDK
MH HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5EWN@6]]JB7[SW$;JJJR1L K[=V
MPG()RI=B,$>^<"M2BFFT!FMH<#:&^D":9+-K/[&$7;E5VE=P./O8/?CCI5>W
M\-1P7Z7S:A>37:MS-)Y>67 &P@(!MP#T /S'G/-;5%5SR%96L8-_X2MM1N+M
MY[Z]6&[D$LEO&R*F\1A P.W=D!0<;L9'2JUOX"TNWT]K-)KGRV(/RB-,?/OX
M"H% SV Z5T]%'M))6N#5]SF]*\"Z3HUU#/9F4-#+YB K&/X7&"0@9A^\8\DG
M@<]J9-X$L;F Q7-]?2J(FACR8QY:-G(&$&>O\6>GUST]%/VD[WOJ%DCEH/A[
MH]O>2W,;3;YI&E8E8R=Y.20VS<.F,9QCMGFNAL+*/3[3[/"S,F]WRY!.68L?
MU8U8HI2G*6[!12V"BBBH&%%%% !1110 4444 87CG_DGGB+_ +!=S_Z*:C_A
M.?"?_0T:+_X,(O\ XJMVBK4E:S0CC/$?BKP]J6GVEIIVO:9=W,FJ:?LA@O(W
M=L7D).%!R> 3^%=G110Y)JR *XGP;XR\,6O@70;>Y\1Z3#-%IMNDD<E]$K(P
MB4$$%L@@]J[:BB,DE9@<3XR\9>&+KP+KUO;>(])FFETVX2...^B9G8Q,   V
M22>U=M111*2:L@"LK5O#UKK-Q#)=23H(QM=(G 65=RN%;C.-R@\$'KV)K5HJ
M4VG=#,G2O#L&D0R16]S<.DJX<2;.<*J+T4?=5 !^.<GFLVT^'^E65PDUM/>+
M)&P9274X(\H]UZ9B!QZLWKQU%%7[2:=[BY5:QEZAH%MJ:DW4T_F& 0B52H92
M&#!QQ@,&4$'I[58DTU9I;22>>:5[29ID8[1DLK+@X X <X[\#)/.;E%3S.U@
MLCE5^'FD)<+/')<)*FQDD"Q%T= H5PQ3.<(.,[>OR\U*? ]FT\\CZCJ+_:=O
MVA7D0^;M"\$[,]4!X([CIQ72T57M)]PL8&H^#M-U.RL;6Z>X\NRA$$>UP"RA
MHVYX[^4 <8X+>O%27X?:7+>17)N;M9(4VQD>7E2!P0Q3/!YQG;GG'7/544>T
MFNH<JM8YN;P/8W$<OF7U^9YI&DDN3(ID;=&(V4_+C:0H.W&,@8P!BJMC\/\
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M1Z3--+IMPD<<=]$S.QB8  !LDD]J[:BBB4DU9 %%%%0,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7@__ ) =Q_V%-1_]+9JW:PCX.TGS97C?4X?.E>9T@U>ZB3>[%F(59 HRS$\
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MN=HU). ,#D]J4,#.?PR7X_Y ZB6Z-RBH/-?U_2N+/Q#-OXKUBPO(/]!LHO\
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MWO(C+:3Q3QAF0O$X8;E.",CN"""/45+2^NXC^;\%_D'LH=B+R?\ :_2CR?\
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MM(ZCV%>B45+KW5K=_P 0Y0HHHKF+"BBB@ HHHH **** "BBB@ HHHH ****
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MVM9I;>:7=M=HR5.24V]1D8+<=<=*S-2\9ZE'X<C\@^1>1DK)-N63<5>2,\;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K&O[KQ-'?2+I>D:3<6HQY<MQJLL+MP,Y1;=P.<C[QXYXZ5LT
M4T[= .>^V^,_^@!H/_@\F_\ D2C[;XS_ .@!H/\ X/)O_D2NAHJN9=OS_P Q
M6.>^V^,_^@!H/_@\F_\ D2C[;XS_ .@!H/\ X/)O_D2NAHHYEV_/_,+'/?;?
M&?\ T -!_P#!Y-_\B4?;?&?_ $ -!_\ !Y-_\B5T-%',NWY_YA8Y[[;XS_Z
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MS+M^?^86.>^V^,_^@!H/_@\F_P#D2C[;XS_Z &@_^#R;_P"1*Z&BCF7;\_\
M,+'/?;?&?_0 T'_P>3?_ ")1]M\9_P#0 T'_ ,'DW_R)70T4<R[?G_F%CGOM
MOC/_ * &@_\ @\F_^1*/MOC/_H :#_X/)O\ Y$KH:*.9=OS_ ,PL<]]M\9_]
M #0?_!Y-_P#(E'VWQG_T -!_\'DW_P B5T-%',NWY_YA8Y[[;XS_ .@!H/\
MX/)O_D2C[;XS_P"@!H/_ (/)O_D2NAHHYEV_/_,+'/?;?&?_ $ -!_\ !Y-_
M\B4?;?&?_0 T'_P>3?\ R)70T4<R[?G_ )A8Y[[;XS_Z &@_^#R;_P"1*/MO
MC/\ Z &@_P#@\F_^1*Z&BCF7;\_\PL<]]M\9_P#0 T'_ ,'DW_R)1]M\9_\
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M_P!H78RNQ5<-G!R5QQZCUJ[/^7\Q?,K_ &WQG_T -!_\'DW_ ,B4?;?&?_0
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MC/;%GC#RK(N6+_,%V[0 %&/3J2^^%]S?RW1FU]1'<&X<H++I)/"(W;._ID9
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M2 < GJ,=:P;7X:W5HT-U'KR_VA;?9_L\_P!B^1?*B>+YDW_,"K^HP1FI-/\
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M21(ZEI&E10HWJBJ2<N2N/]DFMNX\0:;:Q6LLUP?*NPIAD2)W4AB I) (7)8
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MZ]#HHYJ7\K^]?Y![W<\\_P"%\_#;_H8__)&Y_P#C='_"^?AM_P!#'_Y(W/\
M\;KT.BCFI?RO[U_D'O=SSS_A?/PV_P"AC_\ )&Y_^-T?\+Y^&W_0Q_\ DC<_
M_&Z]#HHYJ7\K^]?Y![W<\\_X7S\-O^AC_P#)&Y_^-T?\+Y^&W_0Q_P#DC<__
M !NO0Z*.:E_*_O7^0>]W,_0=>TWQ/HEOJ^AW/VJQN-WE2^6R;MK%3PP!'*D<
MCM6A7GGP&_Y(EH/_ &\?^E,M>AU-2*A-Q71CB[JX44$@=2!0"",@\5/+*U[!
M=!12;@>A'YTM)IK<845%;W5O=J[6L\4XC=HW,;AMK@X*G'0@]14N03@'FBS
M**-PYY''6C(QG/'K3Y9=A7044 YZ5$EU;RW,MO'/$\\(4RQ*X+1ANF1U&<'&
M:5F,EHH!!Z&C</4?G3Y9=A70449 ZFBE9H84444@"BBB@ HHHH **** "LVY
MT*UN]8CU&9I#)''Y8CR-A&'&2,9SB1N]:5<CXG\'RZWJLE]$MJSB&"-!+C)"
MO(SJ2R. #N0_=.2O3H:N.^KL'1CC\.-$\BWCS<%K:W2WC=]DAPK%MQ#*5+$L
M<Y%2S^%='UZUTQXYIA;Z:1' L:(!F-P/XDRO,>,KMR,CI6$OP[OXB=TMG?1Q
MQ>5;Q73L!'O3YY"0IR_F$L.!]0:CC^'6L1W2%[^&:/SGE,C28D1F<$$;HF^Z
M%R,8.9'^8=^G1OXS/7HCH;7P)8VMQ!,+^_D:%U<;VC^8*(@JG"#@>2G3!ZY)
MS3K3P-I]G]D6.ZO&BLW62")W3:K J2W"Y.=@SSCDXQFL_P 1>#]0UKQ+]L4V
M1M&0(ZR'#,F.5(\LDC//W]O^SGFCPSX<GTOQ1>EEVV<$;-$BQLL?FR,<[20
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M_D>C_A']2_Z&_6O^_-E_\CUNT4<[_I(+&-!H>H0W$<DGBG5IT1PS1216@60
M_=.V '!Z<$'T(K9HHJ6VQA1112 **** "BBB@ HHHH *QK_QCX9TJ^DLM4\1
MZ39746/,@N+Z*-TR 1E68$9!!^AK9I@GB-PT E0S*H=HPPW!22 2.N"0>?8T
MU;J!@_\ "PO!G_0W:#_X,X?_ (JC_A87@S_H;M!_\&</_P 56[!<0W,?F6\B
MRIN9=R'(RI((_ @C\*6&>*XC\RWE25-Q7<C!AD'!&1W!!'X5?N]G]_\ P!:F
M#_PL+P9_T-V@_P#@SA_^*H_X6%X,_P"ANT'_ ,&</_Q5:<FNZ1%J#V$NJ627
MB!2UNUP@D7<0!E<Y&2P ^H]:O4>ZNC_KY!J<]_PL+P9_T-V@_P#@SA_^*H_X
M6%X,_P"ANT'_ ,&</_Q5;TT\5M \UQ*D448+/)(P55'J2>E#7$*3I"TJ++(I
M9$+#<P&,D#N!D9^HI>[V?W_\ -3!_P"%A>#/^ANT'_P9P_\ Q5'_  L+P9_T
M-V@_^#.'_P"*K5M-9TS4&5;#4;6Z+%@/(F5\E<;AP>V1GTR*L17$,SRK#(KM
M"^R0*<[&P#@^^"#^-/W5T?\ 7R#4PO\ A87@S_H;M!_\&</_ ,51_P +"\&?
M]#=H/_@SA_\ BJZ&F//%'-'$\BK)+GRT)Y; R<4O<[/[_P#@!J8/_"PO!G_0
MW:#_ .#.'_XJC_A87@S_ *&[0?\ P9P__%5T-0"_LS((Q=P%VE,(42#)D W%
M,?W@!G'7%'N]G]__   U,7_A87@S_H;M!_\ !G#_ /%4?\+"\&?]#=H/_@SA
M_P#BJWS(BR+&SJ'<$JI/+8ZX'XU$+ZT/F_Z3#^Y_UOSCY.2.?3D$?@:?N]G_
M %\@U,7_ (6%X,_Z&[0?_!G#_P#%4?\ "PO!G_0W:#_X,X?_ (JM]Y8XV17=
M5:1MJ G!8X)P/4X!/X4ZE>';\?\ @!J<]_PL+P9_T-V@_P#@SA_^*H_X6%X,
M_P"ANT'_ ,&</_Q5;<-Y;7$CQP7$4KH,LJ."5Y(Y Z<@C\#4U'N]G]__   U
M.>_X6%X,_P"ANT'_ ,&</_Q5'_"PO!G_ $-V@_\ @SA_^*KH:*+P[?C_ , -
M3GO^%A>#/^ANT'_P9P__ !5'_"PO!G_0W:#_ .#.'_XJNAHHO#M^/_ #4Y[_
M (6%X,_Z&[0?_!G#_P#%4?\ "PO!G_0W:#_X,X?_ (JNAHHO#M^/_ #4Y[_A
M87@S_H;M!_\ !G#_ /%4?\+"\&?]#=H/_@SA_P#BJZ&@G R>!1>';\?^ &IS
MW_"PO!G_ $-V@_\ @SA_^*H_X6%X,_Z&[0?_  9P_P#Q5;MM<P7ELEQ:31SP
M2#<DL3AE8>H(X-24>[V?W_\  #4Y[_A87@S_ *&[0?\ P9P__%4?\+"\&?\
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MD&IC?\+"\&?]#=H/_@SA_P#BJ/\ A87@S_H;M!_\&</_ ,570T4KP[?C_P
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M -3GO^%A>#/^ANT'_P &</\ \51_PL+P9_T-V@_^#.'_ .*KH:*+P[?C_P
M-3GO^%A>#/\ H;M!_P#!G#_\51_PL+P9_P!#=H/_ (,X?_BJZ&BB\.WX_P#
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M1XCAOCL;4)[1#@1)?%6<>7A#YC2$\-][*C/^UTJLVA>+7D699KA9\F-F-SM
M5RJNRG>QP 2ZCY>5X44W-R5G):K\S-)1U2*,OPWUM[-$7^RF=!)$B32-*(XV
M$0PKO&3_ ,LV #!@H;&6 Q5>+X6ZRLB;[C3]PA4-)'*0X?R40DDQ$D$H1P5.
MTGW%=3;:7KQ\,&&[:>2^$XD7?*-RXC )#;VXWY(Y'7H.E4/[!\16]W.+1KU4
M>6/;,UV96*A7QG=*"0&.2"3G(X/2FJLM5S+^O^'*:T6AF7GPJO20NFM8VT!<
MEXHF\O=P0ISY; %2Q8<=>A!Y#YOA???;IYXUTV3SXYU<N[*Q>1IOGR$/S;7C
M4GT!Z@ '1@\,ZTKQ;Y=07]U%YK+J3AG?$>_<0^3T<#T[=JTKC0K^Y2YGE@@>
MX?3XHE:1%:4R!6W8?=\O)].<]:'5ERVYA62EHC2T+1KS3O#VFV5Q>^5+:1!'
M6U1/+;'0<IZ<<!?H*YO4? FIW.L75U!<VGDRRRSI%(3_ *R1&C+'*D?<V#H1
M][@]Z]UHOBY+2*"S:_8^7\TAORS!C$@;YC*,?.'QPWMMZU;N='U]9BD4%[<B
M.8M \FH_(J"1RH8,Q+-]WD\@=^,5&J?,I+4JUER_UL,T_P !7MG+9W+-9?:(
M+P3R8/$J!44(Q"#.W#,!@ ,%( JQ>>"I[G4;VZB6Q2260E),G>%;SLY(7C)D
M7H>=OTINFZ)K+^']2BUBVGEFF,>Q3,C.RK(S<;WD!P"/E=B#T)]*0T/Q'#+
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M49/ ,ALX8(=6,8C&&Q"P#C?(W.V0?\].AR..0>S2IZZA[UK]3H'\2:(D3O\
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M_LF\N=)NK6WM_.O'MK.6)HRV1&@+2L,G!/3@#W%6/&WBJ7PUIT?]GP)<WTK
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M)4&U&<Y*R$]%/;K7I=%%<LW%OW5;\2U?J%%%%0,**** "BBB@ HHHH ****
M"BBB@ HJ*YN8;.UDN;E]D42EG;&< ?2L]?$^CN^Q;T%]NXIL;<O[P1_,,9!W
MD#!YII-[!>QJT5B1^,-$E\O;=N/,C65=UM*N8VSA^5^[Q][H.YK1TW5+/6+(
M7>FSK/ S,H=01DJ2#U]Q^/6FXR6Z"Y:HHHJ0"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@""^LX]0L)K2<L(YE*DJ<$>X]ZRSX5LBB!IK@E=Q+;ERY:99F8_+
MC)9>V!@FMNBJ4FMA6N<O??#_ $>]T!-)0S6D:P^2\]L(TEE7;M^9MIS^5:^D
M:'::''+%I_FK%*5;RWD+A2%"\$\]%'?M6C13=235FPLKW"BBBH&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>aurinialogoweb700pxa02.jpg
<TEXT>
begin 644 aurinialogoweb700pxa02.jpg
M_]C_X0[-17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3@@*$UA8VEN=&]S:"D ,C Q.#HQ,#HQ." Q,SHT-SHS
M-P     #H $  P    $  0  H ( !     $   *\H , !     $   $2
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #8\         2     $
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MGO&][7_O,]+8Q=+B9->7C59-7T+6AP'<3^:?ZJX?KC7-ZQEAW/J3\BUKF_\
M15+J?UBR*>D5]%Q7FLDO=E6-T(K<=[,>MP_TFYSKG?Z/]'_A%?/+>Y#$(:&A
M9_JGU2+D_#\^7)SW,8B28R,I?W/:E[?_ $7I.M?7OIW3['8V$S[?DL,/V.#:
M6GNU]\/W/;^Y2RS_ (3TU4^J_P!:.M=:ZUZ%_HUXM=+[7LJ89F65U@V6/?\
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M9=9>#4&DAKQ_.[?WUEW_ .,CZMUW>E6;\CMOKK 'W7OIL_\  TE/5+GOJ_\
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M/_,^HC]WEKKH /KQ?*(JX&_T?ZL-Z5UC/ZE7>'UYVC,85A@K$[]K7A[M[?\
MK;%N+&Z(_-&3?3E>M?M:)R[!8QCW;G?0QLBJGT7._P"ZK\C'_P"+_1^ILJ+)
M PEPE!%&E))))B'_V?_M%L90:&]T;W-H;W @,RXP #A"24T$)0      $
M                   X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 4@
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300
M       "   X0DE-! (       (  #A"24T$,        0$ .$))300M
M   &  $    ".$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      TD    &              $2   "O     H
M50!N '0 :0!T &P 90!D "T ,0    $                          0
M           "O    1(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   1(     4F=H=&QO;F<   *\    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $2
M     %)G:'1L;VYG   "O     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$%       !
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M+/\ A/353ZK_ %HZUUKK7H7^C7BUTOM>RIAF9976#98]_P"<]<'[6M[-:T?
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MN8,C&?E>L<5N3C.I]5MA=O?7EU7MJ;D5U9;]KO1W_H?T;/T_\SZB/W>6NN@
M^O%\HBK@;_1_JPWI76,_J5=X?7G:,QA6&"L3OVM>'NWM_P"ML6XL;HC\T9-]
M.5ZU^UHG+L%C&/=N=]#&R*J?1<[_ +JOR,?_ (O]'ZFRHLD#"7"4$4:4DDDF
M(?_9 #A"24T$(0      70    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <    !< 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M :(    & @,!              <(!@4$"0,* @$ "P$   8# 0$!
M    !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R(
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M4V0WUL'$5&YA!H$5/O;$"3;V^J.-4L%BH]X8FMB3A3H4&PO;V7.NEF7I4#4
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M=!@HDRLL:$^-:G)R0R9.ILU^9)6)/^/OG5[O_>W^]=[]?5VONS[T<S;MMLX
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M'O[Y?W)RO]XONOX-]]_#:O\ NE]SX_\ B^_>V_X Z_3X-5_N?VM=O7[[O?\
M)Q#G;_@3?]=W_6=W/^OOU/[O^H^DG_<GC:?^2E]1_P HVKL^FUZOJ_\ %O&T
M_J]8J?ZSVV?U_P#ZO?UC@_=.CQM'B+]5IK_8Z/XZ9UTIX??IKV]?_];?X]^Z
M]U[W[KW7O?NO=>]^Z]U\_P _G&_(#_9@/GMV]4T%;]YM;J::EZ3VIID\D24^
MP9:N#=#PNI,4L-7V!79B:-TX>%TY-KE="NE!ZGI.YJQZJY]N]4ZWL/Y$_0O^
MAWX)[:WCDJ+[;<W?>Y\YVC7M-'IJX]NAX]K;*I6>PUT51@\",I .;#*,?J2
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MHN(BL<M.+03#5!<)_P ,@DD3^EUD3LV_[+S!;"[V7<X;F'ST-4K7R9<,A^3
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M8D*D:,Q( )&B: D^76P*D#KZ;NPMEX+K?8VS.O-K4PHML[#VKM[9NWJ,:?\
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M>8I:&F-56U,DTFB-=<LC.UV8DK8E4QJ2!7_9Z8<G4<]5@_[-#\E_^\B.]/\
MT;>__P#[(/;FE?X1U2I]>MO+_A/IO_??8GQ.[:R_8&]=V[ZRU'\A\YC:3*;Q
MW)F-SY&EQT?6W6=4E!3UN;K*ZI@HDJ:J601*P0/(S6NQ)23@!Q0>73T?PG[>
MKX_;/3G7O?NO=>]^Z]U[W[KW7O?NO=:XG_"B/LKL;KC8/Q@J.O-_[VV'497>
M'9<.4GV9NK.[7FR4-+A=I/315\N#KZ%ZR.G>9S&LA8(7)%KGVHMP"6J.FY.
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M+EMH/LF7'?9MN6CRF+IHZFDW/*=+4LFMH2;V%O;\**^K4.'3;L5I3K6,WO\
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M^_\ LO\ A_\ $+=D_P#N1MGVS/\ V?Y].1_%^76\;[1=/]>]^Z]UHI?SZ_\
MMXCO+_Q&O5W_ +SWM;!_9C[>D\GQ'JF/V]U3KWOW7NCZ_%+^6G\O/F'+19#J
M[K.KQ&PJJ11)VMV U1M+KR*'5HDGQ^4JJ2?([I\+^EX\-29&6,_K51R&VD1.
M)SU8*QX#K93^+_\ PGT^,_6,>/S_ ,B=R9WY!;NB\51+@('K-C=8T=0MI!",
M7B:X[IW!]M-QY*K)0TU2@_<HE#%/:=IV/PB@Z=$8''/5X?775/6/4& BVMU5
MU[LKK?;D6@KA-C[9PVU\:\B+H$\]+AJ.CBJ:EA?5+(&D<DEF))/MDDGB>K@
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M]1Z]>_TS]/?\_7ZU_P#0ZVO_ /73W[2WH>O5'KU[_3/T]_S]?K7_ -#K:_\
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M^SJR_$/MZ^E7[+NE/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UHI?SZ_^WB.\O\
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MK7UZ]_P]E_+&_P"\F/\ V#/R!_\ M4^_>#)_#_@Z]K7UZ]_P]E_+&_[R8_\
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M]U[W[KW6@E_.Y_[>9_(K_J%Z<_\ ?%]:>UT/]FO^KSZ3O\1ZJC]N]4ZW.?\
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M[]U[KWOW7NM%+^?7_P!O$=Y?^(UZN_\ >>]K8/[,?;TGD^(]4Q^WNJ=;?/\
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M*;(;ZV#B*C<P@T"*GWMB!)M[?5'&J6"Q4>\,36Q)PIT*#87M[+G72S+TJ!J
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M;-4LRWU15.*V)GJZ"1=/JNDL (MSQ[VOQ+]O6CP/7S)/9ETEZ][]U[KZ._\
M+KZIPO3/P@^,>R\-1PTC2]0[.W?G3"BJU7NS?^(I][;JJY9 -=0SY[/3JCM<
MB%$4650H+Y#5V/SZ4J**.CI>Z=6Z][]U[KWOW7NO>_=>Z][]U[K1\_X4&_\
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M_P"W8WR8_P#*,_\ P0/5/MV'^T7_ %>75'^$]:!'M=TGZ,]\(_\ LL_XB_\
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MS\V^BH_DM\3^^.E!3)5Y3>G7V87:T<@4JN^,"(]S;%F;5^E(=X8:B9B"#H!
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M[KW55O\ .R_[=C?)C_RC/_P0/5/MV'^T7_5Y=4?X3UH$>UW2?HSWPC_[+/\
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M^\C-[27'Q+]G3T7 ];*'M/T[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= 5\HO\
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M-?3R4M73N\3I*JS4\K*2K!@#P0??NO=5C?\ #+/\LS_O&2E_]&QWI_\ ;/\
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M&;MPE'E1CZF1/&:[#U<T?W^$R8CX6JHY8*A!^EQ[V&*FH-#UH@'B.J=>T?\
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M^Y/.EAMUI%!8Q7\BI'&JHB*#A510%4#R  '15OD<<.\;C%%&JQK*0    /0
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MXI\M3I5-54M70""EDIZ:4%&)CD<M]ZO9GE;ECE?:>?\ D'<))>7;EXPR._B
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ML-LC-$A(.GQ9#6AHYI3H=S['RKLP2/=+UWN2*TJ?VZ4!*CTU'\^CJ_'?<_\
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M?_\ E3ME_P";/_5INMHWWA#U&_6KE_+Z_P"WY?S<_P!?Y*?^_AV9[S>]V/\
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M+90\U[,]G)<JS1AGC?4$(#4,;N!0L*@D'(ZCN^VR_P!L,:WUN8RX-*D&M./
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MOGT6[O\ \E.^^/\ M#\?Q<?Q?/UZ*/\ S?O^R7=M?]D^?\SGVK_V4I_QX/\
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M/4H\M?\ )*A_W-^'\?#_ )M_T?X>KY?@9_V05VO_ -D,?\>)O3_LG'_CP_\
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MQ?\  A_^9A?]G_\ \[+_ *;-?OJ#['_\JKM?_*S_ -FO_)1_L^'^@?\ "/\
M??\ 0IU-'+?^X,/^YO ?VW#_ &O]'T^74?\ EF?\SYZQ_P"R%_\ C^ML?]E%
M_P#'R_\ %[I?^9?_ /9^_P#.D_ZN?@]V]Z/^56WK_E9_]Q9/^2?_ &?P'^W_
M .$?[^_X7JZWS%_N%<?[F_ W]EPX?B_H_P 7RKUNZ=N_\RN[!_YEW_QZ&>_Y
MF[_S*[_BW3_\S!_[-#_E?_Z9M7OFGL'_ "6]I_W,_P!R$_W%_P!R?B']A_PW
M^#^E3J'K3_<F#^T^,?V?Q\?P_P!+T^?7STODY_S,[/?]DK_\7:;_ +)C_P"9
M8_YZ7_BP_P#5I_U'^T:??6ODK_DBVO\ R7?[,?\ )2_W)X?C_I>OSZG7;O\
M<9/]R>'^C?'^?SZLV_E _P#90G6?_9!G_%]H_P#F8_\ S/C]$G_,G_\ L_\
M_E7_ ,-?N%OO!?\ *I;U_P K3_9'_<?_ '!_ZB_^$?Q?ET'>:O\ <&X_W-X?
M@_L_]O\ T?7K:O\ ES_V3-W9_P R:_X\',_]E"?\R8_S:?\ '_\ _5H_U/\
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MY6;^UC_Z5G]HO]O\_P#?/_#='01YQ_W#?_<SXA_S1X_B_P"??Z5.K!/YX?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>aurinialogoweb700pxa05.jpg
<TEXT>
begin 644 aurinialogoweb700pxa05.jpg
M_]C_X0[-17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3@@*$UA8VEN=&]S:"D ,C Q.#HQ,#HQ." Q,SHT-SHS
M-P     #H $  P    $  0  H ( !     $   *\H , !     $   $2
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #8\         2     $
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MGO&][7_O,]+8Q=+B9->7C59-7T+6AP'<3^:?ZJX?KC7-ZQEAW/J3\BUKF_\
M15+J?UBR*>D5]%Q7FLDO=E6-T(K<=[,>MP_TFYSKG?Z/]'_A%?/+>Y#$(:&A
M9_JGU2+D_#\^7)SW,8B28R,I?W/:E[?_ $7I.M?7OIW3['8V$S[?DL,/V.#:
M6GNU]\/W/;^Y2RS_ (3TU4^J_P!:.M=:ZUZ%_HUXM=+[7LJ89F65U@V6/?\
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M9=9>#4&DAKQ_.[?WUEW_ .,CZMUW>E6;\CMOKK 'W7OIL_\  TE/5+GOJ_\
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M/_,^HC]WEKKH /KQ?*(JX&_T?ZL-Z5UC/ZE7>'UYVC,85A@K$[]K7A[M[?\
MK;%N+&Z(_-&3?3E>M?M:)R[!8QCW;G?0QLBJGT7._P"ZK\C'_P"+_1^ILJ+)
M PEPE!%&E))))B'_V?_M%L90:&]T;W-H;W @,RXP #A"24T$)0      $
M                   X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 4@
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300
M       "   X0DE-! (       (  #A"24T$,        0$ .$))300M
M   &  $    ".$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      TD    &              $2   "O     H
M50!N '0 :0!T &P 90!D "T ,0    $                          0
M           "O    1(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   1(     4F=H=&QO;F<   *\    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $2
M     %)G:'1L;VYG   "O     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$%       !
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M+/\ A/353ZK_ %HZUUKK7H7^C7BUTOM>RIAF9976#98]_P"<]<'[6M[-:T?
M !>C?4/HUF#TY^=D-+,C/VN:T\MI;/H-</S7OWON=_QG_!J3/@PX,)TXIGTQ
ME+?B=R48QCXO_]#U5<IUCZ^5=.ZED8%.#9E_9 /6M:\!H)#7.GVV;65^I6Q]
MC_\ "+I<O*JP\2[+N,58];K7G^2P%[OR+BOJ-TS]J8?6,_.$NZH7X[CW >'6
MY19_UW(V?^@Z2GK^D=2IZKTW'ZA2TL9D-W;'<M<#LLK='^CL:YBN+B_\7&9;
M73G=&R=+\.TO#3_*)IR&C^IDTO?_ -?74]4ZGB=*PGYN87-H86M<6M+S+W-J
M9[&>[Z;TE-M)5NGY^/U'"JSL4DT7MW5EP+3$QJQWN:@]9ZW@=%QF96>YS:K'
M^DTL8YYW%K[/HL!_,J>DIOI+/SNN]/P.E-ZMD.>,1X8YKFL<YT6QZ?Z-HW_G
M(>=]9NB]/Q:<G*R0QN0P6T5@%UKVN&YKFT,#K/[7T$E-SJ&6,' R<TMWC&J?
M<6 Q/IM-FW=_*VK/^K'UA'7\*W*^S_9C5::BS>+)AM=N[=MK_P!+^ZH]-^LO
M2NL]-S<QE5GV/%WLR!<QI#@*Q=:T5L=;O;Z3_H.1?JYF]$S<%]O1*6T8K;2U
M[&5>B/4VL<YWI[6?X-U?O24ZJ2R>G?6CHO4<*_/IO]/%QG!EUEX-0:2&O'\[
MM_?67?\ XR/JW7=Z59OR.V^NL ?=>^FS_P #24]4N>^K_P!;6=:ZEEX Q31]
ME#BVPV!^X-L-'T UNSC=^>M;IG4\+JN(W,P;/5I>2)@@APT=78QT/8]O\I9_
M1.H_5S*ZCFT]*H95F4DC+>VCTBXA[ZW;K=C/5_3,L24[:2P^K_7+H/2,EV)E
MW/\ M+ USJF5O,!PW,]^T5?^"+-_\<WZO%VT5Y)\PVO\GK;DE)?K=T\LM;U)
M@_1%NW(([%OT+'?UF_H_^VUYZ#9DVDL:;;;"7%K 7'7^JO6\#JO2>MX+[L>Q
MM^,9KO98V()'NJOJM'M]KOSOIJI;T&FL3@LK%1XJ$-_S=OL<I,GQ/-RN"\?+
M'F9C3TSX.&/]SAE[G^ CD^6PX\^;(9<)S\/3;AXN/7_6/!XGU;ZC=97OV4M)
M&]Y<'>F/WW,;]-[?]&QR]0PQ6W&KKKM=>VMH9ZKW;GNVB-UK_P#2._/6(<'+
M;[?1<([ :?\ 1]JMX73\UEHLGT .>Y(_=VCVK#Q?&OB7,YP,W*DQNOU<9XO:
M_P##9<'^,Z/,#'+'&(E&(A9_>EDD?WC\S__1ZO\ QB]1^S=#&&W6S.L#"T<^
MG7^FN_SME=/_ %Y2^KW7/JUTOHN)@OZECBVNL&[WC^<?^EO_ /!7O61UX#K_
M ->L7I1]V+B ,N$F( ^UY>K/<WU&_9L;^NNA_P"8OU6_[A'_ +>N_P#2R*GF
M*^I8&)]?F9W3\BN_"ZB6UVNJ,@.O J<Q_P#*^UTT7_\ 7ET?U^_\3&1_QE'_
M )^J6%]=?JITWIO2F9O2J30ZNUK;R'O?['_HZW_I7V;?3R/1^BM#ZQ]1'4_J
M"W/'-_V9U@'9XNJ;<S^Q:U[$E.K]3/\ Q+]._P"*_P"_.65_C-_Y"QO_  T/
M_/.2M3ZED'ZK]/@S%9!^(<]K@L3_ !F9V([I]& VYKLMMXN=2#+FL%5S-[VC
MZ'NM9LW_ $T.JDOUH_\ $%B_U,/\M2?ZJ?53HV1TW%ZMG5G.RLFMCS]H.]C0
M!L9572?9LK9[&>KZB;ZT?^(/%_J8?Y:EL_5#_P 3'3?^(:BI-U3%QL;H74*\
M:IE##CW.+:VA@)]-PW;6 ?NK#_Q9?\A9'_AIW_GK'70];_Y%S_\ PM=_Y[>N
M>_Q9?\A9'_AIW_GK'04\]]1OJ_A];];[>ZQ^-AFMXQ6N+6/>\/;ZEFWW>QE>
MSV+O\GH_2OV9=AMQ*68YK</3:QK0-/I-VCVO_EKD_P#%9_-]1_ZQ^2Y=QD_T
M>W^H[\B)4\;_ (K7O=T[-#C(]6MT?RG5,W._M;&H7U$_\4G7/Z[_ /VXR%/_
M !6?\GYO_&5?^>VJ'U$_\4O7/Z[_ /VXR$NZGH^KYWU7Z?D-LZJ<9F58T$%[
M ^TM$AIVM:^[TU2?]:OJ/96:K+Z'UN$.8ZAY:1YM-.U8'3,/$ZI]?^HU]2:+
MVL=<YE=FK7&IU-%+7,/\XVJEW\VNNR>C?5;$H?DY6#A4TUB7V/JK:T?-S4E/
M)?4&NJSJ/6,.ITXEU4,/,L%EU=#_ '_\"_\ /7:MZ3CLS1EM)!#_ %16 -@?
MZ7V/?&WZ7H;*UQO^+QU3^N]4?1 H>S=2 ('IFZPU0W\W]'M]J] 2*E)))(*?
M_]+M>A?50]*ZKE]5OR_M>1E[^*_3#?4?Z]W^$MW;G>FW^1Z:Z!)))34ZKT^O
MJ?3<G M.UN36ZO?$[21[+-NG\V_](LKIOU29C=!R>AYN4<O'R'.<U[6>DZO=
MM?\ H_?<WV9#/M#/Y:Z!))3P^/\ 4/KV+NHQNNOQ\5Q)(J%C"2>7>DR]M;7N
M_DN5NW_%UTS]EVXF/<YN9>YKK,^YHM?[3N>UC)J;6VS\[9[_ /2^JNM22M3A
M]:Z'7E?5ROI5N8W%92*6G*>T1^A+/S'65[?4V?Z17.AXU.!TK$P*\AN3Z-0#
M;6P-[6Z>HUC76>W7]]!^L0)HQ "QKOME&UU@W-!W?G,W5[_\]93L2RM[FX65
MZEXQ<^YMF&&-!N-U3_0JK_6-C:LAOOKW_I+OZ1_.>FI88XRB/51).GDN$0>K
MTF=C?:\+(Q-VS[14^K?$[=[2S=M]N[;N6=]6/J^>@8%F&<C[5ZEIMW[/3B65
MU;-N^W_1(#KNJNZF-C+V-:\LM$/-;J_LUCV6LWU_9Z_UQM/\U;9D;_YS^=?6
MH6U=;^Q4[;\DW.P;\BXAK XY31B_9J8;5^C]WK[<>O9ZOZ3U?41]@Z D#B /
MV_\ HJN%G]5/JL?JZW)!R_M?VGT_\'Z>WT]__"6[MWJ+<M9ZE;V3&YI;/A(A
M8-YZG18^EQRKZ++*";?<',W5W.R'#[)4ZUU7JUTU^E7_ #-EWJ>RE/@6=2==
MB_M%^4QPQZ?3:VMWINOW7-R?MCL>MVWZ./\ SSJZ?]%_A4O8E5W?73KY?]TK
M@+/ZJ?5D_5W'OI.5]K]=S7;O3].-K?3X]2W<H]!^JYZ-U+/Z@[+]<9I<[T_3
MV;-UEF1]/U+-_P#.[/HJM@9'7&8HOR3D%[78OVJKT['O#B\_;GUM./4QU6W]
M'Z&#]JK9L]6JS_2E:<E_4<._*=>U[AU!M;=I'M]>MV(+ZFM]E'V8,_2W;*_Y
MCUK/5L_2$\O($V=K&W41]Q7 4/6_J75U/.'5NF9KL'*LA[GL!<US@-C+ZGU6
M4V56.K]KW5V;+4''^H=;\BN_ZP=2NZH6F*J;'.;7NYV_I+;K'_U*W5?\)ZBN
M=-OS_3;9>,FRYN-4["QZF[*+!]F:YXLMJK^S4WOR_79^L/K]/]7]*O\ TE=E
MN8,C&?E>L<5N3C.I]5MA=O?7EU7MJ;D5U9;]KO1W_H?T;/T_\SZB/W>6NN@
M^O%\HBK@;_1_JPWI76,_J5=X?7G:,QA6&"L3OVM>'NWM_P"ML6XL;HC\T9-]
M.5ZU^UHG+L%C&/=N=]#&R*J?1<[_ +JOR,?_ (O]'ZFRHLD#"7"4$4:4DDDF
M(?_9 #A"24T$(0      70    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <    !< 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# $, (  R #  ,0 X     0 X0DE-! 8       < "     $! /_A#@IH
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB
M[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N-BUC,30P(#<Y+C$V,#0U,2P@,C Q-R\P-2\P-BTP,3HP.#HR
M,2 @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#
M<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3@@*$UA8VEN=&]S
M:"DB('AM<#I#<F5A=&5$871E/2(R,#$X+3$P+3$X5#$S.C0W.C,W+3 U.C P
M(B!X;7 Z365T861A=&%$871E/2(R,#$X+3$P+3$X5#$S.C0W.C,W+3 U.C P
M(B!X;7 Z36]D:69Y1&%T93TB,C Q."TQ,"TQ.%0Q,SHT-SHS-RTP-3HP,"(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#IA.6)F8F1A-"TQ,&(Y+31B.#8M
M86(R-2UB86-B,#@S,#,P830B('AM<$U-.D1O8W5M96YT240](F%D;V)E.F1O
M8VED.G!H;W1O<VAO<#HS-S0X93$R.2TV,F%B+3AC-#(M83$X-"UF83$U,34V
M9F9A9&(B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HT,38T
M83@R-RUA,3)C+30U,&0M.3AE82TR83 Y8C=D,&8Y-F(B(&1C.F9O<FUA=#TB
M:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P
M.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@/'AM<$U-.DAI<W1O
M<GD^(#QR9&8Z4V5Q/B \<F1F.FQI('-T179T.F%C=&EO;CTB8W)E871E9"(@
M<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HT,38T83@R-RUA,3)C+30U,&0M
M.3AE82TR83 Y8C=D,&8Y-F(B('-T179T.G=H96X](C(P,3@M,3 M,3A4,3,Z
M-#<Z,S<M,#4Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O
M<VAO<"!#0R R,#$X("A-86-I;G1O<V@I(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#IA.6)F8F1A
M-"TQ,&(Y+31B.#8M86(R-2UB86-B,#@S,#,P830B('-T179T.G=H96X](C(P
M,3@M,3 M,3A4,3,Z-#<Z,S<M,#4Z,# B('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#0R R,#$X("A-86-I;G1O<V@I(B!S=$5V=#IC
M:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B \+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M :(    & @,!              <(!@4$"0,* @$ "P$   8# 0$!
M    !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R(
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M4V0WUL'$5&YA!H$5/O;$"3;V^J.-4L%BH]X8FMB3A3H4&PO;V7.NEF7I4#4
M]&<]UZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!#W]T[@?D'TIVCTEN>KJL=A.T
M-DY[9U9E**-):W$/EZ&6"CS-'#*R0SU>'KC%51QN1'(\05O23[VITD'TZT14
M$=:A6X?^$ZOS4H,Q74VW>P?CWN'"1U$HQF6J=U[WP=95T8<^"6NQ$G7M>N.J
MWCL9(8ZFJC1N%E<>HJ_J$]#TSX;>HZ<MD?\ "='Y?93<N*I=^]F=$;3VDU7!
M_'<S@\_O+=6>IL<9 *E\+@)=D8&BR606.^B.HKZ.(GZR#Z>_&X3R!KUOPSZC
MK<3Z_P!E87K78>R>N=M)-'MW8&T=M[*P$=3(LM0F%VKAJ+!8I)Y52-9)EH:"
M,,P506N;#VD)J23QZ>&!3I7>]=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM6KY\?R(NZ.Z/
MD;V/WA\>=_\ 6(V_VON.NWMG]I]BY/<FW<Q@-UYV3[S<?\,K\-MC<V/S6)R6
M8>:L1I31S4_W'AT2A/*RE)U"A6!QTTT9))!Z)2G_  G@^=KNJMNKXYQ*S &1
M]_[U*(">681=8R2%1^=*D_X>[^.GH>J^&WRZV2OY8GP+E^ G1&6V#GMV8[>W
M86^=V2[TWSF\)3U=/MZEJUQ=!A\9M[;WW\5-D*S%8FDH6D^ZJ(8)IYZF4F*-
M B*GD?6U0,=.HND?/JR'VWU;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HI?RW^)VS_E)L<8RN-/A-_;?BJ9]
MC;Q\.ML?52J'DP^8$:M-6;;RDB*)XQ=X6 FB]2E''O(7N!NO(>X23VJ^-MTH
MI+ 6TAZ<&4T.AU\FH:BH((I2$/>?V#Y'][8>77YD@\+>-KO(IH+E%!D$:RH\
MULX-/$@G52K(2-#Z9%(((;4ZSW\G7?6PMQSX'>_8GEJ:%F^]HL)MJ&CDDCO^
MU/1Y+,9_Q34U2GJBDCIYE<?T/'O&3WF_OY![6<Z[M[>-]U>YMN9K4L&&Z;XE
MD M?TYE";9/;SPS#OB>&]*NO U! ZD\J\C['S1M5ON\/."+;2 4TV[29\U)$
MBE64X8,H(/2CP'\NGJG!-))FL)V'NL?I*YBNJJ*BC*\,86VUCL),0Q_U4T@_
MI[PBYW_OT_OB\[07\'MWROREL%@Q(CGM+*?<;J+RKXUW<SV4A!X$V(7U4CJ4
M]N]H^183 UYODMS*,E?%CC1O]JJ^(OY25^?1B-H=.[#V"0NSNO<'M^I$<<+U
M=!@HDRLL:$^-:G)R0R9.ILU^9)6)/^/OG5[O_>W^]=[]?5VONS[T<S;MMLX
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M'O[Y?W)RO]XONOX-]]_#:O\ NE]SX_\ B^_>V_X Z_3X-5_N?VM=O7[[O?\
M)Q#G;_@3?]=W_6=W/^OOU/[O^H^DG_<GC:?^2E]1_P HVKL^FUZOJ_\ %O&T
M_J]8J?ZSVV?U_P#ZO?UC@_=.CQM'B+]5IK_8Z/XZ9UTIX??IKV]?_];?X]^Z
M]U[W[KW7O?NO=>]^Z]U\_P _G&_(#_9@/GMV]4T%;]YM;J::EZ3VIID\D24^
MP9:N#=#PNI,4L-7V!79B:-TX>%TY-KE="NE!ZGI.YJQZJY]N]4ZWL/Y$_0O^
MAWX)[:WCDJ+[;<W?>Y\YVC7M-'IJX]NAX]K;*I6>PUT51@\",I .;#*,?J2
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MHN(BL<M.+03#5!<)_P ,@DD3^EUD3LV_[+S!;"[V7<X;F'ST-4K7R9<,A^3
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M8D*D:,Q( )&B: D^76P*D#KZ;NPMEX+K?8VS.O-K4PHML[#VKM[9NWJ,:?\
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M>8I:&F-56U,DTFB-=<LC.UV8DK8E4QJ2!7_9Z8<G4<]5@_[-#\E_^\B.]/\
MT;>__P#[(/;FE?X1U2I]>MO+_A/IO_??8GQ.[:R_8&]=V[ZRU'\A\YC:3*;Q
MW)F-SY&EQT?6W6=4E!3UN;K*ZI@HDJ:J601*P0/(S6NQ)23@!Q0>73T?PG[>
MKX_;/3G7O?NO=>]^Z]U[W[KW7O?NO=:XG_"B/LKL;KC8/Q@J.O-_[VV'497>
M'9<.4GV9NK.[7FR4-+A=I/315\N#KZ%ZR.G>9S&LA8(7)%KGVHMP"6J.FY.
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M+EMH/LF7'?9MN6CRF+IHZFDW/*=+4LFMH2;V%O;\**^K4.'3;L5I3K6,WO\
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M^_\ LO\ A_\ $+=D_P#N1MGVS/\ V?Y].1_%^76\;[1=/]>]^Z]UHI?SZ_\
MMXCO+_Q&O5W_ +SWM;!_9C[>D\GQ'JF/V]U3KWOW7NCZ_%+^6G\O/F'+19#J
M[K.KQ&PJJ11)VMV U1M+KR*'5HDGQ^4JJ2?([I\+^EX\-29&6,_K51R&VD1.
M)SU8*QX#K93^+_\ PGT^,_6,>/S_ ,B=R9WY!;NB\51+@('K-C=8T=0MI!",
M7B:X[IW!]M-QY*K)0TU2@_<HE#%/:=IV/PB@Z=$8''/5X?775/6/4& BVMU5
MU[LKK?;D6@KA-C[9PVU\:\B+H$\]+AJ.CBJ:EA?5+(&D<DEF))/MDDGB>K@
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M]1Z]>_TS]/?\_7ZU_P#0ZVO_ /73W[2WH>O5'KU[_3/T]_S]?K7_ -#K:_\
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M^SJR_$/MZ^E7[+NE/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UHI?SZ_^WB.\O\
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MK7UZ]_P]E_+&_P"\F/\ V#/R!_\ M4^_>#)_#_@Z]K7UZ]_P]E_+&_[R8_\
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M]U[W[KW6@E_.Y_[>9_(K_J%Z<_\ ?%]:>UT/]FO^KSZ3O\1ZJC]N]4ZW.?\
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M[]U[KWOW7NM%+^?7_P!O$=Y?^(UZN_\ >>]K8/[,?;TGD^(]4Q^WNJ=;?/\
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M*;(;ZV#B*C<P@T"*GWMB!)M[?5'&J6"Q4>\,36Q)PIT*#87M[+G72S+TJ!J
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M;-4LRWU15.*V)GJZ"1=/JNDL (MSQ[VOQ+]O6CP/7S)/9ETEZ][]U[KZ._\
M+KZIPO3/P@^,>R\-1PTC2]0[.W?G3"BJU7NS?^(I][;JJY9 -=0SY[/3JCM<
MB%$4650H+Y#5V/SZ4J**.CI>Z=6Z][]U[KWOW7NO>_=>Z][]U[K1\_X4&_\
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M_P"W8WR8_P#*,_\ P0/5/MV'^T7_ %>75'^$]:!'M=TGZ,]\(_\ LL_XB_\
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MS\V^BH_DM\3^^.E!3)5Y3>G7V87:T<@4JN^,"(]S;%F;5^E(=X8:B9B"#H!
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M[KW55O\ .R_[=C?)C_RC/_P0/5/MV'^T7_5Y=4?X3UH$>UW2?HSWPC_[+/\
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M^\C-[27'Q+]G3T7 ];*'M/T[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= 5\HO\
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M-?3R4M73N\3I*JS4\K*2K!@#P0??NO=5C?\ #+/\LS_O&2E_]&QWI_\ ;/\
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M&;MPE'E1CZF1/&:[#U<T?W^$R8CX6JHY8*A!^EQ[V&*FH-#UH@'B.J=>T?\
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M^Y/.EAMUI%!8Q7\BI'&JHB*#A510%4#R  '15OD<<.\;C%%&JQK*0    /0
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MXI\M3I5-54M70""EDIZ:4%&)CD<M]ZO9GE;ECE?:>?\ D'<))>7;EXPR._B
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ML-LC-$A(.GQ9#6AHYI3H=S['RKLP2/=+UWN2*TJ?VZ4!*CTU'\^CJ_'?<_\
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M?_\ E3ME_P";/_5INMHWWA#U&_6KE_+Z_P"WY?S<_P!?Y*?^_AV9[S>]V/\
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M+90\U[,]G)<JS1AGC?4$(#4,;N!0L*@D'(ZCN^VR_P!L,:WUN8RX-*D&M./
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MOGT6[O\ \E.^^/\ M#\?Q<?Q?/UZ*/\ S?O^R7=M?]D^?\SGVK_V4I_QX/\
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M/4H\M?\ )*A_W-^'\?#_ )M_T?X>KY?@9_V05VO_ -D,?\>)O3_LG'_CP_\
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MQ?\  A_^9A?]G_\ \[+_ *;-?OJ#['_\JKM?_*S_ -FO_)1_L^'^@?\ "/\
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M8_YZ7_BP_P#5I_U'^T:??6ODK_DBVO\ R7?[,?\ )2_W)X?C_I>OSZG7;O\
M<9/]R>'^C?'^?SZLV_E _P#90G6?_9!G_%]H_P#F8_\ S/C]$G_,G_\ L_\
M_E7_ ,-?N%OO!?\ *I;U_P K3_9'_<?_ '!_ZB_^$?Q?ET'>:O\ <&X_W-X?
M@_L_]O\ T?7K:O\ ES_V3-W9_P R:_X\',_]E"?\R8_S:?\ '_\ _5H_U/\
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MY6;^UC_Z5G]HO]O\_P#?/_#='01YQ_W#?_<SXA_S1X_B_P"??Z5.K!/YX?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>checkmarka08.jpg
<TEXT>
begin 644 checkmarka08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-   DI(
M @    ,S-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( !D ' ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ9YY]JWK-F>RA>1B[L@8L0.21[5F75BMAX9N(P=TC)ND?NS9Y-:5C_R#[?\
MZY+_ "%=&7TZM+%2C4D]8IV<G)*[>FK?;5]_(SKRC*FG%+>U[)7T\BEK%O<R
MW%E-:0><8)"[+O"^G<U&TEZ]RMP^A*TJ#"N;E<@5L45V5,O4ZLJD:C7,TVK1
M:NE9/WHOL91KVBHN*=O7]&C%OI=4O+*6W_LK9Y@QN^TJ<5JVJ-'9PHXPRQJ"
@/0XJ6BM:.$]E5=64W)M6UY=M^B1,ZO-'E227S_5L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>checkmarka09.jpg
<TEXT>
begin 644 checkmarka09.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-   DI(
M @    ,S-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( !D ' ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ9YY]JWK-F>RA>1B[L@8L0.21[5F75BMAX9N(P=TC)ND?NS9Y-:5C_R#[?\
MZY+_ "%=&7TZM+%2C4D]8IV<G)*[>FK?;5]_(SKRC*FG%+>U[)7T\BEK%O<R
MW%E-:0><8)"[+O"^G<U&TEZ]RMP^A*TJ#"N;E<@5L45V5,O4ZLJD:C7,TVK1
M:NE9/WHOL91KVBHN*=O7]&C%OI=4O+*6W_LK9Y@QN^TJ<5JVJ-'9PHXPRQJ"
@/0XJ6BM:.$]E5=64W)M6UY=M^B1,ZO-'E227S_5L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>checkmarka10.jpg
<TEXT>
begin 644 checkmarka10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-   DI(
M @    ,S-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C Q.3HP-3HR.2 P-SHS-#HR.  R,#$Y.C U.C(Y
M(# W.C,T.C(X    3 !I ', ( !7 &$ ; !K &4 <@   /_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 U+3(Y5# W.C,T.C(X+C,S-3PO>&UP
M.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D
M9CIL:3Y,:7,@5V%L:V5R/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC
M<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T
M83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_
M/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_  !$( !D ' ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M 0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q0083
M46$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7
MF)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7F
MY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)
M"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@4
M0I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I3
M5%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U
M]O?X^?K_V@ , P$  A$#$0 _ /?=8N+F*XLH;2?R3/(49M@;T[&E^PZI_P!!
MC_R56H]9_P"0EI?_ %W_ ,*K7>M7EO-/8M$IN6(6%XP<$'O@U\SB*]&GB*TL
M3*5DTE:4DOA3M:+6KZ>9Z-.$Y4XJFEUO=+OYHCOKG4K5I$@U/SVA7=+BW0!!
MZ9YY]JWK-F>RA>1B[L@8L0.21[5F75BMAX9N(P=TC)ND?NS9Y-:5C_R#[?\
MZY+_ "%=&7TZM+%2C4D]8IV<G)*[>FK?;5]_(SKRC*FG%+>U[)7T\BEK%O<R
MW%E-:0><8)"[+O"^G<U&TEZ]RMP^A*TJ#"N;E<@5L45V5,O4ZLJD:C7,TVK1
M:NE9/WHOL91KVBHN*=O7]&C%OI=4O+*6W_LK9Y@QN^TJ<5JVJ-'9PHXPRQJ"
@/0XJ6BM:.$]E5=64W)M6UY=M^B1,ZO-'E227S_5L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>checkmarka11.jpg
<TEXT>
begin 644 checkmarka11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-   DI(
M @    ,S-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( !D ' ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ9YY]JWK-F>RA>1B[L@8L0.21[5F75BMAX9N(P=TC)ND?NS9Y-:5C_R#[?\
MZY+_ "%=&7TZM+%2C4D]8IV<G)*[>FK?;5]_(SKRC*FG%+>U[)7T\BEK%O<R
MW%E-:0><8)"[+O"^G<U&TEZ]RMP^A*TJ#"N;E<@5L45V5,O4ZLJD:C7,TVK1
M:NE9/WHOL91KVBHN*=O7]&C%OI=4O+*6W_LK9Y@QN^TJ<5JVJ-'9PHXPRQJ"
@/0XJ6BM:.$]E5=64W)M6UY=M^B1,ZO-'E227S_5L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>faxa01.jpg
<TEXT>
begin 644 faxa01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q-@  DI(
M @    ,Q-@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( #X /@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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G4'N?6OM'3X(;73X+:TC\J""-8XT_NJ!@#\A4ZQHOW54?04Z@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>interneta01.jpg
<TEXT>
begin 644 interneta01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,X-   DI(
M @    ,X-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C Q.3HP-3HR-R Q-#HU,3HS,  R,#$Y.C U.C(W
M(#$T.C4Q.C,P    3 !I ', ( !7 &$ ; !K &4 <@   /_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 U+3(W5#$T.C4Q.C,P+C@S-CPO>&UP
M.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D
M9CIL:3Y,:7,@5V%L:V5R/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC
M<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T
M83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_
M/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_  !$( %< 40,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M>4<@@ #Y3G.: /2:*\D_X6;\2!_S2>Z_\&"__$TG_"S?B1_T2>Z_\&"__$T
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ML_\ HQJ />J*** "BBB@ KP?XR_\ET^'G^^?_1@KWBO!_C+_ ,ET^'G^^?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>laurelhill.jpg
<TEXT>
begin 644 laurelhill.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G < # 2(  A$! Q$!_\0
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M;?=?WI:-]U_>EHN'M*G8]I_X7IXZ_P"@]_Y)V_\ \11_PO3QU_T'O_).W_\
MB*\6WW7]Z6C?=?WI:+A[2IV/:?\ A>GCK_H/?^2=O_\ $4?\+T\=?]![_P D
M[?\ ^(KQ;?=?WI:-]U_>EHN'M*G8]I_X7IXZ_P"@]_Y)V_\ \11_PO3QU_T'
MO_).W_\ B*\6WW7]Z6C?=?WI:+A[2IV/:?\ A>GCK_H/?^2=O_\ $4?\+T\=
M?]![_P D[?\ ^(KQ;?=?WI:-]U_>EHN'M*G8]I_X7IXZ_P"@]_Y)V_\ \11_
MPO3QU_T'O_).W_\ B*\6WW7]Z6C?=?WI:+A[2IV/:?\ A>GCK_H/?^2=O_\
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M5*78/[,H?WO_  )GPE_PQM\>/^BC^'/_  #'_P 8H_X8V^/'_11_#G_@&/\
MXQ7W;FC-'U2EV#^S*'][_P "9\)?\,;?'C_HH_AS_P  Q_\ &*/^&-OCQ_T4
M?PY_X!C_ .,5]VYHS1]4I=@_LRA_>_\  F?"7_#&WQX_Z*/X<_\  ,?_ !BC
M_AC;X\?]%'\.?^ 8_P#C%?=N:,T?5*78/[,H?WO_  )GPE_PQM\>/^BC^'/_
M  #'_P 8H_X8V^/'_11_#G_@&/\ XQ7W;FC-'U2EV#^S*'][_P "9\)?\,;?
M'C_HH_AS_P  Q_\ &*/^&-OCQ_T4?PY_X!C_ .,5]VYHS1]4I=@_LRA_>_\
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M .,5]VYHH^J4NP?V90_O?^!,^$?^&./CQ_T4;P[_ . @_P#C%?.GQOU?XF?
MGQU)X6U?Q5:7U['!%<>;96<6W:W^_%7Z\>X%?E'_ ,%%./VD[T=?^);;?^@U
MRXFC&E#GB>-FV&CA<-[2G*7_ ($?*\W^L>NC^%WQ*C^&FL:A>2Z9'J37$7E*
MLRH^W_OJN<F_UCUD3MB>2O-J4XU:?LY'S6&K5,+*-2G\43Z _P"&K!_T+EE_
MX"Q?_$4?\-6#_H7++_P%B_\ B*^>:-C;=VSY:\W^RL-WE_X$SZ'_ %BS#O'_
M ,!1]#?\-6#_ *%RR_\  6+_ .(H_P"&K!_T+EE_X"Q?_$5\\44?V7AN\O\
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MA66)MT<B[E:OQO\ ^"7-C;7W[2DRW-O'=*FB2NGFKNVO]HM_FK]EJ $K#O\
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M_P"AM7QE_P %?O\ C^\%?]<S_P"U:^S?V//^39?AY_V"U_\ 0VH)/S3^._\
MRD]3_L<M#_\ ;6OV(M_^/>+_ '5K\=_CO_RD]3_L<M#_ /;6OV(M_P#CWB_W
M5H*/'_VS/^37?B/_ -@IO_0EKY"_X(]_\@_X@?\ 76"OKW]LS_DUWXC_ /8*
M;_T):^0O^"/?_(/^('_76"@D_26DI:2@!G8_2ORC_P""BW_)R=]_V#;;_P!!
MK]7.Q^E?E'_P46_Y.3OO^P;;?^@UPXW^$?-Y]_N?S/E>;_6/6/<?Z]ZV)O\
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MM_%?6-.T?0[B?5=*CUBR\W_CW=G3^!Z\87XA^ V.!\/8?_ J7_XNO3_V@O\
MD3;C_KNO_H#U\O[?F'RUYG#6 IXC \TN;XOYG'\F?0\6YA5PN8<L8Q^'[45+
M\SU#_A8G@+_HGL'_ (%2_P#Q==7\*_&WA#4O'6DP:;X+ATV]:7]U<>>S;?\
MQ^O!%"G.6Q^%=W\"\?\ "TM!Y_Y;U[F9991A@JL^:7PR^T^WJ?.9;FU:6+I1
ME&/Q1^Q'_(^K?'^[[/=[MO\ J&^Y_N5\.ZE_R$;K_KJ__H=?<?C_ /X][O\
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MU_R1/P=_V,/_ +:S5Z5_P31_Y-'\)?\ 72]_]+;BO-?^"O7_ "1/P=_V,/\
M[:S5Z5_P31_Y-'\)?]=+W_TMN*"CYW_X*_?\?W@K_KF?_:M?9O['G_)LOP\_
M[!:_^AM7QE_P5^_X_O!7_7,_^U:^S?V//^39?AY_V"U_]#:@D_-/X[_\I/4_
M['+0_P#VUK]@UFBMK!)Y&5(8X][,W\*[:_'SX[_\I/4_['+0_P#VUK].?VCO
M&4?@3]GOQQJSMY<J:'=+!_UU:W?9_P"/4%'*_M->)K3QE^QUXYURQ61;2]T5
MY8UE78^W<*^6_P#@CW_R#_B!_P!=8*]\^)7_ "CVUO\ [%M__0J\#_X(]_\
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M_ 72O/?VB_!>N>--(TL:'ID^I/;O*\J0_P .[9_\17S2_P 3O%C_ 'M>OO\
MO[47_"R/$_7^WK[_ +^U\9_8N+^N_7N:/XGZ%4XDP4L!_9_LY<O+R]#6C^!_
MCR9MJ>%[[?\ [E=#H_[+7Q!U65%ETJ/34;[SWTZ)MKC/^%E>)_\ H/WW_?\
MH3XE>*$^[K]]_P!_:^CE]=^SR_B?*4Y97'XXS_ ^G/ W[''AC2BEQXO\3?VD
MR_?L=/78G_?=5_VI/&5GX5\$Z?X:T&TATFTO)61;>W3;^Z5/X_\ OM:^;HOB
MAXJ1MP\07WX25E:WXDU+Q),DNJW\]_*GW6F;[M>7]0QV(Q,:N)J1Y8_9B>U+
M-\!0PE2A@J,HRE]HJ6FFW>H2;+2WGNG_ .F43-7U7^S?X?N? ?A#4KG7(OL;
MWLZO%;O]]U5/O_\ C]?+ND^)-2T%7_LZ]GLO-^]Y3[=U6YO'&O3-OEU>\?\
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MR[V["^K^][/F]X^$/BG^S3\5_%G[8[?%33_!-T^@)XAL-26%I425HK?RL_\
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M/^_MQ_\ &J/^&,?'O_/SI'_?VX_^-5PO_"]_%W_013_OW1_PO?Q=_P!!%/\
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MW_GYTC_O[<?_ !JC_AC'Q[_S\Z1_W]N/_C5<+_PO?Q=_T$4_[]T?\+W\7?\
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M1_X1VY_V/SHHKR#\_P#:2$_L"X]8Z/[ N/6.BB@/:2#^P+CUCH_L"X]8Z**
M]I(/[ N/6.C^P+CUCHHH#VD@_L"X]8Z/[ N/6.BB@/:2#^P+CUCH_L"X]8Z*
M* ]I(/[ N/6.C^P+CUCHHH#VD@_L"X]8Z/[ N/6.BB@/:2#^P+CUCH_L"X]8
MZ** ]I(/[ N/6.E_L"X]8Z** ]I(U_!;3>%/&>AZR8H[K^S;ZWOC;B3:9/*E
M1MN[;_LU]_I_P5.VJ ?AHY_[CH_^1Z**UA5E3^$Z\/F&(H?PY6'?\/4/^J9O
M_P"#W_[GH_X>H#_HF;_^#W_[GHHH^M5NYV?VOC?Y_P %_D'_  ]0'_1,W_\
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M ,'O_P!ST44?6JW</[7QO\_X+_(/^'J _P"B9O\ ^#W_ .YZ/^'J _Z)F_\
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=VCE?XMVU?_0:**FI7G4C:3./%9AB<13M4E<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>maila01.jpg
<TEXT>
begin 644 maila01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,U,P  DI(
M @    ,U,P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C Q.3HP-3HR-R Q-#HU,SHQ-  R,#$Y.C U.C(W
M(#$T.C4S.C$T    3 !I ', ( !7 &$ ; !K &4 <@   /_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 U+3(W5#$T.C4S.C$T+C4R-SPO>&UP
M.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D
M9CIL:3Y,:7,@5V%L:V5R/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC
M<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T
M83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_
M/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_  !$( #H / ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M_P"A<U3_ ,!F_P */^$;\7_]"YJG_@,W^% 'L?\ PN:7_GE'_P!\_P#UZ/\
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M;5Q)J#]R3C[N?S^E<WX#O_B=\/)+H:)X?U)X+I"'MYK1R@?'#@=B/U[UA_\
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M:]D.BO#<VQ)*"1]K >A]:^M**!'Q?)\ O'T9_P"0;&W^[(*A/P*\?#_F$?\
MCXK[6HH ^*U^!'CYO^83CZN*M0_L]^/9B,V,$?NTM?95% '@'PO^ EWX9UZ#
>6O$@ANKFW.Z"$'*1M_>/J1VKWU=VT;L9IU% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>perfgraph.jpg
<TEXT>
begin 644 perfgraph.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Y-   DI(
M @    ,Y-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( 3@"T0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'G_ "+MK_V&M*_]
M.%O725S?CS_D7;7_ +#6E?\ IPMZ .DHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KF_'G_(NVO_8:TK_TX6]=)7-^//\
MD7;7_L-:5_Z<+>@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\:6FG7GA>9-8U!],M
MXY8IEOD('V62.17CD)(*@*ZJ3N^7UKAO"?B2VF^%T=SJ6I>'="NXY?L]CJ]P
M%-M=,(47SE5W7<X0M$V&.&C<9(^6O5Z9%%'!"D,$:QQ1J%1$7"J!P  .@H \
M4<RVOA>^L-1MH]+U;5/#-E9Z):+N4--&95V0!OG!5VB<@_,H9"W0D;M\X7Q)
MJ&DF8+KMUXHLKZWB9OWCV:+!ND0=?+$<<Z$]-VX=3SZC10!P'B36-'C\1Z;K
M>HWUM+H5SH]Y;VUR)%>"69VB.Q2.&=T1@H&20K@>_*^'HKRQTVST#5YF'BQ]
M7TJZ,4CYFD@CAMA+(O?RPL<Z$]-VX'EN?::* "N+\?0ZP8+*5+^Q&EC6-*WV
MILG,Y/V^#D3>;M S@X\L\ COD=I7-^//^1=M?^PUI7_IPMZ .DHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'G_ "+M
MK_V&M*_].%O725S?CS_D7;7_ +#6E?\ IPMZ .DHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ^)[R/4OBQXGNM7E!W+86KE(8_;.!@>RJOUKU30O#>C>&+$6>@:;;V$'=84
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MLT^9@^J:IJ%X_J7 !_,$_K6I:_#SPQ:X(TT2MZRR,WZ9Q^E&H<V(EM%+U?\
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M/%2DV_1?YV/<:*\YT7XIV4.@VPUIKJZU'#>:885 /S';W Z8Z5<_X61<W/\
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M  D"-_J=,U27_MS9/_0\4?VQ?-_JO#VH_5Y+=1_Z-S^E:U% <T>QD_;M;?\
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MK117%4J3J/FF[LJU@HHHK,84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MS?CS_D7;7_L-:5_Z<+>NDKF_'G_(NVO_ &&M*_\ 3A;T =)1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444CNL<;/(P1%!+,QP /4T +
M16?HVO:5XBL6O-"U&VU"V65HFEMI0ZAU.",C\#[@@C@@UH4 %<WX\_Y%VU_[
M#6E?^G"WKI*YOQY_R+MK_P!AK2O_ $X6] '24444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP_\ ^#Z?_P"0ZZ2B@#F_MWC?_H7O#_\ X/I__D.C[=XW_P"A>\/_ /@^G_\
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M_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\
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MMF=V/?%/AU;3KC5+C3;>_M9;^U56N+5)E:6$, 5+(#E0001D<YH QOMWC?\
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ME]H3S@O7=LSNQ[XI\.K:=<:I<:;;W]K+?VJJUQ:I,K2PA@"I9 <J""",CG-
M&-]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (=:TNN:3!I,FJ3:I
M91Z?&Q5[Q[A!"A#[""^< AAMZ]>.M.TO6-,URS^UZ+J-IJ-MN*>=:3K*FX=1
MN4D9Y'% &/\ ;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244
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MB#_PG-0_^,4?\)YI'_/GX@_\)S4/_C% '2457T^_MM5TRUU#3Y1-:W<*3P2
M$;T90RG!Y&01UJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-_$?_DEGBO\
M[ MY_P"B'KI*YOXC_P#)+/%?_8%O/_1#UTE !5'5-;TK0X$FUK4[/3HG;:DE
MW<)$K'T!8C)J]6!XJ\#^'?&T%O#XGTU;Y+5F:']Z\90G /*,#S@<>U7#DYES
M[>0:]!G_  L/P7_T-^@_^#.'_P"*J*+XE>")I)D3Q;HH,+[&WW\:@G /RDG#
M#!'(R,Y'4$5A?\*$^&O_ $+?_D]<_P#QRLO3/V;O 5A=22W4>I:FC+@0W=WM
M5#G.1Y01L]N21S78HX*S]Z7W+_,GWCN8O'O@^>9(H/%>AR2.P5$34826)Z
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M/#WAR\U5H1,+90=K2;$&2!N=L':@SEFP<*"<'&*C_P"$0\-_]"]I7_@%'_\
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MDMD# *_E7"%WPP&[(4C<"GS&@#I]1\:Z)I&I"UU'4]/B,EQ%:QJ+Q3()9%+
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MX2;0?^@WIW_@7'_C3+O7X'TF\N=!FL-3N;:(R>3]L"J0.N657*\9_A/-9_\
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M:<F0#.[.1C%<IJ/P:EU.QM[6YUY#'':1V;@6\ZJR1.[1,$6X$9<>8<F19%)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4M:TJ#7=!U#2+QI%M[^VDMI6C(#!'4J2"01G!]#61_P (OJ__
M $/?B#_OQI__ ,BT44 '_"+ZO_T/?B#_ +\:?_\ (M'_  B^K_\ 0]^(/^_&
MG_\ R+110 ?\(OJ__0]^(/\ OQI__P BT?\ "+ZO_P!#WX@_[\:?_P#(M%%
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MO_T/?B#_ +\:?_\ (M'_  B^K_\ 0]^(/^_&G_\ R+110 ?\(OJ__0]^(/\
MOQI__P BT?\ "+ZO_P!#WX@_[\:?_P#(M%% !_PB^K_]#WX@_P"_&G__ "+1
M_P (OJ__ $/?B#_OQI__ ,BT44 '_"+ZO_T/?B#_ +\:?_\ (M'_  B^K_\
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@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>phone.jpg
<TEXT>
begin 644 phone.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<R!786QK
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,X,0  DI(
M @    ,X,0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( #L 0 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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J2S1@SP0R9:0>F>PKZ>TZV%E806L4,<$4$8CCCC&%10,  >F*M44 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
